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ABSTRACT 
Thiosemicarbazone complexes of transition metals: Synthesis, characterization and study 
of reactivity 
Saswati 
Department of Chemistry, National Institute of Technology, Rourkela-769008, Odisha, India 
 
Chapter 1: In this chapter the scope of the present investigation is delineated briefly along with 
the aim of the work. 
Chapter 2: The syntheses and characterization of some new mixed-ligand nickel(II) complexes 
{[Ni(L
1
)(PPh3)] (1); [Ni(L
1
)(Py)] (2); [Ni(L
2
)(PPh3)]∙DMSO (3); [Ni(L
2
)(Imz)] (4), 
[Ni(L
3)(4‒pic)] (5) and [{Ni(L3)}2(μ‒4,4′‒byp)]∙2DMSO (6)} of the selected three 
thiosemicarbazones {4‒(p‒X‒phenyl)thiosemicarbazone of salicylaldehyde} (H2L
1‒3
) are 
described in the present chapter, differing in the inductive effect of the substituent X (X = F, Br 
and OCH3), in order to observe their influence, if any, on the redox potentials and biological 
activity of the complexes. All the synthesized ligands and the metal complexes are successfully 
characterized by elemental analysis, IR, UV‒Vis, NMR spectroscopy and cyclic voltammetry. 
Molecular structures of four mononuclear (1‒3 and 5) and one dinuclear (6) Ni(II) complexes 
have been determined by X‒ray crystallography. The complexes have been screened for their 
antibacterial activity against Escherichia coli and Bacillus. Minimum inhibitory concentration of 
these complexes indicates compound 4 as the potential lead molecule for drug designing.  
Chapter 3: 4–(p–X–phenyl)thiosemicarbazone of napthaldehyde {where, X = Cl (HL1) and X = 
Br (HL
2
)}, thiosemicarbazone of quinoline–2–carbaldehyde (HL3) and 4–(p–
fluorophenyl)thiosemicarbazone of salicylaldehyde (H2L
4
) and their copper(I), 
{[Cu(HL
1
)(PPh3)2Br]·CH3CN (1) and [Cu(HL
2
)(PPh3)2Cl]·DMSO (2)} and copper(II), 
{[(Cu2L
3
2Cl)2(–Cl)2]·2H2O (3) and [Cu(L
4
)(Py)] (4)} complexes are reported herein. The 
synthesized ligands and their copper complexes were successfully characterized by elemental 
analysis, cyclic voltammetry, NMR, ESI–MS, IR and UV–Vis spectroscopy. Molecular 
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structures of all the Cu(I) and Cu(II) complexes have been determined by X–ray crystallography. 
All the complexes (1–4) were tested for their ability to exhibit DNA-binding and -cleavage 
activity. The complexes effectively interact with CT–DNA possibly by groove binding mode, 
with binding constants ranging from 10
4 −105 M–1. Among the complexes, 3 show highest 
chemical (60%) as well as photo-induced (80%) DNA cleavage activity against pUC19 DNA. 
Finally, the in vitro antiproliferative activity of all the complexes was assayed against the HeLa 
cell line. Some of the complexes have proved to be as active as the clinical referred drugs, and 
the greater potency of 3 may be correlated with its aqueous solubility and the presence of 
quinonoidal group in the thiosemicarbazone ligand coordinated to the metal.  
Chapter 4: Oxygen atom transfer (OAT) reactivity of dioxidomolybdenum(VI) complexes 
[Mo
(VI)
O2L
1‒6
] (1‒6) {4–(p–bromophenyl)thiosemicarbazone of salicylaldehyde (H2L
1
), 4–(p–
X–phenyl)thiosemicarbazone of o–vanillin {where, X = F (H2L
2
) and X = Cl (H2L
3
) and  X = 
OMe (H2L
4
)}, 4–(p–bromophenyl)thiosemicarbazone of 5–bromosalicylaldehyde (H2L
5
), and 4–
(p–chlorophenyl)thiosemicarbazone of o–hydroxynaphthaldehyde (H2L
6
)} with PPh3 have been 
investigated. The OAT reactions proceed through the formation of OPPh3, which have been 
characterized by 
31
P NMR. Dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1/5/6
(DMSO)] (1a, 
5a & 6a), [Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) and 
monooxidomolybdenum(IV) complexes [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) {where, N‒N = 
2,2'‒bipyridyl or 1,10‒phenanthroline} are reported as the product of substrate binding and 
oxygen atom transfer reactivity of dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1‒6
] (1‒6) 
respectively. All the complexes have been spectroscopically characterized. Molecular structures 
of some of the Mo(VI) (1a‒4a) and Mo(IV) complexes (7 and 9‒11) have been determined by 
single crystal X–ray crystallography. The catalytic activity of Mo(VI) complexes (1a‒6a) have 
also been studied. 
Chapter 5: The synthesis and characterization of an oxidovanadium(IV) [V
IV
O(L)(acac)] (1) 
and two dioxidovanadium(V) [V
V
O2(L')] (2) and [V
V
O2(L)] (2a) complexes of                               
{(4–(p–fluorophenyl)thiosemicarbazone) of pyridine–2–aldehyde} (HL) is described in the 
present study. The oxidovanadium(IV) species [V
IV
O(L)(acac)] (1) was synthesized in usual way 
by the reaction of metal precursor VO(acac)2 with thiosemicarbazone ligand (HL) in refluxing 
ethanol. The recrystallization of [V
IV
O(L)(acac)] (1) in DMF, CH3CN or EtOH gave the same 
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product i.e. dioxidovanadium(V) complex [V
V
O2(L)] (2a), whereas [V
V
O2(L')] (2) was 
synthesized during recrystallization of [V
IV
O(L)(acac)] (1) in DMSO where the original ligand 
(HL) is transformed to a rearranged new ligand (HL'). The ligand in complex 1 is found to 
undergo methylation at the carbon centre attached to imine nitrogen in presence of DMSO and 
transformed to the corresponding dioxidovanadium(V) species through in situ reaction. The 
synthesized ligand and the metal complexes were characterized by elemental analysis, IR, UV–
Vis, NMR and EPR spectroscopy. Molecular structures of complex 1 [V
IV
O(L)(acac)] and 
complex 2 [V
V
O2(L')] have been determined by single crystal X–ray crystallography. Complexes 
1 & 2 show in vitro insulin mimetic activity against insulin responsive L6 myoblast cells, with 
complex 1 being more potent, is comparable to insulin at 100 µM concentration, while complex 
2 has considerable insulin mimetic activity. In addition, the in vitro antiproliferative activity of 
the complexes 1 & 2 against the MCF–7 and Vero cell lines were also assayed. 
Chapter 6: 4‒(p‒methoxyphenyl)thiosemicarbazone of o‒hydroxynapthaldehyde (H2L
1
), 
4‒(p‒methoxyphenyl)thiosemicarbazone of benzoyl pyridine (HL2) and 4–(p–
chlorophenyl)thiosemicarbazone of o‒vanillin (H2L
3
) and their dimeric Zn(II) complexes 
[{ZnL
1
(DMSO)}2]·3DMSO (1), [{ZnL
2
Cl}2] (2), and a novel tetrameric Zn(II) complex 
[(Zn2L
3
)2(–OAc)2(3–O)2] (3) are reported. The synthesized ligands and their zinc complexes 
were characterized by elemental analysis, NMR, IR and UV–Vis spectroscopy. Molecular 
structures of all the complexes (1‒3) have been determined by single crystal X–ray 
crystallography. 
 
Keywords: Thiosemicarbazone / X-ray crystal structure / Pharmacological (Cytotoxic, 
Antibacterial, Insulin mimetic, DNA binding and cleaving) activity / Oxygen atom transfer 
(OAT) reactivity / Catalytic oxidation. 
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Preface 
The present dissertation describes the design, synthesis, full characterization and the exploration 
of chemical, electrochemical properties and the study of catalytic and biological activities of a 
series of variable valence transition metal (Ni, Cu, Mo, V & Zn) complexes of some selected 
multidentate ONS, NNS and monodentate S donor thiosemicabazone (TSC) ligands. Structures 
of twenty two important transition metal (Ni, Cu, Mo, V & Zn) complexes are determined by 
single crystal X-ray analysis. Structure-reactivity relations are discussed and implications of 
structure determination on the design of new complexes using the structurally characterized 
compounds as precursors are elaborated. All the complexes described in this dissertation are 
characterized by various physicochemical techniques such as elemental analysis, and by various 
spectroscopic techniques (UV-Vis, IR, NMR, EPR and ESI-MS). Electrochemical characteristics 
of the complexes were studied by cyclic voltammetry and, as pointed out before, single crystal 
X-ray crystallography were used to find out crystal and molecular structure of the compounds. 
Biological activities particularly antimicrobial, antiproliferative, insulin mimetic, DNA binding 
and cleavage activity and catalytic activities of some of the above complexes particularly 
oxidation of styrene and oxidation of cyclohexene were also studied. The subject matter of this 
dissertation is divided into six chapters containing the chemistry of transition metals (Ni, Cu, 
Mo, V & Zn) ligated to TSC ligands and a brief resume of the work embodied in this dissertation 
and concluding remarks. 
Chapter 1 is a general introduction to the entire work described in the present dissertation and 
spells out the objectives of the thesis. The objectives of the works are placed at the end of the 
general introduction. The entire subject matter of this dissertation is organized as follows: 
Chapter 2 deals with the syntheses and characterization of some mixed-ligand nickel(II) 
complexes {[Ni(L
1
)(PPh3)] (1); [Ni(L
1
)(Py)] (2); [Ni(L
2
)(PPh3)]∙DMSO (3); [Ni(L
2
)(Imz)] (4), 
[Ni(L
3)(4‒pic)] (5) and [{Ni(L3)}2(μ‒4,4′‒byp)]∙2DMSO (6)} of the selected three 
thiosemicarbazones {4‒(p‒X‒phenyl)thiosemicarbazone of salicylaldehyde} (H2L
1‒3
), differing 
in the inductive effect of the substituent X (X = F, Br and OCH3), in order to observe their 
influence, if any, on the redox potentials and biological activity of the complexes. All the 
synthesized ligands and the metal complexes were successfully characterized by elemental 
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analysis, IR, UV‒Vis, NMR spectroscopy and cyclic voltammetry. Molecular structures of four 
mononuclear (1‒3 and 5) and one dinuclear (6) Ni(II) complexes have been determined by X‒ray 
crystallography. The complexes have been screened for their antibacterial activity against 
Escherichia coli and Bacillus. Minimum inhibitory concentration of these complexes indicates 
compound 4 as the potential lead molecule for drug designing.  
In Chapter 3 4–(p–X–phenyl)thiosemicarbazone of napthaldehyde {where, X = Cl (HL1) and 
X = Br (HL
2
)}, thiosemicarbazone of quinoline–2–carbaldehyde (HL3) and 4–(p–
fluorophenyl)thiosemicarbazone of salicylaldehyde (H2L
4
) and their copper(I), 
{[Cu(HL
1
)(PPh3)2Br]·CH3CN (1) and [Cu(HL
2
)(PPh3)2Cl]·DMSO (2)} and copper(II), 
{[(Cu2L
3
2Cl)2(–Cl)2]·2H2O (3) and [Cu(L
4
)(Py)] (4)} complexes are reported. The synthesized 
ligands and their copper complexes were successfully characterized by elemental analysis, cyclic 
voltammetry, NMR, ESI–MS, IR and UV–Vis spectroscopy. Molecular structures of all the 
Cu(I) and Cu(II) complexes have been determined by X–ray crystallography. All the complexes 
(1–4) were tested for their ability to exhibit DNA binding and cleavage activity. The complexes 
effectively interact with CT–DNA possibly by groove binding mode, with binding constants 
ranging from 10
4−105 M–1. Among the complexes, 3 show highest chemical (60%) as well as 
photo-induced (80%) DNA cleavage activity against pUC19 DNA. Finally, the in vitro 
antiproliferative activity of all the complexes were assayed against the HeLa cell line. Some of 
the complexes proved to be as active as the clinically referred drugs, and the greater potency of 3 
may be correlated with its aqueous solubility and the presence of quinonoidal group in the 
thiosemicarbazone ligand coordinated to the metal.  
Chapter 4 describes oxygen atom transfer (OAT) reactivity of dioxidomolybdenum(VI) 
complexes [Mo
(VI)
O2L
1‒6
] (1‒6) {4–(p–bromophenyl)thiosemicarbazone of salicylaldehyde 
(H2L
1
), 4–(p–X–phenyl)thiosemicarbazone of o–vanillin {where, X = F (H2L
2
) and X = Cl 
(H2L
3
) and X = OMe (H2L
4
)}, 4–(p–bromophenyl)thiosemicarbazone of                                     
5–bromosalicylaldehyde (H2L
5
), and 4–(p–chlorophenyl)thiosemicarbazone of                           
o–hydroxynaphthaldehyde (H2L
6
)} with PPh3. The OAT reactions proceed through the formation 
of OPPh3, which have been characterized by 
31
P NMR. Dioxidomolybdenum(VI) complexes 
[Mo
(VI)
O2L
1/5/6
(DMSO)] (1a, 5a & 6a), [Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and 
[Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) and monooxidomolybdenum(IV) complexes 
3 
 
[Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) {where, N‒N = 2,2'‒bipyridyl or 1,10‒phenanthroline} are reported 
as the product of substrate binding and oxygen atom transfer reactivity of 
dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1‒6
] (1‒6) respectively. All the complexes have 
been spectroscopically characterized. Molecular structures of some of the Mo(VI) (1a‒4a) and 
Mo(IV) complexes (7 and 9‒11) have been determined by single crystal X–ray crystallography. 
The catalytic activity of Mo
(VI) 
complexes (1a‒6a) have also been studied. 
In chapter 5 the synthesis and characterization of an oxidovanadium(IV) [V
IV
O(L)(acac)] (1) 
and two dioxidovanadium(V) [V
V
O2(L')] (2) and [V
V
O2(L)] (2a) complexes of                               
{(4–(p–fluorophenyl)thiosemicarbazone) of pyridine–2–aldehyde} (HL) is described in the. The 
oxidovanadium(IV) species [V
IV
O(L)(acac)] (1) was synthesized in usual way by the reaction of 
metal precursor VO(acac)2 with thiosemicarbazone ligand (HL) in refluxing ethanol. The 
recrystallization of [V
IV
O(L)(acac)] (1) in DMF, CH3CN or EtOH gave the same product i.e. 
dioxidovanadium(V) complex [V
V
O2(L)] (2a), whereas [V
V
O2(L')] (2) was synthesized during 
recrystallization of [V
IV
O(L)(acac)] (1) in DMSO where the original ligand (HL) is transformed 
to a rearranged new ligand (HL'). The ligand in complex 1 is found to undergo methylation at the 
carbon centre attached to imine nitrogen in presence of DMSO and transformed to the 
corresponding dioxidovanadium(V) species through in situ reaction. The synthesized ligand and 
the metal complexes were characterized by elemental analysis, IR, UV–Vis, NMR and EPR 
spectroscopy. Molecular structures of complex 1 [V
IV
O(L)(acac)] and complex 2 [V
V
O2(L')] 
have been determined by single crystal X–ray crystallography. Complexes 1 & 2 show in vitro 
insulin mimetic activity against insulin responsive L6 myoblast cells, with complex 1 being more 
potent, is comparable to insulin at 100 µM concentration, while complex 2 has considerable 
insulin mimetic activity. In addition, the in vitro antiproliferative activity of the complexes 1 & 2 
against the MCF–7 and Vero cell lines were also assayed. 
In chapter 6 4‒(p‒methoxyphenyl)thiosemicarbazone of o‒hydroxynapthaldehyde (H2L
1
), 
4‒(p‒methoxyphenyl)thiosemicarbazone of benzoyl pyridine (HL2) and 4–(p–
chlorophenyl)thiosemicarbazone of o‒vanillin (H2L
3
) and their dimeric Zn(II) complexes 
[{ZnL
1
(DMSO)}2]·3DMSO (1), [{ZnL
2
Cl}2] (2), and a novel tetrameric Zn(II) complex 
[(Zn2L
3
)2(–OAc)2(3–O)2] (3) are reported. The synthesized ligands and their zinc complexes 
were characterized by elemental analysis, NMR, IR and UV–Vis spectroscopy. Molecular 
4 
 
structures of all the complexes (1‒3) have been determined by single crystal X–ray 
crystallography. 
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Chapter 1 
Scope of the present investigation 
ABSTRACT 
 In this chapter the scope of the present investigation is delineated briefly along with the aim of 
the work. 
1.1. REVIEWS ON TRANSITION METAL COMPLEXES OF THIOSEMICARBAZONE 
LIGANDS 
The studies described in the present dissertation involve coordination complexes of various 
transition metals (Ni, Cu, Mo, V & Zn) with thiosemicarbazone (TSC) ligands, in relation to 
their biological and catalytic activities. TSCs are known to exhibit thione–thiol tautomerism 
(Scheme 1.1). It possesses several donor atoms, and generally behaves as an ONS/NNS 
tridentate chelate (I),
1
 or as a monoanionic bidentate N,S–donor forming five–membered (II)2 or 
a rather uncommon four membered chelate ring (III)
3
 towards metal ions. It also behaves as a 
monodentate neutral S–donor ligand (IV).4 
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Scheme 1.1. 
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TSCs are a class of Schiff bases which are considered as one of the most important scaffolds and 
are embedded in many biologically active compounds. Brockman et al. first reported that 2–
formylpyridine TSC possesses antileukemic activity in mice.
5
 TSC complexes of transition 
metals have also demonstrated significant activity as antitumor, antiviral, antimicrobial, anti–
amoebic and anti–inflammatory agents.6 The coordination chemistry of various transition metal 
(Ni, Cu, Mo, V, & Zn) complexes with TSC ligands assumed special importance due to the 
following reasons: 
1. Nickel(II) complexes with N and S donor ligands are highly interesting because several 
hydrogenases and carbon monoxide dehydrogenases
7
 contain such nickel complexes as their 
active site. 
2. Copper complexes have been extensively utilized in metal ion mediated DNA cleavage 
through the hydrogen ion abstraction by activated oxygen species.
8
 Many Cu complexes of 
TSCs have demonstrated efficient antitumor potential.
9 
3. Several enzymes like DMSO reductase, xanthine oxidase and other oxotransferases in their 
prosthetic groups contain Mo(IV), Mo(V) or Mo(VI) ions coordinated by nitrogen, oxygen or 
sulfur donor atoms of a macromolecular ligand system.
10 
4. Vanadium is one of the trace bio–elements existing in the human body; its complexes have 
been found to exhibit antibacterial, antitumor, insulin–enhancing and antiparasitic effects.11 
Thio coordination to vanadium is additionally of interest with respect to the insulin–mimetic 
potential of vanadyl dithiocarbamates.
12 
5. Zn(II) ions, as a cofactor are part of over 300 enzymes like carbonic anhydrases, zinc 
proteinases, histone deacetylases, alkaline phosphatases, alcohol dehydrogenases, 
aminopeptidases, etc. Zn(II) complexes of thiosemicarbazone have been considered as agents 
with antitumor activity against MCF–7 and T24 human cancer cell lines.13 
In this context, role of coordination environment around the central metal ion is most important. 
The chemistry of various transition metal complexes with thiosemicarbazone ligands has been of 
significant importance. Review on some of the recent reports of these metals with TSC 
environments which are drawing much interest as are highlighted below. 
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1.1.1. Nickel complexes of thiosemicarbazone: Nickel(II)–TSC complexes gained attention in 
the past few years. The reasons for this are the versatile coordination geometry preferences of 
this metal ion (square–planar, octahedral, tetrahedral), the formation of monomeric and dimeric 
complexes, and its ability to mimic platinum(II) to some extent, which is of great importance in 
chemotherapy.
14
 Some salicylaldehyde TSC–based nickel(II) complexes exhibited similar 
cytotoxicity, under identical conditions on human lung cancer cells (A549) and liver cancer cells 
(HepG2) as compared to cis–diamminedichloridoplatinum(II).15  
K. Natarajan et al. have reported several nickel thiosemicarbazone complexes with biological 
importance in the recent times.
16
 In 2014 they have reported a series of novel nickel(II) 
thiosemicarbazone complexes and characterized them by various spectral, analytical techniques 
and X–ray crystallography. Their efficacy to interact with CT–DNA/BSA was explored. From 
the binding studies, it is inferred that one of the complexes [Ni(Msal–ptsc)(PPh3)] (Figure 1.1) is 
more active than the other complexes. The complexes were bound with CT–DNA by 
intercalation mode. The complexes were also tested for their in vitro cytotoxicity against human 
lung adenocarcinoma (A549) cell line. 
 
 
 
Figure 1.1. 
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In 2013 the same group reported the synthesis (Scheme 1.2), characterization and structure of 
some water soluble Ni(II) complexes of 4N–substituted thiosemicarbazones of 2–oxo–1,2–
dihydroquinoline–3–carbaldehyde and their biological properties such as the binding properties 
with calf thymus DNA (CT–DNA), competitive binding studies with ethidium bromide (EB), 
antioxidant and cytotoxic activities.
14d
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Scheme 1.2. 
T. S. Lobana et al. have reported the study of the bonding patterns (Scheme 1.3), geometry, and 
fluorescence properties of some nickel(II) complexes with salicylaldehyde–based 
thiosemicarbazones [(2–OH–5–R1–C6H3)C(R
2
)=NNHC(=S)NHR
3
, LH2] by invoking the effect 
of substituents at the C–2 and N–1 atoms of the thio ligands and by using 
bipyridines/phenanthrolines as auxiliary ligands.
17 
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Scheme 1.3. 
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In 2012 D. M. Eichhorn et al. have reported synthesis and characterization of dinuclear Ni(II) 
complex of a thiosemicarbazone ligand synthesized by the condensation of 2,2´–
dithiodibenzaldehyde (DTDB) with phenylthiosemicarbazide (Figure 1.2), and is the first 
example of a dinuclear bis(thiolate)-bridged Ni(II) complex with NS3 coordination involving a 
thiosemicarbazide moiety. They also reported a mononuclear Ni(II) complex of TSC ligand 
derived from pyridine carboxaldehyde and phenylthiosemicarbazide.
18
  
 
 
Figure 1.2. 
S. Bhattacharya et al. have reported the synthesis, characterization, structure and catalytic 
activity of nickel complexes of thiosemicarbazones of salicylaldehyde (H2L
1
), 2–
hydroxyacetophenone (H2L
2
) and 2–hydroxynaphthaldehyde (H2L
3
) (Figure 1.3). The 
complexes were found to show efficient catalytic activity for Suzuki cross–coupling reactions.19 
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Figure 1.3. 
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1.1.2. Copper complexes of thiosemicarbazone: Copper is an essential element for most 
aerobic organisms, employed as a structural and catalytic cofactor, and consequently it is 
involved in many biological pathways.
20
 The antitumor activity of copper−TSCs has been 
reported as early as 1960s,
21
 and developments are still in progress.
22
 
A. A. Kumbhar et al. in 2014 have reported the synthesis (Scheme 1.4) and characterization of 
copper(II) complexes of thiosemicarbazone derivative of anthracene; their DNA and protein–
binding ability and DNA–cleavage properties were also studied. Their cellular uptake was 
monitored by fluorescence microscopy, and their anticancer efficacy on cervical cancer cells 
(HeLa cells) was correlated with their redox potential.
9a 
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Scheme 1.4. 
In the year 2013 V. B. Arion et al. have reported synthesis, spectroscopic characterization, and 
evaluation of the biological activity of two enantiomerically pure L– and D–proline–2–
formylpyridine thiosemicarbazone (FTSC), with excellent aqueous solubility, namely, 3–
methyl–(S)–pyrrolidine–2–carboxylate–2–formylpyridine thiosemicarbazone [L–Pro–FTSC or 
(S)–H2L] and 3–methyl–(R)–pyrrolidine–2–carboxylate–2–formylpyridine thiosemicarbazone [D–
Pro–FTSC or (R)–H2L]. The complexes [Cu(S,R)–L] and [Cu(R,S)–L] have been synthesized by 
the reaction of copper(II) acetate with (S)–H2L and (R)–H2L in water and comprehensively 
12 
 
characterized. An X–ray diffraction study of [Cu(S,R)–L] showed the formation of a square–
pyramidal complex (Figure 1.4). Their antiproliferative activity was studied against CH1 
ovarian carcinoma cells, and Topoisomerase IIα inhibition was evaluated in a DNA plasmid 
relaxation assay.
23 
 
Figure 1.4. 
 
J. S. Lewis et al. reported the evaluation of the Topo–IIα inhibition activity of a series of α–
heterocyclic Cu(II)–thiosemicarbazonato complexes and their corresponding thiosemicarbazone 
ligands. Scheme 1.5 showing the schematic representation of the ligands and synthetic pathways 
of their corresponding Cu(II) complexes. The ability of the metal complexes to inhibit the 
proliferation of two breast cancer cell lines, SK–BR–3 and MCF–7, which have been shown to 
express high and low levels of Topo–IIα, respectively.24 
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D. R. Richardson et al. have reported the structure activity relationships of novel copper(II) 
complexes of chelators 2–acetylpyridine–4,4–dimethyl–3–thiosemicarbazone (HAp44mT) 
(Figure 1.5) and di–2–pyridylketone–4,4–dimethyl–3–thiosemicarbazone (HDp44mT) with 
pronounced antitumor activity.
9d 
 
Figure 1.5. 
 
S. Padhye et al. have reported the synthesis of quinoline–2–carboxaldehyde TSC (Figure 1.6 (a)) 
and its copper(II) complex (Figure 1.6 (b)) showing dose–dependent antiproliferative, and 
proapoptotic activity in PC–3 and LNCaP prostate cancer cells   (Figure 1.6 (c)).25 
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Figure 1.6. 
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1.1.3. Molybdenum complexes of thiosemicarbazone: Dioxidomolybdenum(VI) complexes 
have a long standing and successful history in mimicking active sites of molybdenum containing 
enzymes, especially of the sulfite oxidase family.
26–31
 It has been known that the presence of 
sulfur atoms coordinated to molybdenum is favourable for complexes of molybdenum to have 
oxotransfer activity, and many model compounds that mimic such oxotransferases have been 
studied.
32–35
  
M. R. Maurya et al. in 2014 have reported the synthesis and characterization of Schiff bases, 
H3dfmp(sbdt)2, H3dfmp(smdt)2 and H3dfmp(tsc)2 {derived from the condensation of 2,6–
diformyl–4–methylphenol (dfmp) with S–benzyldithiocarbazate (sbdt), S–methyldithiocarbazate 
(smdt) and thiosemicarbazide (tsc)} and their dioxidomolybdenum(VI) complexes 
[Mo
VI
O2{Hdfmp(sbdt)2}(H2O)], [Mo
VI
O2{Hdfmp(smdt)2}(H2O)] and 
[Mo
VI
O2{Hdfmp(tsc)2}(MeOH)] (Figure 1.7). These molybdenum complexes catalyse the 
oxidation of styrene and cyclohexene using 30% H2O2 as oxidant in the presence of sodium 
bicarbonate.
36 
 
 
Figure 1.7. 
 
M. Cindrić et al. have reported the chemistry of some dioxidomolybdenum(VI) complexes with 
thiosemicarbazone ligands derived from 3–thiosemicarbazide and 4–
(diethylamino)salicylaldehyde (H2L
1
), 2–hydroxy–3–methoxybenzaldehyde (H2L
2
) (Figure 1.8) 
15 
 
and 2–hydroxy–1–naphthaldehyde (H2L
3
). The complexes were tested for their antiproliferative 
ability against selected human tumour cell lines.
37 
 
Figure 1.8. 
In 2009 B. Krebs et al. have reported a series of homologous mononuclear dioxidomolybdenum 
complexes {[MoO2(L)(dmf)] (Figure 1.9), [MoO2(LF)(dmf)], [MoO2(LCl)(MeOH)], 
[MoO2(LBr)(dmf)], [MoO2(LI)(dmf)], [MoO2(LMe)(dmf)]·0.5Et2O, [MoO2(LOMe)(dmf)], 
[MoO2(LNO2)(MeOH)], [MoO2(L3OMe)(dmf)], [MoO2(LCl2)(dmf)], and [MoO2(LBrCl)(dmf)] 
with 2–hydroxybenzaldehyde–4–triphenylmethylthiosemicarbazone (H2L) ligand, supplying a 
tridentate O,N,S donor set to the central metal atom. The functional properties of these 
biomimetic model complexes for molybdenum–containing oxotransferases were described.38 
 
Figure 1.9. 
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1.1.4. Vanadium complexes of thiosemicarbazone: The coordination chemistry of vanadium 
attracts increasing interest because of the use of many vanadium complexes as models for the 
biological functions,
39–42
 such as haloperoxidation,
43
 phosphorylation,
44
 insulin mimicking,
45–49
 
nitrogen fixation,
50
 tumour growth inhibition and prophylaxis against carcinogenesis.
51
 
In 2012 A. A. Holder et al. have reported the synthesis (Scheme 1.6) and chemical 
characterization of a series of vanadium(IV) complexes with thiosemicarbazones as ligands. The 
biological study of these compounds against several colorectal cancer cell lines was done, in 
order to evaluate their potential as chemotherapeutic candidates.
52 
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In the same year J. Lu et al. have reported the synthesis (Scheme 1.7) and characterization of 
four oxidovanadium complexes, [VO(hntdtsc)(phen)], [VO(hntdtsc)(bpy)] (hntdtsc = 2–
hydroxy–1–naphthaldehyde thiosemicarbazone, phen = 1,10–phenanthroline), [VO(satsc)(phen)] 
and [VO(satsc)(bpy)] (satsc = salicylaldehyde thiosemicarbazone, bpy = 2,2′–bipyridine). The 
interactions of these four complexes with calf–thymus DNA (CT–DNA) were investigated using 
UV–Vis absorption titration, fluorescence spectra, viscosity measurements and thermal 
denaturation. Their photo cleavage reactions with pBR322 supercoiled plasmid DNA were 
17 
 
investigated by gel electrophoresis. In addition, the cytotoxicity of these four complexes against 
the Myeloma cell (Ag8.653) and Gliomas cell (U251) was also assessed by MTT assay.
11d
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Scheme 1.7. 
M. Cindrić et al. have reported the reactions of salicylaldehyde 4–phenylthiosemicarbazone 
(H2L), with different vanadium precursors. They have investigated several synthetic strategies, 
structural and spectroscopic characterizations, as well as the reactivity of two different types of 
vanadium(V) complexes: (a) mononuclear alkoxido [VOL(OR)]; (b) dinuclear dialkoxido 
[V2O3(Lcycl)2(OR)2] (Figure 1.10), where Lcycl is the thiadiazole ligand formed by oxidative 
cyclization of H2L.
53
 
 
Figure 1.10. 
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R. Yanardag et al. have reported the synthesis and characterization of oxidovanadium(IV) 
chelate [VOL] (Figure 1.11) (L = N
1–2,4–dihydroxybenzylidene–N4–2–hydroxybenzylidene–S–
methyl–TSC); the biochemical and immunohistochemical effects of the administration of VOL 
to the pancreas of normal and streptozotocin–induced diabetic rats was also investigated.54 
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Figure 1.11. 
In 2009 V. M. Deflon et al. have reported the preparation and structural characterization both in 
solution and in the solid state, of some oxidovanadium(IV) and the cis–dioxidovanadium(V) 
complexes (Figure 1.12) with different thiosemicarbazone derivatives {2–acetylpyridine–
thiosemicarbazone (Haptsc), 2–acetylpyridine–N(4)–methylthiosemicarbazone (Hapmtsc) and 2–
acetylpyridine–N(4)–phenylthiosemicarbazone (Happtsc)}. The activity of complexes, free 
ligands and common vanadium salts against M. tuberculosis H37Rv ATCC 27294 was 
evaluated. The vanadium compounds show comparable or larger anti– M. tuberculosis activities 
than the free thiosemicarbazone ligands, with MIC values within 62.5–1.56 (μg/mL).55 
 
Figure 1.12. 
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1.1.5. Zinc complexes of thiosemicarbazone: Zn(II) is an essential metal ion because of its 
presence in certain metalloenzymes. Zn(II) is present in the human body and plays a significant 
role in a variety of fundamental physiological processes.
56 
Moreover Zn(II) ion has structural and 
catalytic role in several proteins.
57
 Zinc complex also exhibited significant antitumor activity 
against lung cancer A549 cell lines.
58
 
In 2013 A. G. Samuelson et al. have reported the synthesis (Scheme 1.8) and characterization of 
dinuclear zinc bis(thiosemicarbazone) complexes. The cytotoxicity of the complexes has been 
evaluated in five cancer cell lines of different tissue origin. The cellular uptake was investigated 
by estimating the amount of accumulation of zinc in two cell lines using ICP–OES. The ability 
of zinc complexes to fluoresce within HepG2 cells has been examined by flow cytometry. 
Effects of these complexes on DNA binding and DNA cleavage have also been investigated.
59
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Scheme 1.8. 
 
D. Kovala–Demertzi et al. have reported the synthesis and characterization of zinc(II) complexes 
[Zn(AcPipPheF)2] and [Zn(OAc)(AcPip–PheF)]2 (Figure 1.13) of 2–acetyl pyridine 1–(4–
fluorophenyl)–piperazinyl thiosemicarbazone (HAcPipPheF). The compounds were tested for 
20 
 
their antiproliferative activity in vitro against the cells of four human cancer cell lines: HeLa 
(cervix adenocarcinoma cell line), K562 (chronic myelogenous leukaemia), MDA–MB–361 and 
MDA–MB–453 (breast cancer cell lines).60 
 
Figure 1.13.
 
S. I. Pascu et al. in 2008 have reported the synthesis and characterization of a highly fluorescent, 
zinc complex of bis(thiosemicarbazone) ligand incorporating extended aromatic backbones 
which where cytotoxic against A431 cell line (Figure 1.14(a)) and IGROV cell line          
(Figure 1.14(b)) at levels comparable to cisplatin; cellular fluorescence imaging studies 
suggested that these cause cell death by disruption of mitochondria.
61 
 
 
Figure 1.14. 
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J. R. Dilworth et al. have reported the synthesis and characterization of zinc 
bis(thiosemicarbazone) complexes and the use of their intrinsic fluorescence to track their uptake 
in a range of human cancer cell types, studied by fluorescence microscopy and the cellular 
distribution.
62 
ORTEP representation of the structure of [ZnCl(ATSpyrH)] {ATSpyrH = 
diacetylbis(4–pyrrolidinyl–3–thiosemicarbazone)} is shown in Figure 1.15. 
 
Figure 1.15. 
In 2005 M. B. Ferrari have reported synthesis and characterization of cyclic α–ketoglutaric acid 
thiosemicarbazone (H3ct) and their zinc complexes, with the aim to compare the biological 
effects of these compounds with the properties of the corresponding linear forms and their 
complexes. These molecules interact with DNA and, from the comparison of the Kb values of the 
cyclic and the open chain forms, it can be observed that the cyclic form binds nucleic acid more 
strongly.
63
 The X–ray structures of ligands Me–H2ctC, Allyl–H2ctc and of complex [Zn(Me–
HctC)2(OH2)2]·2H2O (Figure 1.16) have also been determined. 
 
Figure 1.16. 
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1.2. AIM OF THE PRESENT WORK 
The aim of the present work has been to study the chemistry of variable valence transition metal 
(Ni, Cu, Mo, V & Zn) complexes with thiosemicarbazone ligand systems. All the ligand systems 
and their synthesized metal complexes are collectively summarized below: 
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1.3. THE MAIN OBJECTIVES OF THE PRESENT STUDY 
1. To develop some ONS, NNS and S donor thiosemicarbazone ligand systems, inspired by the 
paradigm of biologically and catalytically important transition metal–TSC complexes. 
2. To develop versatile variable valence transition metal (Ni, Cu, Mo, V & Zn) complexes of the 
synthesized thiosemicarbazone ligands, for use as reagent in some bio– and catalytic reactions 
and as model complex for few metalloenzymes. This work uses synthetic and analytical 
approaches to generate and study the metal complexes, relying upon current mechanistic 
understanding of their mode of action. 
3. Study of spectral, magnetic and redox behavior of these metal complexes, and solve their X–
ray structure and develop the structure–reactivity correlation. 
4. Exploration of pharmacological studies such as antimicrobial, DNA binding and cleavage, 
insulin mimetic and antiproliferative activity.  
5. Study of catalytic activities particularly oxidation of styrene and oxidation of cyclohexene 
using the synthesized metal complexes. 
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Chapter 2 
 
Mixed-ligand nickel(II) thiosemicabazone complexes: Synthesis, characterization and 
biological evaluation 
 
ABSTRACT 
___________________________________________________________________________ 
The syntheses and characterization of some new mixed-ligand nickel(II) complexes 
{[Ni(L
1
)(PPh3)] (1); [Ni(L
1
)(Py)] (2); [Ni(L
2
)(PPh3)]∙DMSO (3); [Ni(L
2
)(Imz)] (4), 
[Ni(L
3)(4‒pic)] (5) and [{Ni(L3)}2(μ‒4,4′‒byp)]∙2DMSO (6)} of the selected three 
thiosemicarbazones {4‒(p‒X‒phenyl)thiosemicarbazone of salicylaldehyde} (H2L
1‒3
) (A, 
Scheme 2.1) are described in the present chapter, differing in the inductive effect of the 
substituent X (X = F, Br and OCH3), in order to observe their influence, if any, on the redox 
potentials and biological activity of the complexes. All the synthesized ligands and the metal 
complexes are successfully characterized by elemental analysis, IR, UV‒Vis, NMR spectroscopy 
and cyclic voltammetry. Molecular structures of four mononuclear (1‒3 and 5) and one dinuclear 
(6) Ni(II) complexes have been determined by X‒ray crystallography. The complexes have been 
screened for their antibacterial activity against Escherichia coli and Bacillus. Minimum 
inhibitory concentration of these complexes indicates compound 4 as the potential lead molecule 
for drug designing.  
___________________________________________________________________________ 
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2.1. INTRODUCTION 
Nickel(II) complexes with nitrogen and sulfur donor ligands are highly interesting
1‒5
 because 
several hydrogenases and carbon monoxide dehydrogenases
6
 contain such nickel complexes as 
their active site. Thiosemicarbazones are an important class of N, S donor ligand which has 
considerable pharmacological interest due to their significant antibacterial, antiviral, antimalarial, 
antileprotic and anticancer activities.
7‒10
 Metal complexes of thiosemicarbazone ligands have 
shown variable bonding properties and structural diversity along with promising biological 
implications, and ion sensing abilities.
9,11‒17
 Among transition metals, thiosemicarbazone 
complexes of nickel(II) also show marked and diverse biological
18‒21
 as well as catalytic 
activity,
22,23
 but there are limited Ni(II) complexes reported with N1-substituted 
thiosemicarbazones.
24‒29
  
 
Thiosemicarbazones obtained by condensation of ring-substituted 4-phenyl thiosemicarbazides 
with salicylaldehyde and substituted salicylaldehydes
30–33
 form a class of versatile NS/NSO 
chelating ligands and are known to exhibit diverse biological activities.
32
 However, not only the 
bioinorganic relevance of the complexes the chemistry of transition metal complexes of the 
thiosemicarbazones are also receiving significant current attention because of the variable 
binding mode displayed by these ligands in their complexes.
34-43
 The variable mode of binding of 
thiosemicarbazone ligands and the ability of nickel to take up different coordination 
environments (such as octahedral, square-planar and tetrahedral), has encouraged us to explore 
its coordination chemistry further, and herein we report the syntheses, X‒ray structure and 
physical properties of some new mixed-ligand nickel(II) complexes of thiosemicarbazone with 
special reference to their antibacterial activity. Three thiosemicabazones 
{4‒(p‒X‒phenyl)thiosemicarbazone of salicylaldehyde} (H2L
1‒3
) have been used, differing in 
the inductive effect of the substituent X (X = F, Br and OCH3) in order to observe its influence, 
if any, on the redox potentials and biological activities of the complexes.  
32 
 
2.2. EXPERIMENTAL SECTION 
2.2.1. General methods and materials. Reagent grade solvents were dried and distilled prior to 
use. All other chemicals were reagent grade, available commercially and used as received. HPLC 
grade DMSO and CH3CN was used for spectroscopic and electrochemical studies and ethanol, 
methanol were used for synthesis of ligands and metal complexes. Commercially available 
TEAP (tetra ethyl ammonium perchlorate) was properly dried and used as a supporting 
electrolyte for recording cyclic voltammograms of the complexes. Elemental analyses were 
performed on a Vario ELcube CHNS Elemental analyzer. IR spectra were recorded on a Perkin-
Elmer Spectrum RXI spectrometer. 
1
H and 
13
C NMR spectra were recorded with a Bruker 
Ultrashield 400 MHz spectrometer using SiMe4 as an internal standard. Electronic spectra were 
recorded on a Lamda25, PerkinElmer spectrophotometer. Electrochemical data were collected 
using PAR Versastat‒II instrument driven by E‒chem software (PAR) at 298 K in a dry nitrogen 
atmosphere. Cyclic voltammetry experiments were carried out with Pt working and auxiliary 
electrodes and Ag/AgCl as the reference electrode and TEAP as the supporting electrolyte. 
2.2.2. Synthesis of ligands (H2L
1‒3
). The thiosemicabazides were prepared from distilled 
substituted aniline by a known method reported ear1ier.
44
 Schiff base ligands, 
4‒(p‒fluorophenyl)thiosemicarbazone (H2L
1
), 4‒(p‒bromophenyl)thiosemicarbazone (H2L
2
) and 
4‒(p‒methoxyphenyl)thiosemicarbazone (H2L
3
) of salicylaldehyde were prepared in 80‒90% 
yield by stirring equimolar ratio of the substituted thiosemicabazide with salicylaldehyde in 
methanol medium by standard procedures.
31
 The resulting compound was filtered, washed 
thoroughly with methanol and dried over fused CaCl2.   
H2L
1
: Yield: 85%. Anal. calc. for C14H12N3SOF: C, 58.13; H, 4.18; N, 14.52. Found: C, 58.15; 
H, 4.20; N, 14.51. Main IR peaks (KBr, cm
‒1
): 3357 s ν(O(1)–H), 3247 s ν(N(1)–H), 3028 s 
ν(N(2)–H), 1605 s ν(C=C), 1543 s, 1438 m ν(C(8)=N(3)), 750 s ν(C(7)=S(1)). 1H NMR (DMSO-
d6, 400 MHz) : 11.81 (s, 1H, –C(14)–O(1)H), 10.06 (s, 1H, –C(7)–N(1)H), 9.99 (s, 1H, –C(7)–
N(2)H), 8.48 (s, 1H, –N(3)=C(8)H), 8.11–6.81 (m, 8H, C6H4). 
13C NMR (DMSO‒d6, 100 MHz) 
: 176.52, 161.25, 158.54, 157.05, 140.52, 135.97, 135.95, 131.81, 128.54, 128.46, 127.48, 
120.70, 119.66, 116.48.   
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H2L
2
: Yield: 88%. Anal. calc. for C14H12N3SOBr: C, 48.01; H, 3.45; N, 12.00. Found: C, 48.04; 
H, 3.40; N, 12.03. Main IR peaks (KBr, cm
‒1
): 3307 s ν(O(1)–H), 3297 s ν(N(1)–H), 3098 s 
ν(N(2)–H), 1621 s ν(C=C), 1522 s, 1412 m ν(C(8)=N(3)), 752 s ν(C(7)=S(1)). 1H NMR (DMSO-
d6, 400 MHz) : 11.88 (s, 1H, –C(14)–O(1)H), 10.09 (s, 1H, –C(7)–N(1)H), 9.96 (s, 1H, –C(7)–
N(2)H), 8.49 (s, 1H, –N(3)=C(8)H), 8.09–6.82 (m, 8H, C6H4). 
13
C NMR (DMSO-d6, 100 MHz) 
: 176.07, 157.17, 140.79, 139.09, 132.04, 131.85, 131.28, 129.12, 128.09, 127.53, 120.62, 
119.63, 117.82, 116.51. 
H2L
3
: Yield: 87%. Anal. calc. for C15H15N3SO2: C, 59.78; H, 5.02; N, 13.94. Found: C, 59.75; 
H, 5.04; N, 13.91. Main IR peaks (KBr, cm
‒1
): 3325 s ν(O(1)–H), 3278 s ν(N(1)–H), 3019 s 
ν(N(2)–H), 1623 s ν(C=C), 1563 s, 1457 m ν(–C(8)=N(3)), 749 s ν(C(7)=S(1)). 1H NMR 
(DMSO-d6, 400 MHz) : 11.70 (s, 1H, –C(14)–O(1)H), 10.07 (s, 1H, –C(7)–N(1)H), 9.95 (s, 1H, 
–C(7)–N(2)H), 8.47 (s, 1H, –N(3)=C(8)H), 8.10–6.81 (m, 8H, C6H4), 3.76 (s, 3H, –C(4)–OCH3). 
13
C NMR (DMSO-d6, 100 MHz) : 176.58, 157.32, 156.99, 140.29, 139.13, 132.51, 131.69, 
131.06, 127.91, 127.53, 120.78, 119.67, 116.48, 113.69, 55.6. 
 
2.2.3. Synthesis of Ni (II) complexes (1–6) 
2.2.3.1. Synthesis of [Ni(L
1
)(PPh3)] (1). To a solution of H2L
1
 (0.289 g, 0.100 mmol) in hot 
methanol, triethylamine (0.202 g, 0.2 mmol) was added followed by solid Ni(OAc)2 salt (0.248 
g, 0.100 mmol) and triphenylphosphine (0.262 g, 0.100 mmol). The mixture was refluxed for 3 h 
and a clear reddish brown solution was obtained, which was filtered and allowed to evaporate at 
room temperature. Reddish brown colored crystals were obtained from the filtrate after 3‒4 days.  
[Ni(L
1
)(PPh3)] (1): Yield: 67%. Anal. calc. for C32H25FN3NiOPS: C, 63.18; H, 4.14; N, 6.91. 
Found: C, 63.13; H, 4.17; N, 6.87. Main IR peaks (KBr, cm
‒1
): 3215 s ν(N(1)–H), 1627 s 
ν(C=C), 1542 s, 1408 m ν(–C(8)=N(3)), 1094 s ν(P–C), 739 s ν(C(7)–S(1)). 1H NMR (DMSO-
d6, 400 MHz) : 9.45 (s, 1H, –C(7)–N(1)H), 8.66 (s,1H, –N(3)=C(8)H), 7.78–6.34 (m, 23H, 
C6H4).  
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2.2.3.2. Synthesis of [Ni(L
1
)(Py)] (2); [Ni(L
2
)(PPh3)]∙DMSO (3); [Ni(L
2
)(Imz)] (4) and 
[Ni(L
3)(4‒pic)] (5). Complexes 2‒5 were prepared following the same procedure as complex 1. 
Reddish brown crystals of complex 3, suitable for X‒ray crystallography were obtained by slow 
evaporation from DMSO. 
[Ni(L
1
)(Py)] (2): Yield: 70%. Anal. calc. for C19H15FN4NiOS: C, 53.68; H, 3.56; N, 13.18. 
Found: C, 53.65; H, 3.59; N, 13.16. Main IR peaks (KBr, cm
‒1
): 3229 s ν(N(1)–H), 1613 s 
ν(C=C), 1521 s, 1417 m ν(–C(8)=N(3)), 736 s ν(C(7)–S(1)). 1H NMR (DMSO‒d6, 400 MHz) : 
9.47 (s, 1H, –C(7)–N(1)H), 8.35 (s, 1H, –N(3)=C(8)H), 8.84–6.59 (m, 13H, C6H4).  
[Ni(L
2
)(PPh3)]∙DMSO (3): Yield: 65%. Anal. calc. for C34H31BrN3NiO2PS2: C, 54.64; H, 4.18; 
N, 5.62. Found: C, 54.69; H, 4.19; N, 5.78. Main IR peaks (KBr, cm
‒1
): 3257 s ν(N(1)–H), 1624 
s ν(C=C), 1545 s, 1425 m ν(–C(8)=N(3)), 1098 s ν(P–C), 747 s ν(C(7)–S(1)). 1H NMR 
(DMSO‒d6, 400 MHz) : 9.58 (s, 1H, –C(7)–N(1)H), 8.69 (s, 1H, –N(3)=C(8)H), 7.77–6.35 (m, 
23H, C6H4), 2.54(s, 6H, DMSO).
  
[Ni(L
2
)(Imz)] (4): Yield: 68%. Anal. calc. for C17H14BrN5NiOS: C, 42.99; H, 2.97; N, 14.74. 
Found: C, 42.95; H, 2.99; N, 14.72. Main IR peaks (KBr, cm
‒1
): 3251 s ν(N(1)–H), 1619 s 
ν(C=C), 1556 s, 1428 m ν(–C(8)=N(3)), 741 s ν(C(7)–S(1)). 1H NMR (DMSO‒d6, 400 MHz) : 
9.60 (s, 1H, –C(7)–N(1)H), 8.71 (s,1H, –N(3)=C(8)H), 7.03–6.79 (m, 12H, C6H4).  
[Ni(L
3)(4‒pic)] (5): Yield: 67%. Anal. calc. for C21H20N4NiO2S: C, 55.90; H, 4.47; N, 12.42. 
Found: C, 55.87; H, 4.43; N, 12.46. Main IR peaks (KBr, cm
‒1
): 3263 s ν(N(1)–H), 1622 s 
ν(C=C), 1542 s, 1430 m ν(–C(8)=N(3)), 739 s ν(C(7)–S(1)). 1H NMR (DMSO‒d6,  400 MHz) : 
9.23 (s, 1H, –C(7)–N(1)H), 8.19 (s, 1H, –N(3)=C(8)H), 8.68–6.57 (m, 12H, C6H4), 3.69 (s, 3H, –
C(4)–OCH3), 2.37 (s, 3H, 4‒pic‒CH3). 
 
2.2.3.3. Synthesis of [{Ni(L
3
)}2(μ‒4,4′‒byp)]∙2DMSO (6). To a solution of H2L
3
 (0.301 g, 
0.100 mmol) in hot methanol, triethylamine (0.202 g, 0.2 mmol) was added followed by solid 
Ni(OAc)2 salt (0.248 g, 0.100 mmol) and 4,4′‒bypiridine (0.078 g, 0.050 mmol). The mixture 
was refluxed for 3 h, clear reddish brown solution was obtained which was filtered and allowed 
to evaporate at room temperature. Reddish brown crystals suitable for X‒ray crystallography 
were obtained from DMSO by slow evaporation. Yield: 65%. Anal. calc. for C44H46N8Ni2O6S4: 
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C, 51.38; H, 4.51; N, 10.89. Found: C, 51.43; H, 4.50; N, 10.84. Main IR peaks (KBr, cm
‒1
): 
3268 s ν(N(1)–H), 1624 s ν(C=C), 1524 s, 1416 m ν(–C(8)=N(3)), 741 s ν(C(7)–S(1)). 1H NMR 
(DMSO‒d6, 400 MHz) : 9.25 (s, 1H, –C(7)–N(1)H), 8.27 (s, 1H, –N(3)=C(8)–H), 9.00–6.59 
(m, 12H, C6H4), 3.70 (s, 3H, –C(4)–OCH3). 
 
2.2.4. X‒ray crystallography. Single crystals of complexes were mounted on a Bruker Smart 
Apex CCD diffractometer (1 and 2), Bruker Smart Apex II diffractometer (3 and 6) and Stoe 
Mark II‒Image Plate diffracttometer (5) equipped with a graphite monochromator and a Mo K 
radiator (λ) 0.71073 Å. Crystallographic data and details of refinement are given in Table 2.1. 
Details of the classical hydrogen bonding are given in Table 2.2. The unit cell dimensions and 
intensity data were measured at 293 (2) K for 1 and 2, 100 (2) K for 3 and 6 and 173 K for 5. The 
intensity data were corrected for Lorentz, polarization and absorption effects. Absorption 
corrections were applied using SADABS
45
 and the structures were solved by direct methods 
using the program SHELXS‒9746 and refined using least squares with the SHELXL‒9746 
software program. Hydrogens were either found or placed in calculated positions and 
isotropically refined using a riding model. The non‒hydrogen atoms were refined 
anisotropically. 
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Table 2.1. Crystal and refinement data of complexes 1‒3, 5 and 6 
Compound 1 2 3 5 6 
Formula C32H25FN3NiO
PS 
C19H15FN4Ni 
OS 
C34H31BrN3Ni
O2PS2 
C21H20N4Ni 
O2S   
C44H46N8Ni2O
6S4 
M 608.29 425.12 747.33 451.18   1028.55 
Crystal system Triclinic Monoclinic Triclinic Triclinic monoclinic 
Space group P 1 P 21/c P ī P ī P 21/n 
a(Å) 7.772(11) 13.081(8) 14.536(6) 9.858(7) 9.106(4)  
b(Å) 9.098(13) 5.800(3) 14.901(7) 10.134(8) 22.964(10)  
c(Å) 11.332(16) 23.584(15) 16.450(7) 11.915(8) 11.561(5)  
 (°) 68.759(2) 90 91.83(4) 112.224(5) 90 
β (°) 82.879(2) 102.298(4) 98.69(3) 98.817(5) 111.370(10) 
γ (°) 69.544(2) 90 110.60(4) 103.001(6) 90 
V(Å3) 699.91(17) 1748.53(18) 3283.00(2) 1035.57(15) 2251.61(17)  
Z 1 4 4 2 2 
Dcalc(g.cm
-3) 1.443 1.615 1.512 1.447 1.517 
F(000) 314 872 1528 468 1068 
(Mo-K)(mm-1) 0.863 1.256 2.020 1.062 1.080 
max./min.trans. 0.991 and  
0.874 
0.987 and  
0.895 
0.927 and 
0.435 
1.000 and 
0.919  
0.963 and 
0.856 
2(max)(o) 26.00 30.5 27.71 25.63 29.51 
Reflections 
collected / 
unique 
7228/5331 
[R(int) = 
0.0176] 
26906/5357 
[R(int) = 
0.0808] 
53431/15052 
 [R(int) = 
0.0713] 
12009/3894 
R(int) =  
0.024]   
40605/5975  
[R(int) = 
0.0868] 
R1[I>2(I)] R1 = 0.0405,  
wR2 = 0.0689 
R1 = 0.0457, 
wR2 = 0.0722 
R1 = 0.0454,  
wR2 = 0.1110 
R1 =0.0239, 
wR2 = 0.0564 
R1 = 0.0413, 
 wR2 = 0.1106 
wR2[all data] R1 = 0.0474,  
wR2 = 0.0733 
R1 = 0.1269,  
wR2 = 0.0916 
R1 = 0.1019, 
 wR2 = 0.1459 
R1 =0.0239, 
wR2 = 0.0581 
R1 = 0.0753,  
wR2 = 0.1354 
S[goodness of 
fit] 
1.053 0.969 0.811 1.01 0.844 
min./max. res. 
(e.Å-3) 
0.468/-0.205 0.298/-0.398 0.546/-0.717 -0.23/0.23 0.377/-0.544 
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Table 2.2. Hydrogen bond distances (Å) and angles (
o
) for 1‒3, 5 and 6 
D‒H...A D‒H(Å) D···A(Å) H····A(Å) <D‒H····A(°) 
[Ni(L
1
)(PPh3)] (1) 
C22‒H22····S1a 0.91(4) 3.707(6) 2.92(5) 144.8(31) 
C30‒H30····F1b 0.93(1) 3.211(7) 2.50(1) 133.4(43) 
C24‒H24····O1c 0.99(5) 3.428(7) 2.57(4) 145.9(35) 
Symmetry transformations used to generate equivalent atoms: 
(a) x,y,z ; (b) x+2,+y‒1,+z+1; (c) x,+y+1,+z 
[Ni(L
1
)(Py)] (2) 
N1‒H1····S1b 0.77(3) 3.584(3) 2.84(3) 162.6(24) 
C12‒H12····F1a 0.88(3) 3.436(4) 2.60(3) 159.2(25) 
Symmetry transformations used to generate equivalent atoms: 
(a) ‒x,+y+1/2+1,‒z+1/2; (b) -x,-y-1,‒z+1 
Ni(L
2
)(PPh3)]∙DMSO (3) 
N1A‒H1A····S2a 0.88 3.769(4) 2.90 169.0 
N1A‒H1A····O2a 0.88 2.854(4) 2.01 161.5 
N1‒H1····S2Ab 0.88 3.829(4) 3.01 155.0 
N1‒H1····O2Ab 0.88 2.917(4) 2.04 171.7 
Symmetry transformations used to generate equivalent atoms: 
(a) ‒x, ‒y+1, ‒z+1; (b)‒x+1, ‒y+1, ‒z+1 
Ni(L
3
)(4-Pic)] (5) 
N1‒H1N .. N2a   0.83(2) 2.14(2)    2.962(2)    173(2) 
C20‒H20B .. S1b 0.98 2.86 3.764(2) 154 
Symmetry transformations used to generate equivalent atoms: 
(a) −x+1, −y+1, −z+1; (b) −x, −y+1, −z 
[{Ni(L
3
)}2(μ‒4,4′-byp)]∙2DMSO (6) 
N1‒H1····O3b 0.93(4) 2.839(3) 1.91(4) 178.2(33) 
N1‒H1····S2b 0.93(4) 3.807(2) 2.95(3) 153.0(29) 
C15‒H15····O3a 0.93(4) 3.308(4) 2.55(4) 138.7(34) 
C6‒H6····O3b 0.94(3) 3.359(3) 2.61(3) 136.7(26) 
C8‒H8····O1c 0.97(3) 3.563(3) 2.61(3) 165.8(24) 
C21‒H21a····O2d 0.99(3) 3.332(4) 2.39(3) 159.2(27) 
C21‒H21c····S1e 0.92(3) 3.814(3) 2.97(4) 153.9(30) 
Symmetry transformations used to generate equivalent atoms: 
(a) x, y, z ; (b) ‒x+1,-y,‒z+1; (c) x+1/2,‒y+1/2,+z+1/2; (d) x,+y,+z‒1; (e) x+1,+y,+z 
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2.2.5. Antibacterial activity. The antibacterial activity of the compounds (ligands and 
complexes) was studied against Escherichia coli (E. coli) and Bacillus by agar well diffusion 
technique. Mueller Hinton-agar (containing 1% peptone, 0.6% yeast extract, 0.5% beef extract 
and 0.5% NaCl, at pH 6.9–7.1) plates were prepared and 0.5 ‒ McFarland culture (1.5 x 108 
cells/mL) of the test organisms were swabbed onto the agar plate (as per CLSI guidelines, 2006). 
The compounds were dissolved in DMSO varying their concentration from 1000 µg/mL–1.95 
µg/mL. Nine millimetre wide wells were dug on the agar plate using a sterile cork borer. 100 
µg/mL of each compound from all dilutions were added into the wells using a micropipette. 
These plates were incubated for 24 h at 35 ± 2 °C. The growth of the test organisms was 
inhibited by diffusion of the compounds and then the inhibition zones developed on the plates 
were measured.
47,48
 The effectiveness of an antibacterial agent in sensitivity is based on the 
diameter of the zones of inhibition, which was measured to the nearest millimeter (mm). The 
standard drug Vancomycin was also tested for its antibacterial activity at the same concentration 
and under similar conditions to that of the compounds as a positive control. DMSO was used as a 
negative control under the same conditions for each organism. 
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2.3. RESULTS AND DISCUSSION 
2.3.1. Synthesis. In order to explore the possibility of forming monomeric complexes by 
splitting the sulfur bridge in the {M(L)}n type complexes, the reaction of the thiosemicarbazones 
with Ni(OAc)2 has been carried out with different monodentate ligands (Q), viz. 
triphenylphosphine (PPh3), pyridine (Py), imidazole (Imz) and 4‒picoline (4‒Pic) in refluxing 
methanol. From each of these reactions a mixed-ligand monomeric complex of type [Ni(L)(Q)] 
(Q = PPh3, Py, Imz, 4‒Pic) (1‒5) has been obtained. The mixed-ligand dinuclear dinickel(II) 
complex [{Ni(L
3
)}2(μ‒4,4′‒byp)]∙2DMSO (6) was achieved by the reaction of 
thiosemicarbazone (H2L
3
) with Ni(OAc)2 using 4,4'‒bipyridine as exo‒bidentate ligand under 
reflux condition. The synthetic methods of all the complexes are illustrated in Scheme 2.1. 
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Scheme 2.1. Schematic representation of ligands (A) and synthesis of mixed‒ligand Ni(II) 
complexes (B and C). 
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2.3.2. Structure. The observed elemental (C, H, N) analytical data of all the complexes are 
consistent with their compositions. It appears from the formulation of the complexes that the 
thiosemicarbazones are serving as tridentate ligands in them. In order to authenticate the 
coordination mode of the thiosemicarbazones in these complexes, the structure of few complexes 
have been determined by X‒ray crystallography. 
2.3.2.1. Description of X-ray structures of complexes 1‒3 and 5. The atom numbering 
schemes for these complexes are given in Figures 2.1‒2.4 respectively with the relevant bond 
distances and angles collected in Table 2.3. The structures show that the thiosemicarbazone 
ligand (L
2‒
) is coordinated to nickel in the expected tridentate fashion (B, Scheme 2.1), forming 
a six- and a five-membered chelate ring with O(1)–Ni(1)–N(3) and N(3)–Ni(1)–S(1) bite angles 
of 94.4 (2)° and 87.0(1)° (1), 95.3(8)° and 87.3(6)° (2), 95.2(1)° and 87.1(1)° (3) and 96.16(6)° 
and 87.49(4)° (5) respectively. The co-ligand {Q = triphenylphosphine (1 and 3), pyridine (2) 
and 4-pic (5)} is coordinated to the metal center, and is trans to the nitrogen atom. The rather 
large Ni(1)–P(1)/N(4) distance are [2.224(1) Å (1), 1.912(2) Å (2), 2.205(2) Å (3) and 1.921(16) 
Å(5)] revealed that the triphenylphosphine, pyridine or picoline moiety are also rather weakly 
coordinated to the Ni-centre.
49
 The nickel center in all compounds is thus nested in a NOSN or 
NOSP core, which is slightly distorted from an ideal square-planar geometry, as reflected in the 
bond parameters around the metal center. The Ni–N, Ni–O, Ni–P/N (co-ligand) and Ni–S 
distances are normal, as observed in other structurally characterized complexes of nickel 
containing these bonds.
22,27,28
 Structural characterization of complex 4 by X‒ray crystallography 
has not been possible, as its single crystals could not be grown. As all five complexes have been 
synthesized similarly and display similar properties, the [Ni(L
2
)(Q)] (Q = Imz) complex is 
assumed to have the similar structure as 1‒3 and 5. 
All the molecules are found to show either inter (1, 2 and 5) or intra (1 and 3) molecular 
hydrogen bonding.  Complex 1 is found to show both inter and intra molecular hydrogen 
bonding. [Ni(L
1
)(PPh3)] (1) molecules form a polymeric unit via a pair of hydrogen bonds 
between the phenolic oxygen O(1) of one molecule with the phenyl (PPh3) proton C(24)‒H of 
other moiety (Figure 2.5) and between the fluorine F(1) of one molecule with the phenyl (PPh3) 
proton C(30)‒H of other moiety (Figure 2.6) forming intermolecular hydrogen bonding. Another 
hydrogen bonding between thione sulfur S(1) and phenyl (PPh3) hydrogen, C(22)‒H, is also 
observed constituting intramolecular hydrogen bond for 1. The complex 2 is found to show only 
41 
 
inter molecular hydrogen bonding. Two [Ni(L
1
)(Py)] (2) molecules form a dimeric unit via a pair 
of reciprocal hydrogen bonds between the N(1)‒H  proton of one molecule with the thione sulfur 
S(1) of other moiety. The complex 2 is also found to show a polymeric one-dimensional zig‒zag 
chain (Figure 2.7) through inter molecular hydrogen bonding between the fluorine F(1) of one 
molecule with the phenyl proton C(12)‒H of other moiety. For complex 3 there is only one 
possible hydrogen bonding found between the N(1)‒H proton of the ligand and the O(2) and S(2) 
atom of solvent (DMSO) molecule. The complex 5 is found to show only inter molecular 
hydrogen bonding (Figure 2.8). In the crystal, [Ni(L
3)(4‒Pic)] (5) molecules are linked to form 
inversion dimmers via a pair of N‒H...N hydrogen bonds between the N(1)‒H proton of one 
molecule with the imine nitrogen N(2) of other molecule. The consequence of this is that to 
minimize steric hindrance the ligand is no longer relatively planar, with the methoxybenzene ring 
[(C(1)–C(6)] being inclined to the mean plane of the remaining hetero atoms 
[N(1)‒N(3)/S(1)/O(1)/C(7)‒C(14); maximum deviation 0.056(2) Å for atom C(7)] of the ligand 
by 76.84(8)°. The same dihedral angle in compounds 1‒3 varies between 15.74(10) to 
25.70(17)°. Complex 5 is also found to show inter molecular C‒H...S hydrogen bonding between 
the thione sulphur S(1) of one molecule with a methoxy proton C(20)‒H of a neighboring 
molecule. 
2.3.2.2. Description of the X-ray structure of complex 6. The molecular structure and atom-
labeling scheme for complex 6 are shown in Figure 2.9. Selected bond distances and angles are 
collected in Table 2.3. Complex, 6 crystallizes in the monoclinic space group P 21/n with the 
molecule sitting across a crystallographic center of inversion. Each half of the complex 
[{Ni(L
3
)}2(μ‒4,4′‒byp)]∙2DMSO closely resembles the structure of 2, which essentially consists 
of the same donor atoms attached to its Ni(II) center in the same geometric pattern with closely 
matching dimensions. The only significant difference observed in the case of 6 is that the 
Ni(1)‒N(4) bond involving the nickel acceptor center and the N(4) aromatic nitrogen atom of 
4,4'-byp is longer (1.920(2) Å) than the corresponding Ni(1)‒N(4) (pyridine) bonds in 2, which 
is 1.912(2) Å. This lengthening indicates comparatively weaker binding of 4,4'‒byp nitrogen 
N(4) to the Ni(II) center. This is quite usual for this type of bridging systems.
50,51
 The two 
pyridine rings of 4,4'‒byp lie in the same plane and are perpendicular to the equatorial planes of 
the two halves of the two [Ni(L)] units. The chelate bite angles for the five- and six-membered 
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rings have values within the expected ranges [S(1)–Ni(1)–N(3), 87.1(7); O(1)–Ni(1)–N(3), 
96.1(9)].52 Complex 6 is found to show both inter and intra molecular hydrogen bonding. 
 
Table 2.3. Selected geometric parameters (Å, º) for [Ni(L
1
)(PPh3)] (1), [Ni(L
1
)(Py)] (2), 
[Ni(L
2
)(PPh3)]∙DMSO (3), Ni(L
3
)(4-Pic)] (5) and [{Ni(L
3
)}2(μ‒4,4′‒byp)]∙2DMSO (6) 
 
 Complex (1) Complex (2) Complex (3) Complex (5) Complex (6) 
 
 
 
Bond Distances 
 
Ni(1)‒O(1) 1.848(4) 1.854(2) 1.838(3) 1.846(11) 1.851(2) 
Ni(1)‒N(3) 1.882(3) 1.849(2) 1.877(3) 1.858(15) 1.856(2) 
Ni(1)‒S(1) 2.137(1) 2.154(8) 2.146(1) 2.148(5) 2.139(8) 
Ni(1)‒P(1) 2.224(1) — 2.205(2) — — 
Ni(1)‒ N(4) — 1.912(2) — 1.921(16) 1.920(2) 
 
 
 
Bond Angles 
 
O(1)‒Ni(1)‒N(3) 94.4(2) 95.3(8) 95.2(1) 96.16(6) 96.1(9) 
O(1)‒Ni(1)‒S(1) 178.1(1) 176.1(6) 177.3(9) 176.00(5) 175.6(6) 
N(3)‒Ni(1)‒S(1) 87.0(1) 87.3(6) 87.1(1) 87.49(4) 87.1(7) 
O(1)‒Ni(1)‒P(1) 88.0(1) — 86.5(9) — — 
O(1)‒Ni(1)‒N(4) — 85.8(8) — 87.18(6) 87.5(9) 
N(3)‒Ni(1)‒P(1) 177.5(1) — 173.1(1) — — 
N(3)‒Ni(1)‒N(4) — 177.9(9) — 176.60(6) 176.3(1) 
S(1)‒Ni(1)‒P(1) 90.5(5) — 91.5(5) — — 
N(4)‒Ni(1)‒S(1) — 91.7(6) — 89.20(4) 89.4(7) 
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Figure 2.1. ORTEP diagram of [Ni(L
1
)(PPh3)] (1) with atom labeling scheme. 
 
 
 
Figure 2.2. ORTEP diagram of [Ni(L
1
)(Py)] (2) with atom labeling scheme. 
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Figure 2.3. ORTEP diagram of [Ni(L
2
)(PPh3)]∙DMSO (3) with atom labeling scheme. 
 
 
 
Figure 2.4. ORTEP diagram of [Ni(L
3
)(4‒Pic)] (5) with atom labeling scheme 
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Figure 2.5. Inter molecular hydrogen bonding diagram of complex 1. 
 
 
 
 
 
Figure 2.6. One-dimensional zig‒zag chain through inter molecular hydrogen bonding in 1. 
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Figure 2.7. One-dimensional zig-zag chain through inter molecular hydrogen bonding in 2. 
 
 
 
Figure 2.8. Hydrogen bonding diagram of complex 5. 
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Figure 2.9. ORTEP diagram of [{Ni(L
3
)}2(μ‒4,4′‒byp)]∙2DMSO (6) with atom labeling scheme. 
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2.3.3. Spectral characteristics  
2.3.3.1. IR spectroscopy. The infrared spectra of all the complexes are mostly similar. The 
ligands exhibit, bands due to ν(–C(7)N(1)–H), ν(–C(7)N(2)–H) and ν(–C(14)O(1)–H) moieties 
in 3357–2994 cm-1 region, however the complexes do not exhibit, ν(–C(7)N(2)–H) as well as the 
ν(–C(14)O(1)–H) bands. Thus it reveals that the ligands coordinate to the metal centre in the 
anionic forms. The sharp band in the range, 752–749 cm-1 due to ν(C(7)–S(1)) stretching in the 
ligand is lowered by 10‒15 cm‒1, indicating participation of the thione sulfur in coordination.53,54 
The characteristic ν(P–C) bands at 1094 and 1098 cm‒1 in complexes 1 and 3 respectively 
attribute to the presence of PPh3.
27
 The representative IR Spectra of complex [Ni(L
1
)(PPh3)] (1) 
is shown in Figure 2.10. 
 
Figure 2.10. FTIR spectra of [Ni(L
1
)(PPh3)] (1). 
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2.3.3.2. UV spectroscopy. The electronic spectra of the complexes (Table 2.4) were recorded 
using DMSO solutions. The main features of all the spectra are quite similar. Three strong 
absorptions are observed in the wavelength range 430–220 nm. The lower energy absorptions at 
around 404–428 nm are ascribable to the ligand‒to‒metal charge transfer transitions whereas the 
higher energy absorptions are likely to be due to ligand centered transitions.
55
 The representative 
electronic absorption spectra of [Ni(L
1
)(Py)] (2) is shown in Figure 2.11.
 
 
Table 2.4. Electronic spectral
[a]
 data for the studied complexes 
Complex                                                                      λmax/nm (ε/dm
3
 mol
_1
 cm
_1
) 
 
[Ni(L
1
)(PPh3)] (1)                                                      416 (7300), 372 (14100), 269 (22700) 
[Ni(L
1
)(Py)] (2)                                                         420 (8400), 371 (13400), 262 (23300) 
[Ni(L
2
)(PPh3)]∙DMSO (3)                                         412 (5500), 368 (13510), 264 (19654) 
[Ni(L
2
)(Imz)] (4)                                               422 (7600), 354 (13650), 256 (18968) 
[Ni(L
3
)(4‒Pic)] (5)                                               428 (8500), 335 (13480), 292 (20843) 
[{Ni(L
3
)}2(μ‒4,4′‒byp)]∙2DMSO (6)                       404 (6700), 357 (13780), 280 (22156) 
 
[a] 
In DMSO 
 
 
Figure 2.11. Electronic absorption spectra of [Ni(L
1
)(Py)] (2). 
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2.3.3.3. NMR spectroscopy. The 
1
H NMR spectral data of the free ligands and its corresponding 
nickel(II) complexes (1‒6) were recorded using DMSO-d6. The spectrum of the free ligands 
exhibit two close but separate singlets in the range 11.88–9.95 ppm due to OH(–C(14)–O(1)H) 
and NH (–C(7)–N(2)H) groups respectively which are absent in the spectra of complexes 
indicating coordination of these groups to the metal center. Signals for aromatic protons are 
found as multiplets in the 9.00–6.34 ppm range.56 Detailed NMR data has been included in the 
experimental section.
 
The representative 
1
H NMR spectra of [Ni(L
1
)(PPh3)] (1) in DMSO‒d6 is 
shown in Figure 2.12. 
 
 
Figure 2.12. 
1
H NMR spectra of [Ni(L
1
)(PPh3)] (1) in DMSO‒d6. 
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2.3.4. Electrochemical properties. Electrochemical properties of the complexes (1‒6) have 
been studied by cyclic voltammetry in acetonitrile solution (0.1 M TEAP). Voltammetric data 
are given in Table 2.5, and a selected representative voltammogram of [Ni(L
2
)(PPh3)]∙DMSO 
(3) is shown in Figure 2.13. All the mononuclear complexes (1‒5) show one irreversible 
oxidative response
57
 on the positive side of Ag/AgCl and two irreversible reductive responses
57
 
on the negative side. The two waves on the negative side of Ag/AgCl at Epa values within the 
potential window ‒0.886 to ‒1.093 V and ‒1.681 to ‒1.793 V, are assigned to the reduction of 
the central metal Ni(II)/Ni(I) and ligand respectively. The wave on the positive side of Ag/AgCl 
at Epa values within the potential window 0.894 to 1.029V is assigned to the oxidation of the 
metal Ni(II)/Ni(III). The dinuclear complex 6 exhibits three successive irreversible one-electron 
reductions within the potential window -1.096 to -1.251 V versus Ag/AgCl in acetonitrile which 
are assigned to Ni
II–NiII/NiI–NiII and NiI–NiII/NiI–NiI processes and the ligand-centered 
reduction, respectively.
51
 The dinickel(II) also shows two irreversible oxidative response
58
 on the 
positive side of Ag/AgCl within the potential window 0.674 to 0.980 V, are assigned to the 
oxidation of the metal Ni(II)/Ni(III). 
The potentials of both Ni(II)‒Ni(III) oxidation and Ni(II)‒Ni(I) reduction in the complexes has 
been found to be dependent to the nature of the substituent X in the phenyl fragment of                                               
4‒X‒phenylthiosemicarbazone, this reflects the effect of the electronic nature of the substituents. 
The potential increases with increasing electron-withdrawing character of the substituent X. Both 
the reduction and oxidation of the metal centre occurs at the highest potential for the most 
electron withdrawing substituent (X = F, complexes 1 & 2) while for the most electron releasing 
substituent (X = OMe, complexes 5 & 6) it occurs at the lowest potential.
59‒61 
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Table 2.5. Cyclic voltammetric
[a]
 results for nickel(II) complexes at 298 K 
  
Complex                                                                   Potentials (V) versus Ag/AgCl 
                                                                 
 
M(II)/M(III) M(II)/M(I) Ligand‒centered 
reduction 
[Ni(L
1
)(PPh3)] (1) 1.023 ‒0.984 ‒1.684 
[Ni(L
1
)(Py)] (2) 1.029 ‒0.886 ‒1.681 
[Ni(L
2
)(PPh3)]∙DMSO (3) 0.998 ‒1.012 ‒1.774 
[Ni(L
2
)(Imz)] (4) 0.921 ‒1.008 ‒1.781 
[Ni(L
3
)(4‒Pic)] (5) 0.894 ‒1.093 ‒1.793 
[{Ni(L
3
)}2(μ‒4,4′‒byp)]∙2DMSO (6) 0.674, 0.980 ‒1.096, ‒1.251 ‒1.803 
 [a]
 Solvent: CH3CN; working electrode: platinum; auxiliary electrode: platinum; reference 
electrode: Ag/AgCl; supporting electrolyte: 0.1 M TEAP; scan rate: 100 mV/s.  
 
 
 
Figure 2.13. Cyclic voltammogram of [Ni(L
2
)(PPh3)]∙DMSO (3). 
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2.3.5. Antimicrobial activity. In the present study, the synthesized compounds (1‒6) showed 
potential antibacterial activity against the pathogens tested (E. coli and  Bacillus) by agar well-
diffusion method and in some cases they showed promising results by giving the MIC value 
lesser than the standard drug examined. The results (Table 2.6, Figure 2.14) also indicate that 
the corresponding nickel(II) complexes showed much better antibacterial activity with respect to 
the individual ligand against the same microorganism under identical experimental conditions 
which is in agreement with reported results.
47,48,62‒65
 A possible explanation is that, by 
coordination, the polarity of the ligand and the central metal ion are reduced through the charge 
equilibration, which favors permeation of the complexes through the lipid layer of the bacterial 
cell membrane.
 47,48,62‒65
 
From the zone of inhibition, it is observed that the complex 4 showed most promising results as 
compared to the other compounds of this study and the difference in value may be attributed to 
the nature of compounds synthesized with imidazole as co‒ligands.66,67. The antibacterial activity 
of a similar type of oxo‒metal complexes has also been reported 68, 69 recently using the agar well 
diffusion technique against E. coli, Shigella, Pseudomonas, Salmonella, Staphylococcus and 
Bacillus, and the present results are in accordance with the reported values. However, the 
difference in value may be attributed to the nature of compounds synthesized with different 
ligands. 
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Table 2.6. Minimum inhibitory concentration (MIC) value in µg/mL of the Schiff base 
ligand (H2L
1‒3
), nickel(II) complexes and standard drugs against pathogenic strains 
 E.coli Bacillus 
H2L
1
 500 250 
[Ni(L
1
)(PPh3)] (1) 125 125 
[Ni(L
1
)(Py)] (2) 62.5 125 
H2L
2
 125 250 
[Ni(L
2
)(PPh3)]∙DMSO (3) 31.2 125 
[Ni(L
2
)(Imz)] (4) 15.6 15.6 
H2L
3
 125 250 
[Ni(L
3
)(4-Pic)] (5) 31.2 31.2 
[{Ni(L
3
)}2(μ-4,4′-byp)]∙2DMSO (6) 62.5 125 
Vancomycin 30 30 
 
 
Figure 2.14. Minimum inhibitory concentration (MIC) of the Schiff base ligand (H2L
1‒3
), their 
corresponding nickel(II) complexes (1‒6) and standard drugs against pathogenic strains. 
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2.4. CONCLUSION 
The study of 6 new Ni(II) complexes of 4‒(p‒X‒phenyl)thiosemicarbazone of salicylaldehyde 
reported in this chapter reveals that the structural parameters (e.g., Ni–N and Ni–P bond 
distances) and the redox potentials of these complexes can be fine-tuned by changing the 
substitution in the 4‒aryl (X) part. The complexes have been screened for their antibacterial 
activity against E. coli and Bacillus. The minimum inhibitory concentration of these complexes 
and antibacterial activity indicates compound 4 is the potential lead molecule for drug designing. 
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Chapter 3 
 
Synthesis, X-ray structure and in vitro cytotoxicity studies of Cu(I/II) complexes of 
thiosemicarbazone: Special emphasis on their interactions with DNA 
ABSTRACT 
___________________________________________________________________________ 
4–(p–X–phenyl)thiosemicarbazone of napthaldehyde {where, X = Cl (HL1) and X = Br (HL2)}, 
thiosemicarbazone of quinoline–2–carbaldehyde (HL3) and 4–(p–
fluorophenyl)thiosemicarbazone of salicylaldehyde (H2L
4
) and their copper(I), 
{[Cu(HL
1
)(PPh3)2Br]·CH3CN (1) and [Cu(HL
2
)(PPh3)2Cl]·DMSO (2)} and copper(II), 
{[(Cu2L
3
2Cl)2(–Cl)2]·2H2O (3) and [Cu(L
4
)(Py)] (4)} complexes are reported herein. The 
synthesized ligands and their copper complexes were successfully characterized by elemental 
analysis, cyclic voltammetry, NMR, ESI–MS, IR and UV–Vis spectroscopy. Molecular 
structures of all the Cu(I) and Cu(II) complexes have been determined by X–ray crystallography. 
All the complexes (1–4) were tested for their ability to exhibit DNA-binding and -cleavage 
activity. The complexes effectively interact with CT–DNA possibly by groove binding mode, 
with binding constants ranging from 10
4 −105 M–1. Among the complexes, 3 show highest 
chemical (60%) as well as photo-induced (80%) DNA cleavage activity against pUC19 DNA. 
Finally, the in vitro antiproliferative activity of all the complexes was assayed against the HeLa 
cell line. Some of the complexes have proved to be as active as the clinical referred drugs, and 
the greater potency of 3 may be correlated with its aqueous solubility and the presence of 
quinonoidal group in the thiosemicarbazone ligand coordinated to the metal.  
___________________________________________________________________________ 
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3.1. INTRODUCTION 
Cisplatin (cis−diamminedichloroplatinum(II)) is a well-known metal based drug for cancer; 
despite its wide application as a chemotherapeutic agent, cisplatin exhibits severe side effects, 
such as nausea, kidney and liver failure, typical of heavy metal toxicity.
1–5
 Therefore endeavors 
are constantly made to replace it with suitable alternatives; hence various transition metal 
complexes have been synthesized and tried for their anticancer properties. 
 
Metal complexes which efficiently bind and cleave DNA under physiological conditions are 
considered as potential to be used as therapeutic agents for medicinal applications and for 
genomic research.
6–9
 Depending on the exact nature of the metal and ligand, the complexes can 
bind with nucleic acid covalently or non-covalently.
10,11
 Non-covalent interactions between 
transition-metal complexes and DNA can occur by intercalation, groove binding, or external 
electrostatic binding. Therefore, the study on the interaction of the transition metal complexes 
with DNA is of great significance for the design of new drugs and their application. 
Among the transition metals, the coordination chemistry of the copper attracts increasing interest 
because of the use of many copper complexes as models for biological functions, such as amine 
oxidases,
12
 catechol oxidase,
13
 nitrite reductase,
14
 superoxide dismutase
15
 and tyrosinase.
16
 
Copper complexes have been extensively utilized in metal ion mediated DNA cleavage through 
the hydrogen ion abstraction by activated oxygen species.
17
 In the recent years, a large number of 
biocompatible Cu(II) complexes, have been investigated for their anticancer properties.
18
 
Additionally, thiosemicarbazones (TSCs) are a class of Schiff bases which are considered as one 
of the most important scaffolds and are embedded in many biologically active compounds.
19
 
Brockman et al. first reported that 2-formylpyridine TSC possesses antileukemic activity in 
mice.
20 
Following this report, various aliphatic, aromatic, and heteroaromatic carbaldehyde TSCs 
were synthesized and evaluated for their antitumor activity against a wide spectrum of 
transplanted murine neoplasms.
21–25
 The lists of TSC derivatives have been found to exhibit 
intense anticancer activities are shown in Chart 3.1.
18b,26 
Again, the transition metal complexes 
with TSCs as ligands have raised interest amongst many researchers, and they continue to be the 
subject of many studies, especially as anticancer chemotherapeutic
27–29
 and as DNA–binding and 
cleaving agents.
18b,30
 TSC complexes have also demonstrated significant activity as antitumor, 
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antiviral, antimicrobial, anti–amoebic and anti–inflammatory agents.31–33Many Cu complexes of 
TSCs have demonstrated efficient antitumor potential.
18b,18c,26a,26b,34–38
 Although the chemistry of 
Cu(II) TSC complexes is well developed,
30g,39–41
 relatively less information is available for Cu(I) 
complexes,
42–46
 particularly related to their pharmacological properties. 
Again, while many TSC complexes exhibit good biological activities, their water solubility is 
still unsatisfactory, which may restrict their application. Hence, it seemed of interest to 
synthesize some new water–soluble transition metal complexes of TSCs which may have 
significant pharmacological effects.  
Considering these facts and as a continuation of ongoing research our group on the study of 
pharmacological properties
47 
of transition metal complexes,
 
in this chapter, two new Cu(I) 
complexes {[Cu(HL
1
)(PPh3)2Br]·CH3CN (1) and [Cu(HL
2
)(PPh3)2Cl]·DMSO (2)}, a novel 
tetranuclear copper(II) complex [(Cu2L
3
2Cl)2(–Cl)2]·2H2O (3) and a new Cu(II) monomeric 
complex [Cu(L
4
)(Py)] (4) were synthesized and fully characterized. The interaction of these 
complexes with calf−thymus DNA (CT–DNA) utilizing UV–Vis absorption titration, 
competitive DNA binding fluorescence experiments, circular dichroism and thermal denaturation 
studies were studied. Their chemical as well as photo-induced cleavage activity with pUC19 
supercoiled plasmid DNA were investigated. Furthermore, the cytotoxicity of the complexes 
against the HeLa cell line was surveyed by the MTT assay. 
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Chart 3.1. Lists of TSC derivatives exhibiting intense anticancer activities. 
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3.2. EXPERIMENTAL SECTION 
3.2.1. General methods and materials. All chemicals were purchased from commercial sources 
and used without further purification. Reagent grade solvents were dried and distilled prior to 
use. The thiosemicabazides were prepared from distilled substituted aniline by a known method 
reported ear1ier.
48
 The ligands 4‒(p‒X‒phenyl)thiosemicarbazone of napthaldehyde {where X = 
Cl (HL
1
) and X = Br (HL
2
)}, thiosemicarbazone of quinoline–2–carbaldehyde, (HL3) and 4–(p–
fluorophenyl)thiosemicarbazone of salicylaldehyde (H2L
4
) were prepared by reported 
methods.
47c,49
 MTT (3‒[4,5‒dimethylthiazol‒2‒yl]‒2,5‒diphenyl tetrazolium) and DAPI 
(4′,6‒diamidino‒2‒phenylindole dihydrochloride) were purchased from Sigma Aldrich (USA). 
Minimal essential medium (MEM) was purchased from Gibco, India. The supercoiled (SC) 
pUC19 DNA was purified from E. coli cells with the aid of GeneJET Plasmid Isolation Kit 
(Thermo Scientific, USA). Calf thymus (CT) DNA was purchased from SRL (India) 
(biochemistry grade). Elemental analyses were performed on a Vario ELcube CHNS Elemental 
analyzer. IR spectra were recorded on a Perkin–Elmer Spectrum RXI spectrometer. 1H, 13C and 
31
P NMR spectra were recorded with a Bruker Ultrashield 400 MHz spectrometer using SiMe4 as 
an internal standard. Electronic spectra were recorded on a Lamda25, Perkin-Elmer 
spectrophotometer. Mass spectra were obtained on a SQ–300 MS instrument operating in ESI 
mode. Electrochemical data were collected using PAR electrochemical analyzer and a PC-
controlled potentiostat/galvanostat (PAR 273A) at 298 K in a dry nitrogen atmosphere. Cyclic 
voltammetry experiments were carried out with Pt working and auxiliary electrodes and 
Ag/AgCl as reference electrode and TEAP as supporting electrolyte. Commercially available 
TEAP (tetra ethyl ammonium perchlorate) was properly dried and used as a supporting 
electrolyte for recording cyclic voltammograms of the complexes. 
 
3.2.2. Synthesis of complexes {[Cu(HL
1
)(PPh3)2Br]·CH3CN (1) and 
[Cu(HL
2
)(PPh3)2Cl]·DMSO (2)}. Cu(I)X (X = Br/Cl) (1.0 mmol) was added to a solution of the 
ligand HL
1–2
 (1.0 mmol) in 20 mL of CH3CN, the contents were refluxed for 1 h, followed by the 
addition of PPh3 (1.0 mmol) and continued refluxing for another 1 h. The resulting yellow 
solution was filtered and slow evaporation of the filtrate over 4–5 days produced yellow 
crystalline product. Crystals suitable for X‒ray analysis were isolated for complex 1. X‒ray 
quality crystals of complex 2 were obtained by recrystallizing in DMSO. 
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[Cu(HL
1
)(PPh3)2Br]·CH3CN (1): Yield: 67%. Anal. calc. for C56H47BrClCuN4P2S: C, 64.12; 
H, 4.52; N, 5.34. Found: C, 64.13; H, 4.54; N, 5.38. Main IR peaks (KBr, cm
‒1
): 3285 m ν(N(1)–
H), 3049 m ν(N(2)–H), 2901 m ν(C(8)–H), 1632 s ν(C=C), 1547 s ν(–C(8)=N(3)), 1096 s ν(P–
CPh), 770 s ν(C(7)=S).
 1
H NMR (DMSO‒d6, 400 MHz) : 12.03 (s, 1H, –C(7)–N(1)H), 10.25 (s, 
1H, –C(7)–N(2)H), 9.094 (s, 1H, –N(3)=C(8)H), 8.42–7.27 (m, 26H, Ph + PPh3). 
13
C NMR 
(DMSO‒d6, 100 MHz) : 175.39 (C(7), C–S), 138.6 (C(8), N=CH), 136.72, 136.32, 135.87, 
135.23, 134.85, 134.43,  133.81, 133.12, 132.83, 132.25, 131.91, 131.33, 130.78, 130.26, 130.02, 
129.83 (16C, C6H6), 128.96, 128.47, 127.80 (PPh3). 
31
P NMR (DMSO‒d6, 162 MHz) δ: 46.26 
and 44.79 (2s, 2PPh3). ESI MS (CH3OH): m/z 1047.74 (100%, [M ‒ H]
+
); m/z 1071.95 (30%, [M 
+ Na]
+
); m/z 1087.69 (65%, [M + K]
+
). 
 
[Cu(HL
2
)(PPh3)2Cl]·DMSO (2): Yield: 67%. Anal. calc. for C56H50BrClCuN3OP2S2: C, 61.93; 
H, 4.64; N, 3.87. Found: C, 61.90; H, 4.67; N, 3.88. Main IR peaks (KBr, cm
‒1
): 3284 m ν(N(1)–
H), 3047 m ν(N(2)–H), 2908 m ν(C(8)–H), 1627 s ν(C=C), 1551 s ν(–C(8)=N(3)), 1090 s ν(P–
CPh), 768 s ν(C(7)=S). 
1
H NMR (DMSO–d6, 400 MHz) : 12.47 (s, 1H, –C(7)–N(1)H), 10.29 (s, 
1H, –C(7)–N(2)H), 9.09 (s, 1H, –N(3)=C(8)H), 8.07–7.25 (m, 26H, Ph + PPh3), 2.53 (s, 6H, 
DMSO). 
13
C NMR (DMSO‒d6,100 MHz) :178.18 (C(7), C–S), 140.51 (C(8), N=CH), 137.82, 
137.12, 136.87, 135.73, 134.95, 134.41,  133.85, 133.19, 132.79, 132.41, 131.86, 131.23, 130.96, 
130.26, 130.12, 129.92 (16C, C6H6), 129.12, 128.87, 128.17 (PPh3). 
31
P NMR (DMSO‒d6, 162 
MHz) δ: 46.85 and 44.72 (2s, 2PPh3). ESI MS (CH3OH): m/z 1086.70 (12%, [M + H]
+
); m/z 
1051.92 (20%, [M ‒ Cl]). 
 
3.2.3. Synthesis of complex [(Cu2L
3
2Cl)2(–Cl)2]·2H2O (3). CuCl2·2H2O (1.0 mmol) was 
added to a solution of ligand, HL
3
 (1.0 mmol) in 20 mL of hot methanol and the mixture was 
refluxed for 2 h. The resulting dark green solution was filtered and slow evaporation of the 
filtrate over 4–5 days produced deep green crystals suitable for X‒ray analysis.  
 
[(Cu2L
3
2Cl)2(–Cl)2]·2H2O: Yield: 58%. Anal. calc. for C44H40Cl4Cu4N16S4O2: C, 39.17; H, 
2.99; N, 16.61. Found: C, 39.19; H, 2.97; N, 16.63. Main IR peaks (KBr, cm
‒1
): 3228 m ν(–
N(1)–H2), 3047 m ν(C(2)–H), 1635 s ν(C=C), 1557 s, ν(–C(2)=N(3)) 752 s ν(C(1)–S). ESI MS 
(CH3OH): m/z 1318.80 (68%, [(M ‒ 2H2O) + 5H]
+
); m/z 1352.55 (100% [(M + 3H]
+
). 
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3.2.4. Synthesis of complex [Cu(L
4
)(Py)] (4). CuCl2·2H2O (1.0 mmol) was added to a solution 
of H2L
4
 (1.0 mmol) in 20 ml of hot methanol followed by the addition of pyridine (1.0 mmol). 
The mixture was refluxed for 3 h and a clear bluish green solution was obtained, which was 
filtered and slow evaporation of the filtrate over 3–4 days produced bluish green crystals suitable 
for X–ray analysis. 
 
[Cu(L
4
)(Py)]: Yield: 67%. Anal. calc. for C19H15CuFN4OS: C, 53.08; H, 3.52; N, 13.03. Found: 
C, 53.11; H, 3.56; N, 13.07. Main IR peaks (KBr, cm
‒1
): 3224 s ν(N(1)–H), 2356 m ν(C(8)–H), 
1602 s ν(C=C), 1531 s ν(–C(8)=N(3)), 748 s ν(C(7)–S(1)). ESI MS (CH3OH): m/z 430.07 
(100%, [M]
+
); m/z 431.72 (50%, [M + H]
+
); m/z 351.14 (46%, [M – Py]+). 
 
3.2.5. X‒ray crystallography. Single crystals of complexes were mounted on Stoe IPDS 2 
diffractometer equipped with an Oxford Cryosystem open flow cryostat. (1 & 2) & on a Bruker 
Smart Apex CCD diffractometer (3 & 4), equipped with a graphite monochromator and a Mo K 
radiator (λ) 0.71073 Å. Crystallographic data and details of refinement of 1–4 are given in Table 
3.1. The unit cell dimensions and intensity data were measured at 200(2) K for 1 & 2, 273(2) K 
for 3 & 296(2) for 4. Absorption correction was partially integrated in the data reduction 
procedure for crystals of 1 & 2.
50
 The intensity data were corrected for Lorentz, polarization and 
absorption effects. Absorption corrections were applied using SADABS
51
 and the structures were 
solved by direct methods using the program SHELXS−9752 and refined using least squares with 
the SHELXL−9752 software program. Hydrogens were either found or placed in calculated 
positions and isotropically refined using a riding model. The non-hydrogen atoms were refined 
anisotropically. 
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Table 3.1. Crystal and refinement data of complexes 1–4 
Compound 1 2 3 4 
Formula C56H47BrClCuN
4P2S 
C56H50BrClCu
N3OP2S2 
C44H40Cl4Cu4 
N16S4O2 
C19H15CuFN4 
OS 
M 1048.88 1085.95 1349.12 429.95 
Crystal system Triclinic Triclinic Triclinic Monoclinic 
Space group P ī P ī P ī P 21/c 
a(Å) 9.498(4) 9.660(5) 8.947(15) 13.304(5) 
b(Å) 13.122(5) 13.154(6) 9.813(16) 5.839(2) 
c(Å) 20.658(9) 20.341(10) 14.928(2) 23.187(9) 
 (°) 100.185(3) 99.305(4) 85.086(3) 90 
β (°) 95.359(3) 94.696(4) 72.973(3) 102.115(2) 
γ (°) 96.502(3) 93.570(4) 80.782(3) 90 
V(Å
3
) 2500.96(18) 2534.7(2) 1236.0(4) 1761.22(11) 
Z 2 2 1 4 
Dcalc(Mg.cm
-3
) 1.393 1.423 1.813 1.621 
F(000) 1076 1116 680 876 
(Mo-K)(mm-1) 1.436 1.460 2.142 1.386 
max./min.trans. 0.9460 and 
0.8576 
0.8921 and 
0.7026 
0.9873 and 
0.8343 
0.9728 and 
0.7787 
2(max)(o) 25.00 25.00 21.99 30.5 
Reflections collected / 
unique 
48158/8790 
[R(int) =  
0.0383] 
48925/8938 
[R(int) =  
0.0576] 
8969/4328 
[R(int) =  
0.0406] 
33365/5407  
[R(int) =  
0.0410] 
R1[I>2(I)] R1 = 0.0301, 
wR2 = 0.0788 
R1 = 0.0477, 
wR2 = 0.1269 
R1 = 0.0743, 
wR2 = 0.1738 
R1 = 0.0345, 
wR2 = 0.0796 
wR2[all data] R1 = 0.0353, 
wR2 = 0.0814 
R1 = 0.0754, 
wR2 = 0.1400 
R1 = 0.1261, 
wR2 = 0.1963 
R1 = 0.0581, 
wR2 = 0.0885 
S[goodness of fit] 1.040 1.034 1.018 1.015 
min./max. res. (e.Å
-3
) 0.788 / –0.755 0.824 / –0.867 2.059 / –0.897 0.315 /–0.295 
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3.2.6. DNA binding experiments 
3.2.6.1. Absorption spectral studies. The DNA binding experiments were performed with 
Perkin−Elmer Lamda35 spectrophotometer as described previously.47e Briefly, the absorption 
titration experiments were performed by varying the concentration of CT−DNA from 0 to   70 
μM and keeping the metal complex concentration constant at 25 μM in 10 mM Tris–HCl buffer 
(pH 8.0) containing 1% DMF. The binding constant Kb was computed from the data obtained 
using the following equation
47e
 
[DNA]
εa− εf
=  
[DNA]
εb− εf
+  
1
Kb(εb− εf)
;                                (1) 
where [DNA] is the concentration of DNA base pairs, and εa, εf  and εb correspond to apparent 
extinction co−efficient for the complex i.e. Abs/[complex] in presence of DNA, in the absence of 
DNA and to fully bound DNA respectively. A plot of [DNA]/(εa – εf) vs [DNA] gave a slope and 
the intercept equal to 1/(εb – εf) and 1/Kb(εb – εf), respectively. The binding constant Kb was 
calculated from the ratio of the slope to the intercept. Ligand interaction with CT−DNA were 
also studied by titrating a fixed concentration of ligand (25 μM) with variable CT−DNA 
concentration ranging from 0−350 μM in 10 mM Tris–HCl buffer (pH 8.0) containing 1% DMF. 
3.2.6.2. Competitive DNA binding fluorescence measurements. The apparent binding constant 
(Kapp) for the complexes were determined by fluorescence measurements using ethidium 
bromide (2 μM) (EB) bound CT−DNA (50 μM) solution in 10 mM Tris–HCl buffer (pH 8.0) 
containing 1% DMF with the aid of Fluoromax 4P spectrofluorimeter (Horiba Jobin Mayer, 
USA). The fluorescence intensities of EB at 597 nm (excitation 510 nm) with an increase of the 
complex concentration (0−60 μM) were measured. In the presence of DNA, EB showed 
enhanced emission intensity due to intercalative binding with DNA. A competitive binding of 
metal complexes with CT−DNA leads to the decrease in the emission intensity due to emission 
quenching or the displacement of bound EB to CT−DNA by the complexes. The quenching 
constant was calculated by using the following Stern−Volmer equation53 
F0
F
= 1 +  KSV [Q]                                (2) 
where F0 and F are the emission intensity of EB bound CT–DNA in absence and in presence of 
the quencher (complexes) concentration [Q] respectively, which gave the Stern−Volmer 
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quenching constant (KSV). The apparent binding constant (Kapp) was calculated from the 
following equation. 
KEB×[EB]= Kapp×[complex]50                                (3) 
where Kapp is the apparent binding constant of the complex, [complex]50 is the concentration of 
the complex at 50% quenching of the emission intensity of EB bound CT–DNA, KEB is the 
binding constant of EB (KEB = 1.0  10
7
 M
-1
) and [EB] is the concentration of ethidium bromide 
(2 μM).53 
3.2.6.3. Thermal melting studies. Thermal melting studies of CT−DNA (100 μM) in the 
absence and presence of complexes (50 μM) were carried out by monitoring the absorbance at 
260 nm in the temperature range of 30−90oC with a ramp rate of 0.5oC/min in 10 mM Tris−HCl 
buffer (pH 8.0) containing 1% DMF. The experiments were carried out using a Chirascan CD 
spectropolarimeter (Applied Photophysics, UK) in absorbance mode equipped with temperature 
controller. The melting temperature (Tm) was determined from the derivative plot (dA260/dT vs T) 
of the melting profile.
47e
 
3.2.6.4. Circular dichroism studies. The Circular Dichroism (CD) spectroscopic studies were 
performed using Chirascan CD spectropolarimeter (Applied Photophysics, UK) at 25
o
C. CD 
spectra of CT–DNA (50 μM) in absence and presence of complexes (10 μM) were obtained in 
the wavelength range of 240–400 nm in 10 mM Tris–HCl buffer (pH 8.0) containing 1% DMF, 
using quartz cell with 10 mm path length.
47e 
 
3.2.7. DNA cleavage experiments. DNA cleavage was carried out as previously reported.
47e
 The 
chemical−induced and photo−induced DNA cleavage experiments were done with 300 ng 
supercoiled (SC) pUC19 DNA in 50 mM Tris–HCl buffer (pH 8.0) containing 1% DMF. 
3.2.7.1. Chemical−induced DNA cleavage. In order to study the chemical nuclease activity of 
the complexes, reactions were performed in the dark using hydrogen peroxide (0.5 mM) as the 
oxidising agent in absence and presence of complexes (1–300 µM). The solutions were 
incubated at 37
o
C for 1 h and analysed for DNA cleaved products by agarose gel electrophoresis.  
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3.2.7.2. Photo-induced DNA cleavage. The photo−induced DNA cleavage activity was 
performed as described previously.
47e
 Briefly, the photo−induced DNA cleavage experiments 
were carried out using UVA source at 350 nm (Luzchem Photoreactor Model LZC–1, Ontario, 
Canada) fitted with 14 UVA tubes (84 W) for 1 h, on supercoiled (SC) pUC19 DNA (300 ng) 
with complexes (1–300 µM) in 50 mM Tris−HCl buffer (pH 8.0) containing 1% DMF. DNA 
cleavage was indicated by the decrease in the supercoiled pUC19 DNA (Form I) and subsequent 
formation of nicked circular DNA (Form II) and linear DNA (Form III). The percentage of net 
DNA cleavage was calculated by the following equation: 
Net DNA cleavage % =
Form IIs+2 ×Form IIIs
Form Is+ Form IIs+2 ×Form IIIs
−  
Form IIc+2 ×Form IIIc
Form Ic+ Form IIc+2 ×Form IIIc
     (4) 
The subscripts “s” and “c” refers to the sample and control respectively.54 Appropriate DNA 
controls were taken to calculate the net DNA cleavage percent. The observed error in measuring 
the band intensities ranged between 3% – 6%.  
For mechanistic investigations of both hydrolytic and photolytic DNA cleavage, experiments 
were carried out with singlet oxygen quenchers such as sodium azide (NaN3) and L−histidine, 
while for hydroxyl radical scavengers potassium iodide (KI) and D−mannitol were used. Each of 
the additives was used at a concentration of 0.5 mM. 
 
3.2.8. Anticancer activity 
3.2.8.1. Cell culture. Human cervical cells HeLa were obtained from National Centre of Cell 
Science (NCCS), Pune, India and were maintained in minimal essential medium supplemented 
with 10% fetal bovine serum, penicillin-streptomycin solution and incubated at 37°C in 5% CO2 
and 95% humidified incubator. The complexes were dissolved in DMSO at a concentration of 
100 mM as stock solution, and diluted in culture medium at concentrations of 12.5, 25.0, 50.0 
and 100.0 μM as working solution. To avoid DMSO toxicity, the concentration of DMSO was 
less than 0.1% (v/v) in all experiments. 
3.2.8.2. Cytotoxic assay. HeLa cells were harvested from maintenance cultures in logarithmic 
phase, after counting in a hemocytometer using trypan blue solution. The cell concentration was 
adjusted to 5x10
4
 cells/ml and the cells were plated in 96 well ﬂat bottom culture plates and 
incubated for 72 h with various concentrations of the test compounds. The effect of the drugs on 
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the cancer cell viability was studied using MTT dye reduction assay by measuring the optical 
density at 595 nm using micro−plate reader spectrophotometer (Perkin−Elmer 2030).55  
3.2.8.3. Nuclear staining. Nuclear staining using DAPI stain was performed according to the 
method previously described.
56
 Briefly, HeLa cells either treated or untreated with test 
compounds were smeared on a clean glass slide, cells were fixed with 3.7% formaldehyde for 15 
minutes, permeabilized with 0.1% Triton X−100 and stained with 1 μg/ml DAPI for 5 min at 
37°C. The cells were then washed with PBS and examined by fluorescence microscopy 
(Olympus IX 71) to ascertain any condensation or fragmentation of the nuclei indicating cells 
undergoing apoptosis. 
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3.3. RESULTS AND DISCUSSION 
3.3.1. Synthesis. Reaction of Cu(I)X (X = Cl, Br) with 4–(p‒X‒phenyl)thiosemicarbazone of 
napthaldehyde {X = Cl (HL
1
); X = Br (HL
2
)} in the molar ratio of 1:1 in CH3CN formed an 
insoluble product of stoichiometry [CuX(HL
1-2
)] which after addition of two moles of PPh3 
yielded light yellow colored monomeric complexes [CuX(HL
1–2
)(PPh3)2]·Solvent (X = Br, 1; Cl, 
2). Reaction of copper(II) chloride with quinoline–2–carbaldehyde thiosemicarbazone (HL3) in 
the molar ratio of 1:1 in CH3OH yielded dark green colored tertrameric complex [(Cu2L
3
2Cl)2(–
Cl)2]·2H2O (3) whereas with 4–(p–F–phenyl)thiosemicarbazone of salicylaldehyde (H2L
4
) in 
presence of pyridine as coligand yielded dark green monomeric complex [Cu(L
4
)(Py)] (4). The 
electrospray mass spectra (ESI MS) and NMR spectra were consistent with the X–ray structures. 
The purity of these compounds was further confirmed by elemental analyses. The synthetic 
methods of all the complexes are illustrated in Scheme 3.1. All complexes were soluble in 
MeOH, MeCN, DMF and DMSO. Complex 3 was completely and other three complexes (1, 
38%; 2, 35% and 4, 45%, H2O‒DMSO solution) were partially soluble in H2O. All the 
complexes were stable in both solid and solution phases. The solution phase stability of the 
complexes was confirmed by electronic absorption, NMR and ESI–MS spectral studies. 
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Scheme 3.1. Schematic representation of ligands and syntheses of copper complexes. 
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3.3.2. Structure. The observed elemental (C, H, N) analytical data of all the complexes (1–4) are 
in consistent with their composition. It appears from the formulation of 1 & 2 that the TSC is 
serving as a monodentate ligand where as in 3 & 4 it is serving as a tridentate ligand. In order to 
authenticate the coordination mode of the TSC in the complexes, the structures have been 
determined by X–ray crystallography. 
 
3.3.2.1. Description of X-ray structures of [Cu(HL
1
)(PPh3)2Br]·CH3CN (1) and 
[Cu(HL
2
)(PPh3)2Cl]·DMSO (2). The molecular structure and the atom numbering scheme for 
the complexes [Cu(HL
1
)(PPh3)2Br]·CH3CN (1) and [Cu(HL
2
)(PPh3)2Cl]·DMSO (2) are shown in 
Figure 3.1 and Figure 3.2 respectively; the relevant bond distances and angles are collected in 
Table 3.2. Compounds 1 and 2 contain CH3CN and DMSO as a solvent of crystallization 
respectively. The coordination geometry around the Cu(I) atom in 1 and 2 reveals a distorted 
tetrahedral environment with an SXP2 [X = Br (1) and Cl (2)] coordination sphere as the bond 
angles around the copper atom vary from ca. 100–124° in 1 and 2 with P−Cu−P being the largest 
angle.
49,57
 The ligand HL
1-2
 acts as a monodentate ligand coordinating through the S atom. The 
other positions of the tetrahedron are occupied by one halogen atom and two triphenylphosphine 
ligands. In the compound, the Cu−S bond lengths are 2.401(7) Å for 1 and 2.387(1) Å for 2, 
while the Cu-halogen bond distances lie in ranges 2.374(1)–2.517(4) Å as is usually found for 
tetrahedrally coordinated copper(I) and S atom donors.
44,49
 The Cu−P distances [2.276(6), 
2.290(7) Å for 1, 2.274(1), 2.295(1) Å for 2] are comparable to those found in similar 
complexes.
 44,49 
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Table 3.2. Selected geometric parameters (Å, º) for [Cu(HL
1
)(PPh3)2Br]·CH3CN (1) and 
[Cu(HL
2
)(PPh3)2Cl]·DMSO (2) 
 
 Complex (1) Complex (2) 
Bond Distances 
Cu(1)‒S(1) 2.401(7) 2.387(1) 
Cu(1)‒P(1) 2.277(6) 2.274(1) 
Cu(1)‒P(2) 2.290(7) 2.295(1) 
Br(1)‒Cu(1) 2.517(4) – 
Cl(1)‒Cu(1) – 2.374(1) 
Bond Angles 
P(2)‒Cu(1)‒P(1) 124.51(2) 122.72(4) 
P(2)‒Cu(1)‒S(1) 109.26(2) 107.07(4) 
P(1)‒Cu(1)‒S(1) 104.48(2) 105.19(4) 
P(2)‒Cu(1)‒Br(1) 108.41 (2) – 
P(2)‒Cu(1)‒Cl(1) – 108.07(4) 
P(1)‒Cu(1)‒Br(1) 100.29(2) – 
P(1)‒Cu(1)‒Cl(1) – 104.81(4) 
S(1)‒Cu(1)‒Br(1) 108.97(2) – 
Cl(1)‒Cu(1)‒S(1) – 108.35(4) 
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Figure 3.1. ORTEP diagram of [Cu(HL
1
)(PPh3)2Br]·CH3CN (1) with atom labeling scheme. 
 
 
 
Figure 3.2. ORTEP diagram of [Cu(HL
2
)(PPh3)2Cl]·DMSO (2) with atom labeling scheme. 
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3.3.2.2. Description of X-ray structure of [(Cu2L
3
2 Cl)2(–Cl)2]·2H2O (3). The structure of the 
tetranuclear Cu(II) complex [(Cu2L
3
2 Cl)2(–Cl)2].2H2O is illustrated in Figure 3.3 and selected 
bond parameters are collected in Table 3.3. Compound 3 contains two H2O molecules as solvent 
of crystallization. The structure contains four units comprising of two identical Cu(1)LCl outer 
units and two identical Cu(2)LCl inner units. In other words, the tetranuclear Cu(II) species is 
formed by the dimerisation of two binuclear Cu2L2Cl2 units bridged by two reciprocal 
coordinated chlorine atoms of the individual Cu2L2Cl2 unit. Each copper atom in the outer unit is 
coordinated by a quinoline nitrogen, azomethine nitrogen and thiolate sulfur of the 
thiosemicarbazone moiety and a chlorine group. The Cu–Nquinoline bonds are ~ 0.131 Å farther 
away than Cu–Nimine bonds, indicating the strength of the azomethine nitrogen coordination. The 
length of the other metal coordinated bonds (Cu−S and Cu−Cl) is usual like similar systems 
reported earlier.
58,59
 The bond angles also are in conformity with a distorted square pyramidal 
structure around the copper centers. Each copper atom in the inner subunit is pentacoordinate 
with the bonds Cu(2)–S(2), Cu(2)–Cl(2), Cu(2)–N(8), Cu(2)–N(7) and Cu(2)–Cl(2)# adapting a 
distorted square pyramidal geometry with bridging Cl(2)# of the other inner moiety at the apical 
site. The quinoline nitrogen N(8), the imine nitrogen N(7), and the thiolate sulfur S(2) atom, 
together with Cl(2), constitute the basal plane. The bond lengths in the basal plane agree with 
those found in copper(II) complexes containing thiosemicarbazones which act as uninegative 
tridentate ligands.
58,59
 The bond lengths and bond angles reveal a distorted square pyramidal 
geometry around Cu(2). 
 
3.3.2.3. Description of X-ray structure of [Cu(L
4
)(Py)] (4). The atom numbering scheme for 
the complex 4 is given in Figure 3.4 with the relevant bond distances and angles collected in 
Table 3.3. The structure shows that the thiosemicarbazone ligand (L
2−
) is coordinated to copper 
in the expected tridentate fashion (Scheme 3.1), forming a six− and a five−membered chelate 
ring with O(1)–Cu(1)–N(3) and S(1)–Cu(1)–N(3) bite angles of 94.04(7)º and 85.92(5)° 
respectively. The coligand pyridine is coordinated to the metal center, and is trans to the nitrogen 
atom N(3). The rather large Cu(1)−N(4) distance is 2.013(1) Å revealed that the pyridine moiety 
is weakly coordinated to the Cu−center.60 Copper is thus nested in a NOSN core, which is 
slightly distorted from an ideal square-planar geometry, as reflected in the bond parameters 
around the metal center. The Cu–N(3), Cu–O(1), Cu–N(4) (coligand) and Cu–S(1) distances are 
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normal, as observed in other structurally characterized complexes of Cu containing these 
bonds.
60,61 
 
Table 3.3. Selected geometric parameters (Å, º) for [(Cu2L
3
2Cl)2(–Cl)2]·2H2O (3) & 
[Cu(L
4
)(Py)] (4) 
 Complex (3) Complex (4) 
Bond Distances 
Cu(1)–Cl(1) 2.253(3) – 
Cu(1)–O(1) – 1.906 (2) 
Cu(1)–S(1) 2.304(3) 2.247(6) 
Cu(1)–S(2) 2.715(2) – 
Cu(1)–N(3) 1.975(7) 1.932(1) 
Cu(1)–N(4) 2.107(7) 2.013(1) 
Cu(2)–Cl(2) 2.290(2) – 
Cu(2)–S(2) 2.303(2) – 
Cu(2)–N(7) 1.973(6) – 
Cu(2)–N(8) 2.146(6) – 
Cu(2)–Cl(2)1 2.691(2) – 
Bond Angles 
Cl(1)–Cu(1)–S(1) 92.60(1) – 
O(1)–Cu(1)–N(3) – 94.04(7) 
Cl(1)–Cu(1)–S(2) 101.30(1) – 
O(1)–Cu(1)–N(4) – 86.40(7) 
Cl(1)–Cu(1)–N(3) 150.60(2) – 
O(1)–Cu(1)–S(1) – 177.41(5) 
Cl(1)–Cu(1)–N(4) 104.10(2) – 
S(1)–Cu(1)–S(2) 94.15(8) – 
S(1)–Cu(1)–N(3) 82.30(2) 85.92(5) 
S(1)–Cu(1)–N(4) 161.90(2) 93.72(5) 
S(2)–Cu(1)–N(3) 107.90(2) – 
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S(2)–Cu(1)–N(4) 89.40(2) – 
N(3)–Cu(1)–N(4) 79.70(3) 178.10(7) 
Cl(2)–Cu(2)–S(2) 89.88(8) – 
Cl(2)–Cu(2)–N(7) 171.20(2) – 
Cl(2)–Cu(2)–N(8) 108.60(2) – 
Cl(2)–Cu(2)–Cl(2)1 87.25(7) – 
S(2)–Cu(2)–N(7) 81.60(2) – 
S(2)–Cu(2)–N(8) 155.20(2) – 
Cl(2)1–Cu(2)–S(2) 102.01(9) – 
N(7)–Cu(2)–N(8) 79.20(3) – 
Cl(2)1–Cu(2)–N(7) 96.30(2) – 
Cl(2)1–Cu(2)–N(8) 95.50(2) – 
Cu(2)–Cl(2)–Cu(2)1 92.80(9) – 
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Figure 3.3. ORTEP diagram of [(Cu2L
3
2Cl)2(–Cl)2]·2H2O (3) with atom labeling scheme. 
 
 
 
Figure 3.4. ORTEP diagram of [Cu(L
4
)(Py)] (4) with atom labeling scheme. 
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3.3.3. Spectral characteristics 
 
3.3.3.1. IR spectroscopy. The IR spectra of 1 & 2 showed the presence of ν(N‒H) bands in the 
ranges 3284‒3285 cm-1 for ‒N(1)‒H and 3047‒3049 cm‒1 for ‒N(2)‒H stretching, which 
suggests that the thiosemicarbazone ligand is coordinated to the Cu(I) centre in the neutral form. 
In all the complexes (1–4) ν(C=N) and ν(C=C) vibrational modes appeared in the range 
1635‒1531 cm–1, while the thioamide bands ν(C‒S (1 & 2) & C=S (3 & 4)) appeared in the 
range 770‒748 cm–1 (compared to free ligands, 854–785 cm–1).47c The characteristic ν(P–CPh) 
bands at 1096‒1090 cm–1 indicate the presence of Ph3P in 1 & 2. 
 
3.3.3.2. UV spectroscopy. The electronic spectra of all the complexes (Table 3.4) were recorded 
in methanol solutions. In the spectra of 1‒4 three strong absorptions are observed in the 
wavelength range 448–220 nm. The lower energy absorptions at around 448–349 nm are 
ascribable to metal to ligand (1 & 2) the ligand to metal (3 & 4) charge transfer transitions 
whereas the higher energy absorptions are likely to be due to ligand centered transitions.
46,47c
 
Weak absorptions in the range 676−668 nm are also observed for 3 & 4 (Cu(II) complexes), 
which are assigned to d−d transitions.62 A representative spectrum of complex 1 is shown in 
Figure 3.5.
 
 
Table 3.4. Electronic spectra for complexes 1–4 in CH3OH 
Complex                                                        λmax/nm (ε/dm
3
mol
–1
 cm
–1
) 
 
[Cu(HL
1
)(PPh3)2Br]·CH3CN (1) 239(51814), 349(26982) 
[Cu(HL
2
)(PPh3)2Cl]·DMSO (2) 227(45121), 385(27637) 
[(Cu2L
3
2Cl)2(–Cl)2]·2H2O (3) 230(29790), 306(23258), 364(12917), 
448(11768), 676(17788) 
[Cu(L
4
)(Py)] (4) 220(5132), 256(8526), 332(3310), 395(2574), 
668(4353) 
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Figure 3.5. Electronic absorption spectra of [Cu(HL
1
)(PPh3)2Br]·CH3CN (1). 
 
3.3.3.3. NMR spectroscopy. The NMR spectra (
1
H, 
13
C and 
31
P) of 1 & 2 were recorded using 
DMSO–d6. The 
1
H NMR spectrum exhibits three singlets in the range 12.47–9.09 ppm due to 
NH (–C(7)–N(1)H), NH (–C(7)–N(2)H) and CH (–N(3)=C(8)H) groups respectively. Signals for 
aromatic protons found as multiplets in 8.42–7.25 ppm range.47c The 13C NMR spectra of the 
complexes (1 & 2) showed a sharp singlet appearing at 178.18–175.39 ppm due to C–S carbon. 
The peak for the azomethine (–CH=N) carbon exhibited a peak in the region 140.51–138.6 ppm. 
The peaks observed in the 137.82–129.83 ppm region have been assigned to aromatic carbons. 
The PPh3 peaks are assigned in the range 129.12–127.80 ppm.
63
 
31
P NMR spectra were recorded 
in order to confirm the presence of triphenyl phosphine group. The two signals appeared at 
46.85–44.72 ppm and indicated that the two triphenyl phosphine ligands were cis to each other in 
these complexes.
63
 The detailed NMR data has been included in the experimental section.
 
The 
representative 
1
H NMR spectrum of complex 2 is shown in Figure 3.6. 
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Figure. 3.6. 
1
H NMR spectra of complex [Cu(HL
2
)(PPh3)2Cl]·DMSO (2). 
 
 
3.3.3.4. ESI-MS spectroscopy. ESI mass spectra of 1−4 have been recorded in methanol 
solution. Mass spectral analysis for 1 and 2 shows peaks at m/z 1047.34 [(M + H)
+
] and 1086.70 
[(M + H)
+
] respectively, whereas 3 shows the molecular ion peak [(M + 3H)
+
] at m/z 1352.55. 
ESI‒MS peak for 4 shows the characteristic molecular ion peak (M+) at m/z 430.07. Figure 3.7 
depicts a representative ESI mass spectrum of 4. 
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Figure 3.7. ESI-MS of complex 4 in CH3OH. 
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3.3.4. Electrochemical properties. The electrochemical properties of 1–4 were examined in 
CH3CN solution (0.1 M TEAP) by cyclic voltammetry using a platinum working electrode, 
platinum auxiliary electrode and an Ag/AgCl reference electrode. The potential data are listed in 
Table 3.5. Figure 3.8, 3.9 and 3.10 depicts the representative voltammogram of 1 {Cu(I)}, 3 
{Cu(II)} and 4 {Cu(II)} respectively. The voltammograms of all four complexes include both 
oxidation and reduction processes. The voltammogram pattern is similar for 1 & 2, which 
includes a quasireversible (Figure 3.8) process at E1/2 value 0.37 to 0.40 V corresponding to 
Cu(I)/Cu(II) redox couple,
46
 whereas in the cathodic region Cu(I) is reduced to Cu(0) showing an 
irreversible single electron wave at Epc values within the potential window –0.70 to –0.72 V.
64
  
In the voltammogram of tetrameric Cu(II) complex (3), there are three quasireversible/reversible 
(Figure 3.9) processes at E
c/a
1/2 values –0.62, 0.10 and 0.36 V corresponding to Cu(II)/Cu(I) 
redox couples
65
 of four different Cu(II) centers, whereas for the monomeric Cu(II) complex (4) a 
quasireversible (Figure 3.10) process for the above couple appears at E
c
1/2 value –0.52 V.  
For all four complexes (1−4) an oxidation peak in the range 0.87 to 0.91 V66 and two reduction 
peaks in the range –1.37 to –1.45 and –1.61 to –1.65 V31,47c belong to ligand centered processes 
respectively.  
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Table 3.5. Cyclic voltammetric
[a]
 results for complexes 1–4 at 298 K 
 
Complex 
Potentials (V) versus Ag/AgCl 
Cu
I
/Cu
II
 
E
a
1/2(ΔE
a
P) 
Cu
I
/Cu
0
Epc 
Ligand –
centered 
oxidation 
E
a
1/2(ΔE
a
P) 
Ligand –
centered 
reduction 
Epc 
Cu
II
/Cu
I
 
E
c/a
1/2 
(ΔEc/aP) 
[Cu(HL
1
)(PPh3)2Br]·CH3CN 
(1) 
0.40(320) –0.72 0.89(240) –1.41, –1.63 – 
[Cu(HL
2
)(PPh3)2Cl]·DMSO 
(2) 
0.37(326) –0.70 0.87(156) –1.45, –1.65 – 
[(Cu2L
3
2Cl)2(–Cl)2]·2H2O 
(3) 
– – 0.88(190) –1.39, –1.63 –0.62(50) 
0.10(77), 
0.36(113), 
[Cu(L
4
)(Py)] (4) – – 0.91(264) –1.37, –1.61 –
0.52(100) 
[a]
In CH3CN at a scan rate 100 mV/s. E1/2 = (Epa + Epc)/2, where Epa and Epc are anodic and cathodic 
peak potentials vs. Ag/AgCl, respectively. ΔEP = Epa – Epc. 
 
 
Figure 3.8. Cyclic voltammogram of complex 1. 
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Figure 3.9. Cyclic voltammogram of complex 3. 
 
 
 
Figure 3.10. Cyclic voltammogram of complex 4. 
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3.3.5. DNA binding studies 
3.3.5.1. Absorption spectroscopic studies. DNA is often a vital target to mediate apoptosis or 
necrosis to a cell. Therefore the binding affinity of the complexes to CT–DNA was studied using 
different spectral methods. UV–Vis titration experiments were carried out to determine the 
binding constant (Kb) of the complexes to CT–DNA (Figure 3.11 and Table 3.6). The 
complexes 1–4 shows absorption bands in the region 448–349 nm which are attributed to metal 
to ligand (1 & 2) and ligand to metal (3 & 4) charge transfer transitions whereas the absorption 
bands at higher energy is due to intra-ligand transitions. The binding of complexes to DNA either 
leads to hypochromism or hyperchromism which provides a measure of the strength of the 
intercalative or groove binding respectively.
67
 
In order to quantify the binding affinity of the interaction between CT–DNA and each of 1–4, 
the binding constant (Kb) was calculated using Eq. 1 (Experimental Section). The binding 
constant (Kb) of the complexes were in the range of 1.30  10
4
 to 9.60  105 M–1. Complexes 3 
exhibited higher binding affinity than the other complexes (1, 2 and 4). The binding propensities 
of ligands to CT–DNA were also estimated. All the ligands showed lower DNA binding affinity 
than their respective complexes, yielding Kb values in the order of 10
3
 M
–1
. 
3.3.5.2. Competitive DNA binding fluorescence studies. Ethidium dibromide (EB) is a 
standard intercalating agent and exhibits fluorescence upon binding to DNA. The relative 
binding of the complexes 1–4 to CT–DNA was also investigated by monitoring the quenching of 
the fluorescence emission from EB bound CT–DNA, on successive addition of the complexes. 
EB is nonemissive in 10 mM Tris–HCl buffer (pH 8.0) containing 1% DMF due to fluorescence 
quenching of free EB by solvent molecules, while in the presence of DNA, EB shows enhanced 
emission intensity due to intercalative binding.
68
 On addition of the copper complexes to EB 
bound CT–DNA, the emission intensity at 597 nm was quenched by ~ 14% and ~ 13% for 
copper(I) complexes 1 and 2 respectively, whereas copper(II) complexes 3 and 4 exhibited a 
decrease of ~ 82% and ~ 10% respectively (Figure 3.12). The quenching of emission intensity of 
ethidium bromide upon addition of 1–4 showed that the complexes probably compete with EB 
for the binding with DNA. Copper(I) complexes 1 and 2 exhibited a Ksv value of 3.06  10
3
 and 
2.22  103 M-1 as calculated from Eq. 2 and the Kapp value of 6.87  10
5
 and 6.70  105 M–1 as 
calculated from Eq. 3 respectively (Table 3.6). Similarly for copper(II) complexes, 3 exhibited 
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the highest decrease in the emission intensity of EB which is well reflected in its Ksv and Kapp 
values of 5.36  104 and 7.34  105 M–1 respectively. Complex 4 showed the least decrease in the 
emission intensity of EB which is consistent with its lower Ksv and Kapp values of 1.32  10
3
 and 
5.79  105 M–1 respectively (Table 3.6). The higher Ksv and Kapp value of 3 than the other 
complexes may be attributed to its higher solubility in aqueous medium and the presence of 
quinonoidal group in the thiosemicarbazone ligand coordinated to the metal. 
The Kapp of the complexes were of the order of ∼102 lower than the classical intercalator EB 
(i.e. 1.00 × 107 M
−1
), which suggests that the interactions between the complexes and CT–DNA 
were possibly groove binding in nature. The trend in Kapp values are in line with the trend in the 
Kb values which were obtained from the UV–Vis absorption spectral studies (Table 3.6).Control 
competitive DNA binding experiments with ligands (Table 3.7) showed that ligands have lesser 
Ksv and Kapp values than their corresponding complexes. 
3.3.5.3. Thermal melting studies. In order to have an insight into the nature of interaction and 
the conformational changes brought about by the complexes on interaction with CT–DNA, 
thermal denaturation experiments were performed.
69
 The melting temperature of CT–DNA (Tm) 
in absence of any complexes was ~65.7
o
C (Figure 3.13). In the presence of the copper 
complexes the DNA melting temperature (Tm) showed a slight increase from ~1.05
o
C to 1.83
o
C 
(Table 3.6). Among all the complexes, 3 showed the highest shift of the DNA melting 
temperature (∆Tm) of + 1.83
o
C which may be attributed to its better interaction with CT–DNA as 
evidenced from UV–Vis absorption and competitive DNA binding studies. The lower ∆Tm 
values suggest that the complexes interact with CT–DNA primarily through groove binding 
mode rather than an intercalative mode of binding to DNA which generally results in higher 
positive shift in the Tm of CT–DNA.
69,70
 
3.3.5.4. Circular dichroism studies. Circular dichroism was used to investigate the 
conformational changes in CT–DNA due to the interaction with the complexes. CT–DNA shows 
two conserved bands in the UV region, a positive band at 275 nm due to base stacking 
interaction and a negative band at 245 nm due to right handed helicity.
71
 The interaction of 1, 2 
and 4 showed marginal changes in the CD spectra of CT–DNA, whereas the interaction of 3 with 
CT–DNA induced a decrease in the intensity for the negative ellipticity at 245 nm and an 
increase in the positive ellipticity band at 275 nm (Figure 3.14). These results suggest that 
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interaction of 1, 2 and 4 did not bring about any conformational changes in CT–DNA while 3 
perturbed the stacking interaction as well as the right handed helicity of CT–DNA.  
 
3.3.6. DNA cleavage studies 
3.3.6.1. Chemical–induced DNA cleavage. To assess whether the DNA binding properties of 
the complexes are associated with  the chemical nuclease activity, 300 ng of pUC19 DNA was 
incubated in presence of hydrogen peroxide as an oxidising agent, with different concentration of 
the complexes (1–300 μM) in 50 mM Tris–HCl buffer (pH 8.0) containing 1% DMF in dark for 
1h. Upon gel electrophoresis, complexes 1, 2 and 4 showed slight DNA cleavage activity ranging 
from ~ 2–10%, whereas complex 3, exhibited a maximum chemical nuclease activity of ~ 60% at 
complex concentration of 100 μM (Figure 3.15 and 3.16). This enhanced chemical nuclease 
activity of 3 can be possibly rationalized on the basis of its higher binding affinity towards CT–
DNA as observed from the DNA binding studies. Control experiments using the oxidizing agent 
hydrogen peroxide and the ligands showed that, neither hydrogen peroxide nor the ligands were 
cleavage active under similar experimental condition. All the complexes, in the absence of the 
oxidising agent, were cleavage inactive under dark conditions.  
In order to elucidate the probable mechanistic aspects of the chemical–induced DNA cleavage 
activity by these complexes various inhibitors were used. The chemical−induced DNA cleavage 
reactions may involve reactive oxygen species (ROS) such as singlet oxygen (
1
O2) and hydroxyl 
radicals (*OH). Therefore, NaN3 and L–histidine were used as singlet oxygen quenchers, while 
KI and D−mannitol were employed as hydroxyl radical quenchers. Complexes 1, 2 and 4 did not 
show any appreciable inhibition in the chemical–induced DNA cleavage activity in the presence 
of the various additives which may be due to the diminished chemical nuclease activity of these 
complexes. On the other hand, addition of singlet oxygen quenchers like NaN3 and L–histidine 
inhibited the DNA cleavage activity of complex 3 by ~ 6 % and ~ 22 % respectively. Similarly in 
the presence of the hydroxyl radical scavengers KI and D–mannitol, the chemical nuclease 
activity of complex 3 was reduced by ~ 14 % and ~ 11 % respectively (Figure 3.17). These 
results suggest that among all the copper complexes, 3 exhibits chemical−induced DNA cleavage 
activity probably via both singlet oxygen and hydroxyl radical pathways. 
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3.3.6.2. Photo-induced DNA cleavage. To investigate if the chemical nuclease activity of the 
complexes was also associated with photo nuclease activity, photo–induced DNA cleavage was 
carried out with 300 ng pUC19 DNA in the presence and absence of the complexes 1–4 (Figure 
3.18). The extent of DNA cleavage by the complexes was monitored in a concentration 
dependent manner as shown in Figure 3.19. All the complexes (except 4) showed ~ 10% or 
more photo−induced DNA cleavage activity at a complex concentration of 10 μM, which 
ultimately was saturated at a complex concentration of 100 μM. Among the copper(I) complexes, 
2 exhibited greater (~ 55 %) photo-induced DNA cleavage activity than 1 (~ 40 %). On the other 
hand, in copper(II) complexes, 3 showed an abruptly higher photo-induced DNA cleavage 
activity of ~ 80 %, whereas 4 exhibited a minimal DNA cleavage activity of ~ 18 % (Figure 
3.19). The higher DNA cleavage activity of 3 may be attributed due to its higher binding affinity 
to DNA as shown in binding studies and may also is because of its solubility in aqueous medium 
and the presence of quinonoidal group in the thiosemicarbazone ligand coordinated to the metal. 
Control experiments suggest that neither DMF (1%) nor the ligands showed any photo-induced 
DNA cleavage activity, which implies that, the ligands or DMF alone are cleavage inactive under 
similar conditions. 
To understand the mechanistic aspect of the photo nuclease activity of these complexes, we 
used the same additives as used in exploring the mechanism of chemical nuclease activity. The 
DNA cleavage reaction involving molecular oxygen can proceed in two mechanistic pathways, 
namely, by a type–II process involving singlet oxygen species (1O2) or by a photo-redox pathway 
involving reactive hydroxyl radicals (*OH).
72
 In case of copper(I) complexes, the singlet oxygen 
quenchers, like NaN3 and L–histidine showed a reduced photo nuclease activity of complex 1 by 
~ 9 % and ~ 8 % and of complex 2 by ~ 4 % and ~ 12 % respectively. Similarly the hydroxyl 
radical scavengers, KI and D–mannitol, exhibited a significant inhibition of photo–induced DNA 
cleavage activity of complex 1 by ~ 26 % and ~ 13 % and of complex 2 by ~ 19 % and ~ 7 % 
respectively (Figure 3.20). While in case of copper(II) complexes, the presence of singlet 
oxygen quenchers, NaN3 and L−histidine, decreased the photo nuclease activity of complex 3 by 
~ 4 % and ~ 5 % and complex 4 by ~ 3 % and ~ 10 % respectively. Similarly KI and D–mannitol 
(hydroxyl radical quenchers) showed an inhibition of DNA cleavage activity by ~ 12 % and ~ 28 
% for complex 3 and ~ 5 % and ~ 3 % for complex 4 (Figure 3.20). These results suggest that, 1 
& 2 exhibit photo-induced DNA cleavage activity possibly via both singlet oxygen and hydroxyl 
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radical pathways while the mechanistic pathway for 3 & 4 cannot be stated with a degree of 
certainty. Among the two pathways, hydroxyl radical dominates over the singlet oxygen pathway 
as the hydroxyl radical scavengers showed higher inhibitory effect than the singlet oxygen 
quenchers. 
 
Table 3.6. DNA binding parameters for the complexes 1–4 
a
DNA binding constant by UV–vis spectral method. bChange in the melting temperature of CT–
DNA. 
c
Stern–Volmer quenching constant for the CT–DNA–EB complex. dThe apparent DNA 
binding constant. 
 
 
Table 3.7. DNA binding parameters for the ligands 
Ligands  
Binding Constant 
(Kb) 
a
 (M
–1
) 
Stern–Volmer 
Quenching Constant 
(KSV) (M
–1
) 
b 
Kapp
c
 (M
–1
)
 
HL
1
 5.50  103 5.01  102 3.02  105 
HL
2
 5.20  103 5.80  102 3.60  105 
HL
3
 1.80  103 9.28  102 6.70  105 
H2L
4
 7.00  103 4.50  102 2.69  105 
a
DNA binding constant by UV–vis spectral method. bStern–Volmer Quenching constant for CT–
DNA–EB complex. cThe apparent DNA binding constant. 
 
Complex  
Binding 
Constant (Kb)
a
 
(M
–1
) 
∆Tm
b
 (
o
C) 
Stern–Volmer 
quenching Constant 
(KSV) (M
–1
)
c 
Kapp
d
 (M
–1
)
 
1 3.40  105 +1.05 3.06  103 6.87  105 
2 1.20  105 +1.65 2.22  103 6.70  105 
3 9.60  105 +1.83 5.36  104 7.34  105 
4 1.30  104 +1.11 1.32  103 5.79  105 
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Figure 3.11. Electronic absorption spectra of 1 (a), 2 (b), 3 (c) and 4 (d) (25 μM each) upon the 
titration of CT–DNA (0–70 μM) in 10 mM Tris–HCl buffer (pH 8.0) containing 1% DMF. The 
arrow shows the changes in absorbance with respect to an increase in the CT–DNA 
concentration. The inset shows the linear fit of [DNA]/(εa – εf) vs [DNA] and the binding 
constant (Kb) was calculated using Eq. 1. 
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Figure 3.12. Fluorescence emission spectra of ethidium bromide (2 μM) bound to CT-DNA (50 
μM) in the presence of complex 1 (a), 2 (b), 3 (c) and 4 (d) (0–60 μM) in 10 mM Tris–HCl 
buffer (pH 8.0) containing 1% DMF. The arrow indicates the effect of increasing concentration 
of complex on the fluorescence emission of ethidium bromide bound CT–DNA. The inset shows 
the linear fit of F0/F vs [complex] and Stern–Volmer quenching constant (KSV) was calculated 
using Eq. 2. 
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Figure 3.13. Derivative plot of thermal denaturation of CT–DNA (100 μM) in absence and 
presence of 1–4 (50 μM). The experiment was done in 10 mM Tris–HCl buffer (pH 8.0) 
containing 1% DMF. Inset shows the ∆Tm (
o
C) of the complexes as compared to CT–DNA.  
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Figure 3.14. Circular dichroism spectra of CT–DNA (50 μM) in the presence and absence of 1–4 
(20 μM) in 10 mM Tris–HCl buffer (pH 8.0) containing 1% DMF. The path length of the cuvette 
was 10 mm. 
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Figure 3.15. Gel diagram showing concentration dependent chemical nuclease activity by 1–4; 
300ng of SC pUC19 DNA at different concentrations of the complexes [1–300 µM in 50 mM 
Tris–HCl buffer (pH 8.0) containing 1% DMF] was treated with hydrogen peroxide (0.5mM) in 
dark for 1 h at 37
o
C. Lanes 1–9: 1, 2.5, 5.0, 7.5, 10, 50, 75, 100 and 300 µM of 1–4. 
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 Figure 3.16. Concentration dependent chemical nuclease activity by 1–4; 300 ng of SC pUC19 
DNA at different concentration of the complexes [1–300 µM in 50 mM Tris–HCl buffer (pH 8.0) 
containing 1% DMF] was treated with hydrogen peroxide (0.5 mM) in dark for 1 h at 37
o
C. The 
net DNA cleavage percent was calculated using Eq. 4. Inset shows a bar diagram representation 
of the net DNA cleavage of different complexes at 10 and 100 µM. 
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Figure 3.17. Chemical nuclease activity of SC pUC19 DNA by 3 in the presence of various 
additives in 50 mM Tris–HCl buffer (pH 8.0) containing 1% DMF. SC pUC19 DNA (300 ng) in 
the presence of various additives was treated with hydrogen peroxide (0.5 mM) in the dark for 1 
h at 37
o
C with 3 (100 µM). The additive concentrations were: sodium azide (0.5 mM), L–
histidine (0.5 mM), KI (0.5 mM) and D–mannitol (0.5 mM). 
 
 
 
 
Figure 3.18. Gel diagram showing concentration dependent DNA cleavage by 1–4; 300ng of SC 
pUC19 DNA at different concentrations of the complexes [1–300 µM in 50 mM Tris–HCl buffer 
(pH 8.0) containing 1% DMF] was photo–irradiated with UVA at 350 nm for 1 h. Lanes 1–9: 1, 
2.5, 5.0, 7.5, 10, 50, 75, 100 and 300 µM of 1–4. 
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Figure 3.19. Concentration dependent DNA cleavage by 1–4; 300 ng of SC pUC19 DNA at 
different concentration of the complexes [1–300 µM in 50 mM Tris–HCl buffer (pH 8.0) 
containing 1% DMF] was photo–irradiated with UVA at 350 nm for 1 h. The net DNA cleavage 
percent was calculated using Eq. 4. Inset shows a bar diagram representation of the net DNA 
cleavage of different complexes at 10 and 100 µM. 
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Figure 3.20. DNA cleavage of SC pUC19 DNA by 1–4 in the presence of various additives in 
50 mM Tris–HCl buffer (pH 8.0) containing 1% DMF. SC pUC19 DNA (300 ng) in the presence 
of various additives was photo–irradiated at 350 nm for 1 h with 1–4 (100 µM). The additive 
concentrations were: sodium azide (0.5 mM), L–histidine (0.5 mM), KI (0.5 mM) and D–
mannitol (0.5 mM). 
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3.3.7. Anticancer activity 
3.3.7.1. Inhibition of cancer cell viability.  In the present study, the antiproliferative efficacy of 
1–4 was assayed by determining the viability of HeLa cells using the MTT assay. The ligands 
(HL
1
, HL
2 
and H2L
4
) and metal precursors (CuBr, CuCl & CuCl2) gave IC50 values of >200 μM 
but the other ligand (HL
3
) gave IC50 values of 98 μM, whereas corresponding complexes 1–4 
gave values in the range 20–36 μM. The significant decrease in the inhibitory activity for the 
ligand compared to the metal complex clearly indicates that incorporation of copper into the 
ligand environment has a marked effect on cytotoxicity. A possible explanation is that by 
coordination the polarity of the ligand and the central metal ion are reduced through the charge 
equilibration, which favors permeation of the complexes through the lipid layer of the cell 
membrane.
73
 The present results are consistent with the observation that metal complexes can 
exhibit greater biological activities than the free ligand.
36
 
Comparing the activity of four complexes, the cytotoxic activity follows the order 3 > 2 > 1 > 
4, which is reflected from the IC50 values with dose dependency illustrated in Table 3.8 & 
Figure 3.21. It is remarkable that 3, having quinonoidal group in the thiosemicarbazone ligand 
coordinated to the metal is most active. This is in correlation with the fact that the derivatives of 
quinoline are found to show good biological activities such as antioxidation, antiproliferation, 
and anti–inﬂammation.74,75 
 A possible single shot drug for cancer cure has been elusive till date, due to their multiple 
occurrences in more than a hundred forms and several cases of recurrence of cancer post 
chemotherapy and surgery are well known. Interestingly, equating the efficacy of our 
synthesized novel copper compounds against the presently available common chemo drugs sold 
to the patients, we found out that Cisplatin, Gefitinib, Gemcitabine, 5–Florouracil, Vinorelbine 
had an IC50 of 13μM, 20μM, 35μM, 40 μM and 48μM respectively on HeLa cells, under 
conditions similar to our experiment.
76
 These findings give a positive revelation about the 
potential of our copper compounds as future neoplastic precursor drug candidates. 
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3.3.7.2. Nuclear staining assay. To investigate the apoptotic potential of test compounds in 
HeLa cells, DAPI staining was performed. Chromatin condensation during the process of 
apoptosis (type I programmed cell death) is a characterizing marker of nuclear alteration. HeLa 
cells were treated with 30 μM, 25 μM, 15 μM and 30 μM of 1, 2, 3 and 4 respectively. All the 
doses were given below the calculated IC50 and the cells were incubated for 24h before DAPI 
nuclear staining assay. Control cells hardly showed any sort of condensation in comparison to 
the test compound’s activity (as shown in Figure 3.22), when the cells were examined under 
fluorescent microscope, DAPI filter. All images clearly demonstrate the brightly condensed 
chromatin bodies and the nuclear blebbings as marked by arrows in the figure. The drug treated 
groups besides showing nuclear changes also revealed a shrinking morphology, which is another 
important hallmark of apoptosis. 
 
 
Table 3.8. Cytotoxic scores in HeLa cancer cells for 1–4 
 
 
 
 
 
 
Compounds IC₅₀ (μM) 
1 33.5 ±  4.67 
2 31.5 ± 5.72 
3 19.8 ± 3.54 
4 36 ± 6.74 
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Figure 3.21. Effect of 1, 2, 3 and 4 on cancer cell viability and growth: HeLa cells were treated 
with different concentrations of the test compounds for 72h and then cell viability was measured 
by MTT assay. Data reported as the mean ± S.D. for n = 6 and compared against control by using 
a Student’s t–test. (*denotes significance compared to control). 
 
Figure 3.22. Study of apoptosis by morphological changes in nuclei of HeLa cells: After 
treatment, HeLa cells from the control and the treated group were fixed with 3.7% formaldehyde 
for 15 min, permeabilized with 0.1% Triton X–100 and stained with 1µg/ml DAPI for 5 min at 
37°C. The cells were then washed with PBS and examined by fluorescence microscopy 
(Olympus IX 71) (200×). 
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3.4. CONCLUSION 
The following are the salient observations and findings of the work in this chapter:  
a) Two Cu(I) complexes 1 [Cu(HL
1
)(PPh3)2Br]·CH3CN & 2 [Cu(HL
2
)(PPh3)2Cl]·DMSO and 
two Cu(II) complexes 3 [(Cu2L
3
2Cl)2(–Cl)2]·2H2O & 4 [Cu(L
4
)(Py)] of thiosemicarbazone 
ligands were synthesized and characterized by structural, analytical, and spectral methods. 
b) The copper complexes 1–4 showed good DNA binding propensity. Their DNA binding 
activities were determined using UV–Vis absorption titration, competitive DNA binding 
fluorescence experiments, thermal denaturation studies and circular dichroism spectroscopy. The 
experimental results show that the complexes interact with CT–DNA probably by groove 
binding mode, with binding constants ranging from 10
4−105 M-1. The competitive DNA binding 
fluorescence experiments suggest that among all the complexes, 3 showed highest quenching 
constant (Ksv) and Kapp values. 
c) Among all the complexes, 3 displayed significant chemical nuclease activity in presence of 
hydrogen peroxide of ~ 60 %. All the complexes showed good photo–induced cleavage of 
pUC19 supercoiled plasmid DNA with complex 3 showing the highest photo induced DNA 
cleavage activity of ~ 80%.  
d) The results from the mechanistic study suggested that, the chemical nuclease activity of 
complex 3 and the photo nuclease activity of complex 1–2 proceeds probably by both singlet 
oxygen and hydroxyl radical pathways. 
e) In addition, the in vitro antiproliferative activity of complexes 1–4 against HeLa cell line was 
assayed. The cytotoxicity of the complexes is affected by the various functional groups attached 
to the thiosemicarbazone derivative whereby 3 was particularly potent against the cells tested.  
f) The results of pharmacological activity of the copper complexes reported in this chapter 
reveals that the compound 3 shows the highest activity, which may be due to its solubility in 
aqueous medium and the presence of quinonoidal group in the thiosemicarbazone ligand 
coordinated to the metal.  
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g) The results obtained from the present copper complexes are of importance for the 
development of metal–based agents for anti–cancer applications. Further work is in progress to 
better identify the mechanism of action and to prepare more potent related compounds for the 
treatment of cancer. 
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Chemistry of oxido molybdenum(IV/VI) thiosemicarbazone complexes: Active centre of 
molybdenum oxotransferases 
 
ABSTRACT:  
___________________________________________________________________________ 
Oxygen atom transfer (OAT) reactivity of dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1‒6
] 
(1‒6) {4–(p–bromophenyl)thiosemicarbazone of salicylaldehyde (H2L
1
), 4–(p–X–
phenyl)thiosemicarbazone of o–vanillin {where, X = F (H2L
2
) and X = Cl (H2L
3
) and  X = OMe 
(H2L
4
)}, 4–(p–bromophenyl)thiosemicarbazone of 5–bromosalicylaldehyde (H2L
5
), and 4–(p–
chlorophenyl)thiosemicarbazone of o–hydroxynaphthaldehyde (H2L
6
)} with PPh3 have been 
investigated. The OAT reactions proceed through the formation of OPPh3, which have been 
characterized by 
31
P NMR. Dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1/5/6
(DMSO)] (1a, 
5a & 6a), [Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) and 
monooxidomolybdenum(IV) complexes [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) {where, N‒N = 
2,2'‒bipyridyl or 1,10‒phenanthroline} are reported as the product of substrate binding and 
oxygen atom transfer reactivity of dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1‒6
] (1‒6) 
respectively. All the complexes have been spectroscopically charecterized. Molecular structures 
of some of the Mo(VI) (1a‒4a) and Mo(IV) complexes (7 and 9‒11) have been determined by 
single crystal X–ray crystallography. The catalytic activity of Mo(VI) complexes (1a‒6a) have 
also been studied. 
___________________________________________________________________________ 
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4.1. INTRODUCTION 
Molybdenum participates in a wide range of metalloenzymes called molybdoenzymes, in which 
molybdenum forms a part of the active sites.
1,2
 These enzymes utilize molybdenum as a cofactor 
that catalyses the transformation processes such as in sulphite oxidase,
3
 xanthine oxidase,
4
 and 
aldehyde oxidase.
5
 Molybdenum(VI) complexes with thiosemicarbazones serving as ONS donor 
ligands have been regarded as excellent models for the molybdenum binding site of these 
enzymes.
6–9 
Molybdenum is found in a large class of enzymes capable of transferring an oxygen atom from 
or to a substrate referred to as mononuclear molybdoenzymes or oxotransferases. Oxygen atom 
transfer (OAT) processes, as well as oxidation processes, are important in nature and in chemical 
industry.
10
 OAT chemistry has attracted considerable attention in recent years because of its 
relevance in biological processes mediated by molybdenum or tungsten oxotransferases.
11–13
 It 
has been known that the presence of sulfur atoms coordinated to molybdenum is favourable for 
complexes of molybdenum to have oxotransfer activity, and many model compounds that mimic 
oxotransferases have been studied.
14–20
 Molybdenum enzymes catalyze a number of such 
reactions. These oxotransferases contain oxido– (or dioxido)–molybdenum units additionally 
coordinated by sulfur atoms.
2,21
 In order to understand the activity of oxotransferase 
molybdoenzymes, several attempts have been made to monitor the oxotransfer reaction of 
dioxidomolybdenum complexes to substrates such as PPh3.
15
 Oxidomolybdenum complexes 
have been isolated and characterized as end products of such reactions along with PPh3O.
22
 
Some of these reactions have also been kinetically followed.
23 
In addition, molybdenum complexes are known for their catalytic applications in the oxidation
24–
40
 and oxidative bromination of organic substrates,
41–44
 and the oxidation of sulfides.
45–48
 Mo(VI) 
complexes are also known to be very active as epoxidation catalysts, generally in solution of an 
organic solvent, especially for neutral complexes
49
 much as evidenced by number of 
publications.
32,37,39,45,50–57
 
Our group have currently focused on dioxidomolybdenum(VI) complexes with ligands that 
mimic’s the coordination environment of the metal ion in enzymes. Among them, tridentate 
ligands containing ONS donor atoms has attracted our interest. In this work, we describe the 
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synthesis of a series of cis–dioxidomolybdenum(VI) complexes [Mo(VI)O2L
1‒6
] (1‒6). 
Dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1/5/6
(DMSO)] (1a, 5a & 6a), 
[Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) and 
monooxidomolybdenum(IV) complexes [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) {where, N‒N = 2,2'–
bipyridyl or 1,10–phenanthroline} are also reported as the product of substrate binding and 
oxygen atom transfer reactivity of dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1‒6
] (1‒6) 
respectively. All the complexes have been spectroscopically charecterized. Molecular structures 
of some of the Mo(VI) (1a‒4a) and Mo(IV) complexes (7 and 9‒11) have been determined by 
single crystal X–ray crystallography. The catalytic activity (oxidation of styrene and 
cyclohexene) of Mo
(VI) 
complexes (1a‒6a) have also been studied. 
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4.2. EXPERIMENTAL SECTION 
4.2.1. General methods and materials. All chemicals were purchased from commercial 
sources and used without further purification. Reagent grade solvents were dried and distilled 
prior to use. [MoO2(acac)2] was prepared as described in the literature.
58
 The thiosemicabazides 
were prepared from distilled substituted aniline by a known method reported earlier.
59
 The 
ligands 4–(p–bromophenyl)thiosemicarbazone of salicylaldehyde (H2L
1
),                                                    
4–(p–X–phenyl)thiosemicarbazone of o–vanillin {where, X = F (H2L
2
) and X = Cl (H2L
3
) and   
X = OMe (H2L
4
)}, 4–(p–bromophenyl)thiosemicarbazone of 5–bromosalicylaldehyde (H2L
5
), 
and 4–(p–chlorophenyl)thiosemicarbazone of o–hydroxynaphthaldehyde (H2L
6
) were prepared 
by reported methods.
60,61
 Elemental analyses were performed on a Vario ELcube CHNS 
Elemental analyzer. IR spectra were recorded on a Perkin–Elmer Spectrum RXI spectrometer. 
1
H, 
13
C and 
31
P NMR spectra were recorded with a Bruker Ultrashield 400 MHz spectrometer 
using SiMe4 as an internal standard. Electronic spectra were recorded on a Lamda25, 
PerkinElmer spectrophotometer. Electrochemical data were collected using PAR electrochemical 
analyzer and a PC–controlled potentiostat/galvanostat (PAR 273A) at 298 K in a dry nitrogen 
atmosphere. Cyclic voltammetry experiments were carried out with Pt working and auxiliary 
electrodes and Ag/AgCl as reference electrode. Mass spectra were recorded on a SQ–300 MS 
instrument operating in ESI mode. 
4.2.2. Synthesis of dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1‒6
] (1‒6). To a refluxing 
solution of ligand, H2L
1‒6
 (1.0 mmol) in 30 mL of ethanol, MoO2(acac)2 (1.0 mmol) was added. 
The mixture was refluxed for 2 h and filtered. Dark brown coloured microcrystalline residue was 
obtained.  
[Mo
(VI)
O2L
1
] (1): Yield: 78%. Anal. calc. for C14H10BrMoN3O3S: C, 35.31; H, 2.12; N, 8.82. 
Found: C, 35.35; H, 2.14; N, 8.85. Main IR peaks (KBr, cm
‒1
): 3261 ν(N(3)–H), 3012 ν(C(7)–
H), 1597 s ν(C=C), 1512 m ν(C(7)=N(1)), 918 s, 899 s ν(Mo=O), 764 s ν(C(8)–S(1)). 1H NMR 
(DMSO–d6, 400 MHz) : 9.84 (s, 1H, –C(8)–N(3)H), 8.82 (s, 1H, –N(1)=C(7)H), 7.75–6.90 (m, 
8H, C6H4). 
13
C NMR (DMSO–d6, 100 MHz) : 162.15, 160.43, 155.62, 153.57, 148.72, 139.32, 
134.46, 133.77, 130.82, 124.36, 121.63, 121.22, 117.48, 115.12. ESI Mass (CH3CN): m/z 477.07 
(100%, [M + H]
+
). 
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[Mo
(VI)
O2L
2
] (2): Yield: 75%. Anal. calc. for C15H12FMoN3O4S: C, 40.46; H, 2.72; N, 9.44. 
Found: C, 40.45; H, 2.70; N, 9.41. Main IR peaks (KBr, cm
‒1
): 3287 ν(N(3)–H), 3021 ν(C(7)–
H), 1610 s ν(C=C), 1532 m ν(C(7)=N(1)), 922 s, 889 s ν(Mo=O), 776 s ν(C(8)–S(1)). 1H NMR 
(DMSO–d6, 400 MHz) : 9.86 (s, 1H, –C(8)–N(3)H), 8.80 (s, 1H, –N(1)=C(7)H), 7.82–6.78 (m, 
7H, C6H4), 3.89 (s, 3H, OCH3). 
13
C NMR (DMSO–d6, 100 MHz) : 171.41, 163.64, 158.35, 
153.54, 149.33, 138.63, 134.56, 133.79, 130.24, 124.56, 121.33, 121.67, 117.65, 115.37, 58.85. 
ESI Mass (CH3CN): m/z 468.15 (50%, [M + Na]
 +
); m/z 413 (100%, [M–OCH3]
 +
). 
[Mo
(VI)
O2L
3
] (3): Yield: 75%. Anal. calc. for C15H12ClMoN3O4S: C, 39.02; H, 2.62; N, 9.10. 
Found: C, 39.04; H, 2.60; N, 9.12. Main IR peaks (KBr, cm
‒1
): 3236 ν(N(3)–H), 3012 ν(C(7)–
H), 1597 s ν(C=C), 1514 m ν(C(7)=N(1)), 917 s, 886 s ν(Mo=O), 783 s ν(C(8)–S(1)). 1H NMR 
(DMSO–d6, 400 MHz) : 9.79 (s, 1H, –C(8)–N(3)H), 8.65 (s, 1H, –N(1)=C(7)H), 7.67–6.34 (m, 
7H, C6H4), 3.66 (s, 3H, OCH3). 
13
C NMR (DMSO–d6, 100 MHz) : 169.67, 167.56, 163.87, 
158.54, 155.76, 149.45, 147.34, 145.78, 141.67, 138.54, 135.77, 131.45, 126.76, 120.34, 55.87. 
ESI Mass (CH3CN): m/z 462.19 (100%, [M + H]
+
); 466.61(62%, [M + 4H]
+
). 
[Mo
(VI)
O2L
4
] (4): Yield: 73%. Anal. calc. for C16H15MoN3O5S: C, 42.02; H, 3.31; N, 9.19. 
Found: C, 42.05; H, 3.30; N, 9.21. Main IR peaks (KBr, cm
‒1
): 3289 ν(N(3)–H), 2996 ν(C(7)–
H), 1589 s ν(C=C), 1526 m ν(C(7)=N(1)), 923 s, 894 s ν(Mo=O), 756 s ν(C(8)–S(1)). 1H NMR 
(DMSO–d6, 400 MHz) : 9.43 (s, 1H, –C(8)–N(3)H), 8.25 (s, 1H, –N(1)=C(7)H), 7.78–6.56 (m, 
7H, C6H4), 3.87 (s, 3H, OCH3), 3.56 (s, 3H, OCH3). 
13
C NMR (DMSO–d6, 100 MHz) : 174.56, 
168.45, 167.78, 160.34, 157.22, 150.67, 146.23, 142.54, 140.67, 135.76, 128.34, 122.43, 118.56, 
112.89, 54.53, 51.42. ESI Mass (CH3CN): m/z 457.49 (20%, [M]
+
). 
[Mo
(VI)
O2L
5
] (5): Yield: 78%. Anal. calc. for C14H9Br2MoN3O3S: C, 30.29; H, 1.63; N, 7.57. 
Found: C, 30.28; H, 1.64; N, 7.55. Main IR peaks (KBr, cm
‒1
): 3224 ν(N(3)–H), 2964 ν(C(7)–
H), 1585 s ν(C=C), 1523 m ν(C(7)=N(1)), 921 s, 882 s ν(Mo=O), 762 s ν(C(8)–S(1)). 1H NMR 
(DMSO–d6, 400 MHz) : 9.14 (s, 1H, –C(8)–N(3)H), 8.55 (s, 1H, –N(1)=C(7)H), 7.87–6.56 (m, 
7H, C6H4). 
13
C NMR (DMSO–d6, 100 MHz) : 169.67, 158.52, 153.41, 150.34, 144.54, 140.56, 
136.24, 132.74, 130.82, 128.15, 123.46, 120.37, 117.51, 113.56. ESI Mass (CH3CN): m/z 557.42 
(80%, [M + 2H]
+
). 
[Mo
(VI)
O2L
6
] (6): Yield: 72%. Anal. calc. for C18H12ClMoN3O3S: C, 44.88; H, 2.51; N, 8.72. 
Found: C, 44.92; H, 2.50; N, 8.71. Main IR peaks (KBr, cm
‒1
): 3267 ν(N(3)–H), 3011 ν(C(7)–
H), 1586 s ν(C=C), 1523 m ν(C(7)=N(1)), 926 s, 878 s ν(Mo=O), 773 s ν(C(8)–S(1)). 1H NMR 
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(DMSO–d6, 400 MHz) : 9.28 (s, 1H, –C(8)–N(3)H), 8.63 (s, 1H, –N(1)=C(7)H), 7.63–6.55 (m, 
10H, C6H4). 
13
C NMR (DMSO–d6, 100 MHz) : 169.52, 163.52, 162.52, 158.52, 156.36, 153.24, 
146.56, 143.26, 140.26, 138.21, 135.36, 130.63, 125.42, 122.62, 120.76, 117.26, 113.56, 112.68. 
ESI Mass (CH3CN): m/z 481.43 (100%, [M]
+
). 
4.2.3. Synthesis of dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1/5/6
(DMSO)] (1a, 5a & 
6a), [Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a). Complexes 
1a‒6a were obtained during recrystallization of 1‒6 from DMSO. 
[Mo
(VI)
O2L
1
(DMSO)] (1a): Yield: 73%. Anal. calc. for C16H16BrMoN3O4S2: C, 34.67; H, 2.91; 
N, 7.58. Found: C, 34.65; H, 2.90; N, 7.60. Main IR peaks (KBr, cm
‒1
): 3271 ν(N(3)–H), 3018 
ν(C(7)–H), 1598 s ν(C=C), 1504 m ν(C(7)=N(1)), 920 s, 896 s ν(Mo=O), 760 s ν(C(8)–S(1)). 1H 
NMR (DMSO–d6, 400 MHz) : 9.83 (s, 1H, –C(8)–N(3)H), 8.82 (s, 1H, –N(1)=C(7)H), 7.74–
6.90 (m, 8H, C6H4), 2.54 (s, 6H, DMSO). 
13
C NMR (DMSO–d6, 100 MHz) : 161.55, 159.41, 
155.60, 152.56, 147.76, 140.38, 134.74, 134.57, 131.83, 122.02, 121.50, 121.12, 118.58, 114.42, 
50.34. 
[Mo
(VI)
O2L
2
(H2O)] (2a): Yield: 68%. Anal. calc. for C15H14FMoN3O5S: C, 38.89; H, 3.05; N, 
9.07. Found: C, 38.85; H, 3.02; N, 9.10. Main IR peaks (KBr, cm
‒1
): 3395 ν(H2O), 3285 ν(N(3)–
H), 2968 ν(C(7)–H), 1603 s ν(C=C), 1516 m ν(C(7)=N(1)), 931 s, 887 s ν(Mo=O), 738 s ν(C(8)–
S(1)). 
1
H NMR (DMSO–d6, 400 MHz) : 9.74 (s, 1H, –C(8)–N(3)H), 8.77 (s, 1H, –
N(1)=C(7)H), 7.77–6.94 (m, 7H, C6H4), 3.78 (s, 3H, OCH3). 
13
C NMR (DMSO–d6, 100 MHz) : 
172.74, 163.51, 155.51, 147.67, 146.86, 143. 83, 143.74, 137. 75, 134.33, 127.54, 125.59, 
124.76, 120.68, 118.47, 51.56. 
[Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a): Yield: 72%. Anal. calc. for C72H84Cl4Mo4N12O22S10: C, 
37.34; H, 3.66; N, 7.26. Found: C, 37.37; H, 3.68; N, 7.25. Main IR peaks (KBr, cm
‒1
): 3278 
ν(N(3)–H), 3015 ν(C(7)–H), 1592 s ν(C=C), 1521 m ν(C(7)=N(1)), 916 s, 893 s ν(Mo=O), 778 s 
ν(C(8)–S(1)). 1H NMR (DMSO–d6, 400 MHz) : 9.81 (s, 1H, –C(8)–N(3)H), 8.79 (s, 1H, –
N(1)=C(7)H), 7.78–6.97 (m, 7H, C6H4), 3.79 (s, 3H, OCH3), 2.54 (s, 6H, DMSO). 
13
C NMR 
(DMSO–d6, 100 MHz) : 169.49, 167.35, 162.37, 158.23, 155.06, 148.98, 146.77, 144.58, 
140.30, 137.67, 135.53, 131.47, 126.46, 120.96, 53.35, 48.27. 
[Mo
(VI)
O2L
4
(H2O)] (4a): Yield: 67%. Anal. calc. for C16H17MoN3O6S: C, 40.43; H, 3.60; N, 
8.84. Found: C, 40.45; H, 3.62; N, 8.81. Main IR peaks (KBr, cm
‒1
): 3401 ν(H2O), 3299 ν(N(3)–
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H), 2978 ν(C(7)–H), 1591 s ν(C=C), 1517 m ν(C(7)=N(1)), 925 s, 895 s ν(Mo=O), 735 s ν(C(8)–
S(1)). 
1
H NMR (DMSO–d6, 400 MHz) : 9.56 (s, 1H, –C(8)–N(3)H), 8.70 (s, 1H, –
N(1)=C(7)H), 7.64–6.85 (m, 7H, C6H4), 3.78 (s, 3H, OCH3), 3.72 (s, 3H, OCH3). 
13
C NMR 
(DMSO–d6, 100 MHz) : 176.34, 172.45, 167.53, 160.43, 158.76, 150.88, 144.14, 142.46, 
140.21, 135.54, 129.23, 123.52, 119.74, 113.45, 56.13, 50.24. 
[Mo
(VI)
O2L
5
(DMSO)] (5a): Yield: 68%. Anal. calc. for C16H15Br2MoN3O4S2: C, 30.35; H, 2.39; 
N, 6.64. Found: C, 30.38; H, 2.40; N, 6.65. Main IR peaks (KBr, cm
‒1
): 3211 ν(N(3)–H), 2915 
ν(C(7)–H), 1594 s ν(C=C), 1554 m ν(C(7)=N(1)), 938 s, 892 s ν(Mo=O), 767 s ν(C(8)–S(1)). 1H 
NMR (DMSO–d6, 400 MHz) : 9.34 (s, 1H, –C(8)–N(3)H), 8.76 (s, 1H, –N(1)=C(7)H), 7.63–
6.56 (m, 7H, C6H4), 2.53 (s, 6H, DMSO). 
13
C NMR (DMSO–d6, 100 MHz) : 168.63, 159.45, 
154.72, 151.35, 144.74, 141.33, 135.56, 132.35, 130.54, 128.01, 123.65, 120.64, 117.87, 112.53, 
52.67. 
[Mo
(VI)
O2L
6
(DMSO)] (6a): Yield: 71%. Anal. calc. for C20H18ClMoN3O4S2: C, 42.90; H, 3.24; 
N, 7.50. Found: C, 42.92; H, 3.20; N, 7.51. Main IR peaks (KBr, cm
‒1
): 3282 ν(N(3)–H), 3013 
ν(C(7)–H), 1589 s ν(C=C), 1512 m ν(C(7)=N(1)), 933 s, 887 s ν(Mo=O), 766 s ν(C(8)–S(1)). 1H 
NMR (DMSO–d6, 400 MHz) : 9.34 (s, 1H, –C(8)–N(3)H), 8.56 (s, 1H, –N(1)=C(7)H), 7.35–
6.65 (m, 10H, C6H4), 2.53 (s, 6H, DMSO). 
13
C NMR (DMSO–d6, 100 MHz) : 168.53, 167.12, 
165.53, 158.80, 156.35, 153.65, 146.34, 143.67, 140.64, 139.12, 136.57, 130.76, 126.36, 122.56, 
120.65, 117.87, 113.77, 112.63, 56.32. 
4.2.4. Synthesis of Mo
IV
 complexes [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12). To a refluxing solution of 
[Mo
(VI)
O2L
1‒6
] (1‒6) (1.0 mmol) in 30 mL of degassed acetonitrile 1.5 mmol of PPh3 was added 
followed by 1.0 mmol of (N‒N) {coligand, (N‒N) = 2,2'‒bipyridyl (7, 10 & 11) or 
1,10‒phenanthroline (8, 9 & 12)}, and the solution was refluxed for 3 h. X‒ray quality crystal of 
7 and 9‒11 were obtained from reaction mixture. {bipy = 2,2'‒bipyridyl; phen = 
1,10‒phenanthroline}. 
[Mo
(IV)
OL
1
(bipy)] (7): Yield: 78%. Anal. calc. for C24H18BrMoN5O2S: C, 46.77; H, 2.94; N, 
11.36. Found: C, 46.75; H, 2.96; N, 11.37. Main IR peaks (KBr, cm
‒1
): 3322 ν(N(3)–H), 3041 
ν(C(7)–H), 1598 s ν(C=C), 1540 m ν(C(7)=N(1)), 931 s ν(Mo=O), 753 s ν(C(8)–S(1)). 
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[Mo
(IV)
OL
2
(phen)] (8): Yield: 84%. Anal. calc. for C27H20FMoN5O3S: C, 53.21; H, 3.31; N, 
11.49. Found: C, 53.25; H, 3.32; N, 11.51. Main IR peaks (KBr, cm
‒1
): 3315s ν(N(3)–H), 3053 
ν(C(7)–H), 1586 s ν(C=C), 1502 m ν(C(7)=N(1)), 945 s ν(Mo=O), 740 s ν(C(8)–S(1)). 
[Mo
 (IV)
OL
3
(phen)] (9): Yield: 74%. Anal. calc. for C27H20ClMoN5O3S: C, 51.81; H, 3.22; N, 
11.19. Found: C, 51.85; H, 3.20; N, 11.15. Main IR peaks (KBr, cm
‒1
): 3298 s ν(N(3)–H), 3012 
ν(C(7)–H), 1586 s ν(C=C), 1512 m ν(C(7)=N(1)), 922 s ν(Mo=O), 746 s ν(C(8)–S(1)). 
[Mo
(IV)
OL
4
(bipy)] (10): Yield: 76%. Anal. calc. for C26H23MoN5O4S: C, 52.26; H, 3.88; N, 
11.72. Found: C, 52.25; H, 3.86; N, 11.75. Main IR peaks (KBr, cm
‒1
): 3286 s ν(N(3)–H), 2978 
ν(C(7)–H), 1590 s ν(C=C), 1511 m ν(C(7)=N(1)), 941 s ν(Mo=O), 748 s ν(C(9)–S(1)). 
[Mo
(IV)
OL
5
(bipy)] (11): Yield: 88%. Anal. calc. for C24H17Br2MoN5O2S: C, 41.46; H, 2.46; N, 
10.07. Found: C, 41.45; H, 2.42; N, 10.05. Main IR peaks (KBr, cm
‒1
): 3211 s ν(N(3)–H), 2976 
ν(C(7)–H), 1589 s ν(C=C), 1516 m ν(C(7)=N(1)), 934 s, ν(Mo=O), 754 s ν(C(8)–S(1)). 
[Mo
(IV)
OL
6
(phen)] (12): Yield: 85%. Anal. calc. for C30H20ClMoN5O2S: C, 55.78; H, 3.12; N, 
10.84. Found: C, 55.75; H, 3.10; N, 10.81. Main IR peaks (KBr, cm
‒1
): 3311 s ν(N(3)–H), 3017 
ν(C(7)–H), 1584 s ν(C=C), 1501 m ν(C(7)=N(1)), 928 s ν(Mo=O), 748 s ν(C(8)–S(1)). 
4.2.5. X–ray crystallography. Single crystals of complexes were mounted on Bruker Smart 
APEX II CCD diffractometer (1a), Rigaku XtaLAB mini diffractometer (2a–4a), Bruker APEX 
II diffractometer (7, 9 and 11) and Nonius Kappa CCD FR590 diffractometer (10) equipped with 
a graphite monochromator and a Mo K radiator (λ=0.71073 Å). Crystallographic data and 
details of refinement of 1a–4a are given in Table 4.1 and 7 and 9−11 are given in Table 4.2.The 
unit cell dimensions and intensity data were measured at 292(2) K for 1a, 293(2) K for 2a & 3a, 
100(2) K for 4a, 9 & 11, 105 K for 7 and, 130 K for 10. The data were integrated and scaled 
using SAINT, SADABS within the APEX2 software package by Bruker.
62
 Absorption 
corrections were applied using SADABS
63
 and the structures were solved by direct methods 
using the program SHELXS−9764 and refined using least squares with the SHELXL−9764 
software program. Hydrogen atoms were placed in geometrically idealised positions and 
constrained to ride on their parent atoms with C−H distances in the range 0.95−1.00 Å. The non–
hydrogen atoms were refined anisotropically. 
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Table 4.1. Crystal data and refinement details of [Mo
(VI)
O2L
1
(DMSO)] (1a), 
[Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a). 
Compound 1a 2a 3a 4a 
Formula C16H16BrMoN3
O4S2 
C15H14FMoN3 
O5S 
C72H84Cl4Mo4 
N12O22S10 
C16H17MoN3 
O6S 
M 554.29 463.29 2315.67 475.33 
Crystal system Monoclinic Monoclinic Monoclinic Monoclinic 
Space group P 21/a P 21/c C 2/c P 21/c 
a(Å) 16.114(5) 15.082(15) 22.871(13) 16.002(11) 
b(Å) 6.849(2) 13.711(13) 17.611(10) 13.425(6) 
c(Å) 19.545(6) 10.399(10) 11.323(8) 10.581 (4) 
 (°) 90 90 90 90 
β (°) 107.847 93.938(7) 92.129(7) 93.767(7) 
γ (°) 90 90 90 90 
V(Å
3
) 2053.3(11) 2145.3(4) 4557.3(5) 2268.2(2) 
Z 4 4 2 4 
Dcalc(Mg.m
–3
) 1.793 1.434 1.688 1.392 
F(000) 1096 928 2344 960 
(Mo–K)(mm–1) 2.814 0.743 0.959 0.702 
max./min.trans. 0.6313 / 0.5515 0.8778 / 0.8189 0.8313 / 0.8313 0.8960 / 0.8223 
2(max)(o) 25.15 27.48 27.48 27.48 
Reflections 
collected / unique 
14246 / 3683  
[R(int) = 0.1199] 
4912 / 4912  
[R(int) = 0.0293] 
23695 / 5226 
[R(int) = 0.0226] 
5183 / 5183 
[R(int) = 0.0254] 
R1[I>2(I)] R1 = 0.0531,  
wR2 = 0.0905 
R1 = 0.0332,  
wR2 = 0.0973 
R1 = 0.0214,  
wR2 = 0.0548 
R1 = 0.0285,  
wR2 = 0.0802 
wR2[all data] R1 = 0.1287, 
wR2 = 0.1126 
R1 = 0.0383,  
wR2 = 0.1003 
R1 = 0.0233,  
wR2 = 0.0557 
R1 = 0.0330,  
wR2 = 0.0829 
S[goodness of fit] 0.971 1.076 1.052 1.083 
min./max. res. 
(e.Å
–3
) 
0.678 / –0.653 0.720 / –0.459 0.277 / –0.532 0.650 / –0.408 
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Table 4.2. Crystal data and refinement details of [Mo
(IV)
OL
1,3‒5
(N‒N)] (7, 9‒11) 
Compound 7 9 10 11 
Formula C24H18BrMoN5
O2S 
C27H20ClMoN5
O3S 
C26H23MoN5 
O4S 
C24H17Br2MoN5
O2S 
M 616.34 625.93 597.49 695.25 
Crystal system triclinic Monoclinic Monoclinic Triclinic 
Space group P ī P 21/n P 21/n P ī 
a(Å) 9.965(6) 10.406(5) 10.505(4) 7.103(5) 
b(Å) 10.537(6) 9.998(5) 10.549(4) 8.7250(7) 
c(Å) 11.526(7) 24.028(12) 22.145(12) 19.151(16) 
 (°) 101.490(3) 90 90 96.292(5) 
β (°) 96.333(3) 93.926(3) 100.20(10) 92.914(5) 
γ (°) 104.591(3) 90 90 91.650(5) 
V(Å
3
) 1131.25(12) 2494.1(2) 2415.35(18) 1177.54(16) 
Z 2 4 4 2 
Dcalc(Mg.cm
–3
) 1.809 1.667 1.643 1.961 
F(000) 612 1264 1216 680 
(Mo–K)(mm–1) 2.472 0.758 0.675 4.073 
max./min.trans. 0.9295/0.9076 0.9850/0.9280 0.9356/0.8495 0.9604/ 0.8876 
2(max)(o) 28.6 26.39 28.31 26.75 
Reflections 
collected / unique 
51409/5668  
[R(int)=0.0415] 
70158/5058 
[R(int)=0.1008] 
10989/5878 
[R(int)=0.0586] 
27997/4875 
[R(int)=0.1318] 
R1[I>2(I)] R1 = 0.0285,  
wR2 = 0.0556 
R1 = 0.0478, 
wR2 = 0.0769 
R1 = 0.0415, 
wR2 = 0.0881 
R1 = 0.0626, 
wR2 = 0.1217 
wR2[all data] R1 = 0.0384,  
wR2 = 0.0586 
R1 = 0.0812, 
wR2 = 0.0860 
R1 = 0.0753, 
wR2 = 0.0988 
R1 = 0.1351, 
wR2 = 0.1454 
S[goodness of fit] 1.075 1.058 0.950 1.008 
min./max. res. 
(e.Å
–3
) 
0.543/–0.726 0.805/ –0.615 1.081/ –0.920 1.387/ –0.964 
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4.2.6. Substrate binding reactivity of [Mo
(VI)
O2L
1‒6
] (1‒6). Complexes (1‒6) were 
recrystallized in DMSO leading to binding of substrate (solvent) to MoO2L core, and yielding 
dark red crystals of [Mo
(VI)
O2L
1/5/6
(DMSO)] (1a, 5a & 6a), [Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and 
[Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a). 
 
4.2.7. OAT reactivity studies 
 
4.2.7.1. Oxo atom transfer to substrate: PPh3. In a typical experiment, 1.0 mmol of 
[Mo
(VI)
O2L
1‒6
] (1‒6) was dissolved in 30 mL of degassed acetonitrile followed by addition of 
excess of PPh3 and (N‒N) {coligand, (N‒N) = 2,2'–bipyridyl or 1,10–phenanthroline}. The 
solution was refluxed for 24 h. 
31
P NMR spectra of the solution indicated selective formation of 
OPPh3. 
4.2.7.2. Oxo atom transfer from substrate: DMSO. The oxygen atom transfer from the 
substrate (DMSO) to the systems [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) has been studied 
spectrophotometrically. 
 
4.2.8. Catalytic reactions 
 
4.2.8.1. Oxidation of styrene. In a typical oxidation reaction, styrene (0.520 g, 5 mmol), 
aqueous 30% H2O2 (1.71 g, 15 mmol), catalyst (0.0010 g) and NaHCO3 (0.126 g, 1.5 mmol) 
where mixed in 5 ml of CH3CN. The reaction mixture was refluxed at 60°C for 4 h. The progress 
of the reaction was monitored by withdrawing samples at different time intervals and samples 
were extracted with n–hexane and then analysed quantitatively by gas chromatography. The 
effect of various parameters such as amount of catalyst, amount of oxidant, and solvent were 
checked to optimize the conditions for the best performance of the catalyst. The identity of the 
products was confirmed by GC–mass. 
4.2.8.2. Oxidation of cyclohexene. Cyclohexene (0.41 g, 5 mmol), NaHCO3 (0.126 g, 1.5 mmol) 
and 30% H2O2 (1.70 g, 15 mmol) were mixed in 5 ml of CH3CN. Three different amounts of 
catalyst viz. 0.0005, 0.0010 and 0.0015 g as a function of time were added. The reaction mixture 
was refluxed at 60°C for 4 h. The identity of the products was confirmed as mentioned above. 
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4.3. RESULT AND DISSCUSSION 
4.3.1. Dioxidomolybdenum(VI) complexes 
4.3.1.1. Synthesis. Reaction of MoO2(acac)2 with ligands (H2L
1–6
) {4–(p–
bromophenyl)thiosemicarbazone of salicylaldehyde (H2L
1
), 4–(p–X–phenyl)thiosemicarbazone 
of o–vanillin {where, X = F (H2L
2
) and X = Cl (H2L
3
) and X = OMe (H2L
4
)}, 4–(p–
bromophenyl)thiosemicarbazone of 5–bromosalicylaldehyde (H2L
5
), and 4–(p–
chlorophenyl)thiosemicarbazone of o–hydroxy naphthaldehyde (H2L
6
)} in the equimolar ratio in 
ethanol formed dark brown product of stoichiometry [Mo
(VI)
O2L
1‒6
] (1‒6), which when 
recrystallised in DMSO yielded dark red crystals of [Mo
(VI)
O2L
1/5/6
(DMSO)] (1a, 5a & 6a), 
[Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) (Scheme 4.1). All the 
complexes are highly soluble in aprotic solvents, viz. DMF or DMSO and are sparingly soluble 
in alcohol, CH3CN and CHCl3.  
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Scheme 4.1. Schematic diagram of ligands and synthetic pathways of dioxidomolybdenum(VI) 
complexes [Mo
(VI)
O2L
1–6
)] (1–6), [Mo(VI)O2L
1/5/6
(DMSO)] (1a, 5a & 6a), [Mo
(VI)
O2L
2/4
(H2O)] 
(2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a). 
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4.3.1.2. Description of X–ray structure of dioxidomolybdenum(VI) complexes 
[Mo
(VI)
O2L
1
(DMSO)] (1a), [Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and 
[Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a). The molecular structure and the atom numbering scheme 
for the complexes 1a–4a are shown in Figures 4.1–4.4 respectively. The relevant bond distances 
and angles are collected in Table 4.3. The coordination geometry around the molybdenum(VI) 
atom in 1a–4a reveals a distorted octahedral environment with an NO4S coordination sphere 
(Scheme 4.1). Each ligand molecule behaves as a dianionic tridentate one and bonded to the 
metal centre through the phenolate oxygen O(1), thiolate sulfur S(1) and the imine nitrogen N(1) 
forming a five membered and a six membered chelate ring with O(1)–Mo(1)–N(1) and S(1)–
Mo(1)–N(1) bite angles of ~83.00(6)º and ~75.68(4)° respectively. In all the complexes, one of 
the two oxo group O(3) is located trans to the imine nitrogen N(1) in the same plane and the 
other oxo group O(2) is located in the axial plane along with the solvent molecule, DMSO (1a & 
3a) and H2O (2a & 4a). 
We were unable to solve the structures of complexes 1–6 due to poor quality of crystals. 
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Table 4.3. Selected geometric parameters (Å, º) for [Mo
(VI)
O2L
1
(DMSO)] (1a), 
[Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) 
 1 2 3 4 
Bond Distances 
Mo(1)‒O(1) 1.932(5) 1.926(2) 1.929(1) 1.926(1) 
Mo(1)‒O(2) 1.699(5) 1.706(2) 1.703(1) 1.701(2) 
Mo(1)‒O(3) 1.701(5) 1.690(2) 1.707 (1) 1.698(2) 
Mo(1)‒O(4) 2.389(4) 2.342(2) 2.314(1) 2.319(2) 
Mo(1)‒N(1) 2.272(6) 2.266(2) 2.275(1) 2.289(2) 
Mo(1)‒S(1) 2.444(2) 2.426(7) 2.438(4) 2.417(6) 
Bond Angles 
O(2)‒Mo(1)‒O(3) 105.40(2) 105.41(1) 104.95(6) 105.21(9) 
O(2)‒Mo(1)‒O(1) 97.50(2) 100.16(9) 98.15(6) 100.03(8) 
O(3)‒Mo(1)‒O(1) 105.70(2) 104.05(9) 107.68(5) 103.70(7) 
O(2)‒Mo(1)‒N(1) 92.30(2) 90.79(9) 91.12(5) 89.86(8) 
O(3)‒Mo(1)‒N(1) 159.30(2) 160.30(1) 158.93(5) 161.90(8 
O(1)‒Mo(1)‒N(1) 82.05(2) 83.52(7) 82.85(5) 83.00(6) 
O(2)‒Mo(1)‒O(4) 169.10(2) 168.07(9) 169.92(5) 168.18(8) 
O(3)‒Mo(1)‒O(4) 85.30(2) 86.42(1) 85.08(5) 86.59(8) 
O(1)‒Mo(1)‒O(4) 77.03(2) 77.90(8) 77.48(5) 77.24(7) 
N(1)‒Mo(1)‒O(4) 77.65(2) 77.31(8) 79.38(4) 78.43(6) 
O(2)‒Mo(1)‒S(1) 99.05(2) 96.61(8) 97.32(4) 97.54(6) 
O(3)‒Mo(1)‒S(1) 90.74(2) 91.06(8) 88.79(4) 92.15(6) 
O(1)‒Mo(1)‒S(1) 152.59(1) 153.42(6) 153.53(4) 152.23(5) 
N(1)‒Mo(1)‒S(1) 75.64(1) 75.74(5) 75.49(3) 75.68(4) 
O(4)‒Mo(1)‒S(1) 82.75(1) 81.42(6) 83.66(3) 81.17(5) 
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Figure 4.1. ORTEP diagram of [Mo
(VI)
O2L
1
(DMSO)] (1a) with atom labeling scheme. 
 
 
Figure 4.2. ORTEP diagram of [Mo
(VI)
O2L
2
(H2O)] (2a) with atom labeling scheme. 
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Figure 4.3. ORTEP diagram of asymmetric unit of [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) with 
atom labeling scheme. 
 
 
Figure. 4.4. ORTEP diagram of [Mo
(VI)
O2L
4
(H2O)] (4a) with atom labeling scheme. 
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4.3.1.3. Spectral characteristics 
4.3.1.3.1. IR spectroscopy. The infrared spectra of complexes (1‒6) and (1a‒6a), exhibits two 
strong absorptions in the range 938‒878 cm‒1, beside typical ligand vibrations,8,65 which are 
attributed to the symmetric and asymmetric ν(Mo=O) vibrations of the C2v cis– MoO2
2+
 groups, 
thus confirming the formation of mononuclear molybdenum(VI) complexes.
66
 The detailed IR 
data has been included in the experimental section and Figure 4.5(a) depicts the representative 
spectra of [Mo
(VI)
O2L
1
] (1). 
 
 
 
Figure 4.5. Overlay (a) IR spectra and (b) UV‒Vis spectra of [Mo(VI)O2L
1
] (1) and 
[Mo
(IV)
OL
1
(bipy)] (7).  
 
4.3.1.3.2. UV‒Vis spectroscopy. The electronic spectra of complexes (1‒6) and (1a‒6a) were 
recorded in CH3CN and are listed in Table 4.4. Figure 4.5(b) depicts the representative UV‒Vis 
spectra of [Mo
(VI)
O2L
1
] (1). Complexes (1‒6) and (1a‒6a) displays medium intensity band in 
447–422 nm region and two strong absorptions in 346–243 nm range, which are assignable to 
ligand to molybdenum (pπ–dπ) charge transfer (LMCT) and intraligand transitions 
respectively.
67
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Table 4.4. Electronic spectra
[a]
 for complexes [Mo
(VI)
O2L
1–6
)] (1–6), [Mo(VI)O2L
1/5/6
(DMSO)] 
(1a, 5a & 6a), [Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[a]
In CH3CN solution. 
 
4.3.1.3.3. NMR spectroscopy. The NMR spectra (
1
H and 
13
C) of the dioxidomolybdenum(VI) 
complexes (1‒6) and (1a‒6a) were recorded using DMSO–d6. The 
1
H NMR spectrum exhibits 
two singlets in the range 9.86‒8.25 ppm due to NH (–C(8)–N(3)H) and CH (–N(1)=C(7)–H) 
groups respectively. Signals for aromatic protons found as multiplets, in 7.87‒6.34 ppm. The 
detailed NMR data of all the ligands and their corresponding Mo(VI) complexes have been 
included in the experimental section. The representative 
1
H NMR spectrum of ligand H2L
1
 and 
its corresponding Mo
VI
 complexes [Mo
(VI)
O2L
1
] (1) and [Mo
(VI)
O2L
1
(DMSO)] (1a) is shown in 
Figures 4.6‒4.8 respectively. 
Complex λmax/nm(ε/dm
3
mol
–1
cm
–1
)
 
[Mo
(VI)
O2L
1
] (1) 272(16739), 342(14300), 425(3658) 
[Mo
(VI)
O2L
2
] (2) 265(16366), 315(13896), 422(3589) 
[Mo
(VI)
O2L
3
] (3) 278(15967), 345(14253), 447(3786) 
[Mo
(VI)
O2L
4
] (4) 263(16636), 337(14654), 425(3677) 
[Mo
(VI)
O2L
5
] (5) 278(16787), 335(14324), 426(3568) 
[Mo
(VI)
O2L
6
] (6) 258(16746), 342(13877), 442(3578) 
[Mo
(VI)
O2L
1
(DMSO)] (1a) 268(17072), 341(14323), 433(3370) 
[Mo
(VI)
O2L
2
(H2O)] (2a) 265(16341), 321(12543), 428(2789) 
[Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) 264(17534), 346(13535), 436(5422) 
[Mo
(VI)
O2L
4
(H2O)] (4a) 274(16432), 328(14212), 442(3856) 
[Mo
(VI)
O2L
5
(DMSO)] (5a) 270 (16322), 343(13648), 439(3922) 
[Mo
(VI)
O2L
6
(DMSO)] (6a) 243(16429), 338(13768), 437(3425) 
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Figure 4.6. 
1
H NMR spectra of ligand H2L
1
. 
 
Figure 4.7. 
1
H NMR spectra of complex [Mo
(VI)
O2L
1
] (1). 
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Figure 4.8. 
1
H NMR spectra of complex [Mo
(VI)
O2L
1
(DMSO)] (1a) in DMSO–d6. 
4.3.1.3.4. ESI mass spectroscopy. ESI mass spectra of 1−6 have been recorded in CH3CN 
solution. Mass spectral analysis for 1−6 shows peaks at m/z 477.07 [M + H]+, m/z 468.15 [M + 
Na]
 +
, m/z 462.19 [M + H]
+
, m/z 457.49 [M]
+
, m/z 557.42 [M + 2H]
+
.and m/z 481.43 [M]
+
 
respectively. The detailed ESI mass data have been included in the experimental section. 
4.3.1.4. Electrochemical properties. The electrochemical properties of 1a–6a were examined in 
CH3CN solution (0.1 M TEAP) by cyclic voltammetry using a platinum working electrode, 
platinum auxiliary electrode and an Ag/AgCl reference electrode. The potential data are listed in 
Table 4.5 and Figure 4.9 depicts the representative voltammogram of [Mo
(VI)
O2L
2
(H2O)] (2a). 
The voltammogram pattern is similar for 1a‒6a, which includes two irreversible reduction 
processes within the potential window ‒0.71 to ‒0.66 V and ‒0.92 to ‒0.85 V corresponding to 
metal centered reduction from Mo
(VI)/
Mo
(V)
 and Mo
(V)/
Mo
(IV)
 respectively.
68
 The redox properties 
of 1‒6 were also examined, and the results matched well with the above. 
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Table 4.5. Cyclic voltammetric
[a]
 results for complexes [Mo
(VI)
O2L
1/5/6
(DMSO)] (1a, 5a & 
6a), [Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[a]
In CH3CN at a scan rate 100 mV/s. Epc is cathodic peak potentials vs. Ag/AgCl, respectively. 
 
 
Figure 4.9. Cyclic voltammogram of [Mo
(VI)
O2L
2
(H2O)] (2a). 
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Epc 
[Mo
(VI)
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1
(DMSO)] (1a) ‒0.66 ‒0.87 
[Mo
(VI)
O2L
2
(H2O)] (2a) ‒0.71 ‒0.92 
[Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) ‒0.70 ‒0.92 
[Mo
(VI)
O2L
4
(H2O)] (4a) ‒0.68 ‒0.85 
[Mo
(VI)
O2L
5
(DMSO)] (5a) ‒0.66 ‒0.87 
[Mo
(VI)
O2L
6
(DMSO)] (6a) ‒0.70 ‒0.88 
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4.3.1.5. Substrate binding reactivity of [Mo
(VI)
O2L
1‒6
] (1‒6). [Mo(VI)O2L
1‒6
] (1‒6) were 
recrystallized in DMSO yielding dark red crystals of [Mo
(VI)
O2L
1/5/6
(DMSO)] (1a, 5a & 6a), 
[Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) (Scheme 4.1). This can 
be considered as a substrate–binding reaction of the MoO2L core when a solvent molecule 
(substrate) binds to the distorted square–pyramidal MoO2L moiety forming a distorted octahedral 
species (Eq. (1)). This reaction reminds us of the substrate binding property of 
molybdoenzymes.
67b 
MoO2L  +  Solv MoO2L(Solv)
Where,  Solv:  DMSO (1a, 3a, 5a & 6a) 
                         and H2O (2a & 4a)
Eq. (1)
 
4.3.1.6. OAT reactivity studies 
4.3.1.6.1. Oxo atom transfer to substrate: PPh3. The assessment of oxygen atom transfer from 
[Mo
(VI)
O2L
1‒6
] (1‒6) to PPh3 (Scheme 4.2, Eq. (2)) has been performed in acetonitrile in the 
presence of excess of the triphenylphosphine (PPh3) and (N‒N) {coligand, (N‒N) = 2,2'–
bipyridyl or 1,10–phenanthroline} in N2 atmosphere. The reaction has been monitored by the 
gradual appearance of OPPh3 (27 ppm) as probed by 
31
P NMR. The 
31
P NMR spectrum of the 
solution after 24 h displays signals for OPPh3 and residual PPh3.The representative 
31
P NMR 
spectra showing the gradual conversion of PPh3 to OPPh3 by [Mo
(VI)
O2L
6
] (6) is given in Figure 
4.10. In a control experiment, without adding complex only trace amounts of OPPh3 were 
detected after 24 h due to phosphine reacting with atmospheric oxygen. 
MoO2L  +  PPh3 MoOL(N-N)
N-N
N2, CH3CN
+ OPPh3
Where,  N-N:  2,2'-bipyridyl  or
                         1,l0-phenanthroline
Eq. (2)
 
MoVI
O
OO
N S
MoIV
O N
S
O
N
N
PPh3
OPPh3Me2SO
Me2S
N-N
 
Scheme 4.2. Schematic diagram for OAT reactions. 
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Figure 4.10. 
31
P NMR spectra showing the gradual conversion of PPh3 to OPPh3 in a system 
containing initially 1 mmol [Mo
(VI)
O2L
6
] (6) with excess Ph3P and 1,10–phenanthroline in 
degassed CH3CN at (a) 0 h; (b) 1 h; (c) 2 h; (d) 3 h; (e) 4 h; (f) 5 h; (g) 6 h; (h) 7 h; (i) 24 h. 
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4.3.1.6.2. Oxo atom transfer from substrate: DMSO. The oxygen atom transfer from the 
substrate DMSO to the system [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) (Scheme 4.2) has been studied 
spectrophotometrically in DMSO solution. The parent complexes [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) 
exhibits a low–energy bands at ~640 to 550 nm and an intense band at ~430 nm. On addition of 
DMSO to [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12), the intensity of these bands is found to decrease 
gradually. The bands due to d‒d transition at ~640 to 550 nm finally disappear within 30 min, 
and a new the intensity of band, at ~350 nm increases. This observation clearly indicates the 
transfer of an oxygen atom from DMSO (Me2SO) to the MoO
2+
 core, leading to the formation of 
MoO2
2+
 and Me2S species (Eq. (3)). The representative time dependent UV‒Vis spectra of 
[Mo
(IV)
OL
1
(bipy)] (7) in DMSO is given in Figure 4.11. The formation of Me2S was confirmed 
by its characteristic odour. 
Where,  N-N:  2,2'-bipyridyl  or
                         1,l0-phenanthroline
MoO2LMoOL(N-N) + DMSO + Eq. (3)Me2S
 
  
Figure 4.11. Time dependent UV‒Vis spectra of [Mo(IV)OL1(bipy)] (7) in DMSO showing the 
gradual vanish of d–d peak. 
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4.3.2. Monooxidomolybdenum(IV) complexes 
4.3.2.1. Synthesis. Monooxidomolybdenum(IV) complexes [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) were 
synthesized by the reduction of dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1‒6
] (1‒6) with 
PPh3 in presence of 2,2'–bipyridyl or 1,10–phenanthroline in N2 atmosphere. The detailed 
synthetic methods of complexes (7‒12) are illustrated in Scheme 4.3. All the complexes are 
highly soluble in aprotic solvents, viz. DMF or DMSO and are sparingly soluble in alcohol, 
CH3CN and CHCl3.  
MoVI
O
OO
N S
CH3CN,
Reflux, 3 h PPh3, N-N
MoIV
O N
S
O
N
N
Complexes 7-12
N-N: 2,2'-bipyridyl; 1,l0-phenanthroline
Complexes 1-6
 
 
Scheme 4.3. Schematic diagram of synthetic pathways of monooxidomolybdenum(IV) 
complexes [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12). 
 
4.3.2.2. Description of X‒ray structure of monooxidomolybdenum(IV) complexes 
[Mo
(IV)
OL
1,3‒5
(N‒N)] (7 and 9−11). The atom numbering scheme for the complexes 7 and 9−11 
are given in Figures 4.12−4.15 with the relevant bond distances and angles collected in Table 
4.6. The structure shows that the thiosemicarbazone ligand (L
2−
) is coordinated to metal center in 
the expected tridentate fashion (Scheme 4.3), forming a six and a five membered chelate ring 
with O(1)–Mo(1)–N(1) and S(1)–Mo(1)–N(1) bite angles of ~86.82(7)º and ~78.81(5)° 
respectively. The bidentate co−ligands 2,2'−bipyridyl (7, 10 & 11) and 1,10–phenanthroline (9) 
are coordinated to the metal center via N(4) and N(5). The cental metal is coordinated to one 
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oxido group O(2). Thus the complexes form monooxido Mo
IV
 complex with distorted octahedral 
geometry, where the equatorial positions are occupied by the thiolate sulfur S(1), the phenolate 
oxygen O(1) and the imino nitrogen N(1) of ligand and pyridyl nitogen N(4) of the coligand and 
the axial positions are occupied by the oxido oxygen O(2) and pyridyl nitogen N(5). 
 
Table 4.6. Selected geometric parameters (Å, º) for [Mo
(IV)
OL
1,3‒5
(N‒N)] (7 and 9−11). 
 7 9 10 11 
Bond Distances 
Mo(1)‒O(1) 2.067(2) 2.055(2) 2.077(2) 2.070(5) 
Mo(1)‒N(1) 2.135(2) 2.138(3) 2.136(2) 2.129(7) 
Mo(1)‒S(1) 2.390(6) 2.389(1) 2.401(8) 2.358(2) 
Mo(1)‒N(4) 2.172(2) 2.177(3) 2.199(2) 2.248(7) 
Mo(1)‒N(5) 2.314(2) 2.334(3) 2.304(2) 2.265(6) 
Mo(1)‒O(2) 1.685(2) 1.679(3) 1.685(2) 1.686(5) 
Bond Angles 
O(2)‒Mo(1)‒O(1) 104.71(8) 106.19(1) 104.60(9) 108.50(2) 
O(2)‒Mo(1)‒N(1) 104.96(8) 103.74(1) 104.89(1) 95.10(2) 
O(1)‒Mo(1)‒N(1) 86.82(7) 85.68(1) 86.10(8) 84.30(2) 
O(2)‒Mo(1)‒N(4) 89.67(8) 88.18(1) 87.50(9) 81.10(2) 
O(1)‒Mo(1)‒N(4) 85.76(7) 86.65(1) 87.79(8) 99.90(2) 
N(1)‒Mo(1)‒N(4) 164.88(7) 167.25(1) 167.23(9) 175.00(2) 
O(2)‒Mo(1)‒N(5) 160.02(8) 159.46(1) 157.52(1) 150.00(3) 
O(1)‒Mo(1)‒N(5) 78.14(7) 76.54(1) 78.69(8) 74.30(2) 
N(1)‒Mo(1)‒N(5) 94.90(7) 96.75(1) 97.49(9) 114.80(2) 
N(4)‒Mo(1)‒N(5) 70.68(7) 71.53(1) 70.28(9) 69.20(2) 
O(2)‒Mo(1)‒S(1) 101.53(6) 102.03(1) 101.66(7) 106.32(2) 
O(1)‒Mo(1)‒S(1) 152.57(6) 150.24(9) 152.07(6) 142.30(2) 
N(1)‒Mo(1)‒S(1) 78.81(5) 78.58(9) 78.08(6) 78.70(2) 
N(4)‒Mo(1)‒S(1) 102.32(5) 103.66(9) 102.78(6) 99.25(2) 
N(5)‒Mo(1)‒S(1) 79.95(5) 80.40(9) 80.71(6) 82.72(2) 
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Figure 4.12. ORTEP diagram of [Mo
(IV)
OL
1
(bipy)] (7) with atom labeling scheme. 
 
 
Figure 4.13. ORTEP diagram of [Mo
(IV)
OL
3
(phen)] (9) with atom labeling scheme. 
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Figure 4.14. ORTEP diagram of [Mo
(IV)
OL
4
(bipy)] (10) with atom labeling scheme. 
 
 
Figure 4.15. ORTEP diagram of [Mo
(IV)
OL
5
(bipy)] (11) with atom labeling scheme. 
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4.3.2.3. Spectral characteristics 
4.3.2.3.1. IR spectroscopy. In contrast to Mo
VI
 complexes the IR spectra of complexes 
[Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) shows only one strong absorption in the range 945‒922 cm‒1, which 
indicates the presence of single ν(Mo=O) vibration.69 The detailed IR data has been included in 
the experimental section. Figure 4.5(a) depicts the representative spectra of [Mo
(IV)
OL
1
(bipy)] 
(7). 
 
4.3.2.3.2. UV‒Vis spectroscopy. [Mo(IV)OL1‒6(N‒N)] (7‒12) were found to display several 
absorption in the range 659‒260 nm. The electronic data are listed in Table 4.7. The low energy 
charge transfer bands in the range 659‒517 nm were observed due to d‒d transition.67 The 
medium intensity band in 462–414 nm region and two strong absorptions in 347–260 nm range 
are assignable to ligand to molybdenum (pπ–dπ) charge transfer (LMCT) and intraligand 
transitions, respectively. Figure 4.5(b) depicts the representative UV‒Vis spectra of 7. 
 
Table 4.7. Electronic spectra
[a]
 for complexes [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) 
Complex λmax/nm(ε/dm
3
mol
–1
cm
–1
)
 
[Mo
(IV)
OL
1
(bipy)] (7) 275(40062), 339(19229), 436(12080), 557(2958), 659(3821) 
[Mo
(IV)
OL
2
(phen)] (8) 260(41234), 320(20131), 427(12545), 574(2675), 647(3921) 
[Mo
 (IV)
OL
3
(phen)] (9) 274(40663), 345(19854) 462(12245), 523(2642), 634(3643) 
[Mo
(IV)
OL
4
(bipy)] (10) 278(41722), 347(19524), 415(13266), 517(2854), 641(3425) 
[Mo
(IV)
OL
5
(bipy)] (11) 264(40568), 328(18568), 421(13235), 534(2960), 635(3545) 
[Mo
(IV
 OL
6
(phen)] (12) 262(42621), 342(16612), 414(12554), 542(2645), 652(3736) 
[a]
In CH3CN solution 
 
4.3.2.4. Electrochemical properties. The electrochemical properties of 7–12 were examined in 
CH3CN solution (0.1 M TEAP) by cyclic voltammetry using a platinum working electrode, 
platinum auxiliary electrode and an Ag/AgCl reference electrode. The potential data are listed in 
Table 4.8 and Figure 4.16 depicts the representative voltammogram of [Mo
(IV)
OL
1
(bipy)] (7). 
The voltammogram pattern of 7‒12 includes both oxidation and reduction process. In the anodic 
region, an quasi reversible single electron wave at E
a
1/2 values within the potential window 0.71 
140 
 
to 0.66 V is assigned to the oxidation of Mo
(IV)
/Mo
(V)
.
68a,68b,70
 In the cathodic region Mo
(IV)
 is 
reduced to Mo
(III)
 showing an irreversible single electron wave within the potential window –1.38 
to –1.32 V. 68a,68b,70 
 
Table 4.8. Cyclic voltammetric
[a]
 results for complexes [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) 
 
 
 
 
 
 
 
 
[a]
In CH3CN at a scan rate 100 mV/s. E1/2 = (Epa + Epc)/2, where Epa and Epc are anodic and cathodic 
peak potentials vs. Ag/AgCl, respectively. ΔEP = Epa – Epc. 
 
Figure 4.16. Cyclic voltammogram of [Mo
(IV)
OL
1
(bipy)] (7). 
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4.3.3. Catalytic activity studies 
4.3.3.1. Oxidation of styrene. Oxidation of styrene catalyzed by molybdenum complexes have 
been reported, where H2O2 has been used as oxidant in the presence of NaHCO3.
71 
Oxidation of 
styrene, catalyzed by dioxidomolybdenum(VI) complexes using aqueous 30% H2O2 as oxidant 
did not proceed. However, in the presence of NaHCO3 the catalytic oxidation process was 
activated and gave two products namely, styrene oxide and phenyl acetaldehyde (Scheme 4.4). 
Such NaHCO3 assisted oxidation of styrene has been reported in the literature and gave only one 
product, styrene oxide.
72–74 
O O
Catalyst
H2O2, NaHCO3  
Scheme 4.4. Oxidation of styrene with H2O2. 
[Mo
(VI)
O2L
1
(DMSO)] (1a) was considered as a representative catalyst to optimize the reaction 
conditions for the maximum oxidation of styrene, by studying five different parameters viz. the 
effect of amount of oxidant, amount of catalyst, amount of NaHCO3, solvent and temperature of 
the reaction mixture in detail. The effect of oxidant was studied considering styrene:aqueous 
30% H2O2 in the molar ratios of 1:3, 1:4 and 1:5, where the mixture of styrene (0.520 g, 5 
mmol), catalyst (0.0010 g), NaHCO3 (0.126 g, 1.5 mmol) and oxidant were taken in 5 ml of 
CH3CN and the reaction was carried out at 60°C. As illustrated in entries no. 2, 6 and 7 of Table 
4.9, the percent conversion of styrene improved from 77.7% to 92.5% on increasing the styrene 
to oxidant ratio from 1:3 to 1:4 but on further increment of ratio (1:5) there is no remarkable 
improvement in conversion, suggesting that 1:4 (styrene:H2O2) molar ratio is sufficient enough 
to perform the reaction with good conversion. Similarly, for three different amounts viz. 0.0005, 
0.0010 and 0.0015 g of catalyst at styrene to H2O2 molar ratio of 1:4 under above reaction 
conditions, 0.0010 g catalyst gave 92.5% conversion while 0.0005 g gave 79% and 0.0015 g 
catalyst improved the conversion only slightly (93.4%) (entries no. 1, 2 and 3 of Table 4.9). The 
amount of NaHCO3 has played significant role on the conversion of styrene and best conversion 
was obtained with 1.5 mmol of NaHCO3 (entries no. 2, 4 and 5 in Table 4.9). In the absence of 
NaHCO3 there was no conversion of substrate. Amongst three different temperatures of 40, 50 
and 60°C for the fixed operating condition of styrene (0.52 g, 5 mmol), H2O2 (2.27 g, 20 mmol), 
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[Mo
(VI)
O2L
1
(DMSO)] (1a) (0.0010 g), NaHCO3 (0.126, 1.5 mmol) and CH3CN (5 ml), running 
the reaction at 60°C gave much better conversion (entries no. 2, 10 and 11 of Table 
4.9).Variation in the volume of CH3CN (5, 7 and 10 ml) was also studied (entries no. 2, 8 and 9 
of Table 4.9) and it was observed that 5 ml of CH3CN was sufficient enough to get good 
transformation of styrene while running the reaction at 60°C under above reaction conditions. 
Thus, all reaction conditions as concluded above (i.e. styrene (0.52 g, 5 mmol), H2O2 (2.27 g, 20 
mmol), [Mo
(VI)
O2L
1
(DMSO)] (1a) (0.0010 g), NaHCO3 (0.126, 1.5 mmol), CH3CN (5 ml) and 
reaction temperature 60°C) were considered essential and applied for the maximum 
transformation of styrene into a mixture of oxidation products. Table 4.9 and Figure 4.17 
summarize all the conditions and conversions obtained under a particular set of conditions.  
The conversion of styrene and the selectivity of different reaction products using 
[Mo
(VI)
O2L
1
(DMSO)] (1a) as catalyst under the optimized reaction conditions (entry no. 2 of 
Table 4.9) have been analyzed as a function of time and are presented in Figure 4.18 and Table 
4.10. Thus, under the optimized reaction conditions, the selectivity of the two oxidation products 
varies in the order: styrene oxide (98.6%)> phenyl acetaldehyde (1.4%). Complexes 
[Mo
(VI)
O2L
1‒6
(DMSO)] (1a‒6a) follow same order of the selectivity of products with almost 
same conversion. Blank reaction under above reaction conditions gave 30% conversion.  
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Table 4.9. Conversion of styrene (0.520 g, 5 mmol) using [Mo
(VI)
O2L
1
(DMSO)] (1a) as 
catalyst in 4 h of reaction time under different reaction conditions 
Entry 
No. 
Catalyst 
[g] 
H2O2 
[g(mmol)] 
NaHCO3 
[g(mmol)] 
CH3CN 
[ml] 
Temp. 
(
o
C) 
Conv. 
[%] 
1 0.0005 2.27 (20) 0.126 (1.5) 5 60 79 
2 0.0010 2.27 (20) 0.126 (1.5) 5 60 92.5 
3 0.0015 2.27 (20) 0.126 (1.5) 5 60 93.4 
4 0.0010 2.27 (20) 0.084 (1.0) 5 60 72 
5 0.0010 2.27 (20) 0.168 (2.0) 5 60 93.6 
6 0.0010 1.70 (15) 0.126 (1.5) 5 60 77.7 
7 0.0010 2.83 (25) 0.126 (1.5) 5 60 96 
8 0.0010 2.27 (20) 0.126 (1.5) 7 60 72.8 
9 0.0010 2.27 (20) 0.126 (1.5) 10 60 48 
10 0.0010 2.27  (20) 0.126 (1.5) 5 50 75.5 
11 0.0010 2.27 (20) 0.126 (1.5) 5 40 51.7 
 
 
Table 4.10. Oxidation of styrene, TOF and product selectivity using (1a‒6a) as catalyst 
Catalyst 
TOF  
[h
–1
]
a
 
Conv. 
 [%] 
  Selectivity [%]
b
 
phac so 
[Mo
(VI)
O2L
1
(DMSO)] (1a) 642 92.5 1.4 98.6 
[Mo
(VI)
O2L
2
(H2O)] (2a) 600 96 1.3 98.7 
[Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) 676 92 0.8 99.2 
[Mo
(VI)
O2L
4
(H2O)] (4a) 586 94 0.9 99.1 
[Mo
(VI)
O2L
5
(DMSO)] (5a) 651 93.8 1.1 98.9 
[Mo
(VI)
O2L
6
(DMSO)] (6a) 647 93 0.6 99.4 
Blank reaction ‒ 30 3 97 
a
TOF values calculated at 4 h of reaction time.  
b
so:styrene oxide; phac: phenyl acetaldehyde. 
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Figure 4.17. (a) Effect of oxidant amount on the oxidation of styrene. Reaction condition: 
styrene (0.520 g, 5 mmol), catalyst (0.0010 g), NaHCO3 (0.126 g, 1.5 mmol), temperature 60°C 
and acetonitrile (5 ml). (b) Effect of catalyst amount on the oxidation of styrene. Reaction 
conditions: styrene (0.520 g, 5 mmol), 30% H2O2 (2.27 g, 20 mmol), NaHCO3 (0.126 g, 1.5 
mmol), temperature 60°C
 
and acetonitrile (5 ml). (c) Effect of NaHCO3 amount on the oxidation 
of styrene. Reaction condition: styrene (0.520 g, 5 mmol), catalyst (0.0010 g), 30% H2O2 (2.27 g, 
20 mmol), temperature 60°C and acetonitrile (5 ml). (d) Effect of temperature on the oxidation of 
styrene. Reaction conditions: styrene (0.520 g, 5 mmol), 30% H2O2 (2.27 g, 20 mmol), NaHCO3 
(0.126 g, 1.5 mmol), catalyst (0.0010 g) and acetonitrile (5 ml). (e) Effect of solvent amount on 
the oxidation of styrene. Reaction conditions: styrene (0.520 g, 5 mmol), 30% H2O2 (2.27 g, 20 
mmol), NaHCO3 (0.126 g, 1.5 mmol), catalyst (0.0010 g) and temperature 60°C. (f) Plot 
showing conversion of all metal complexes. 
(a) (b) 
(c) (d) 
(e) (f) 
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Figure 4.18. Plot showing conversion and product selectivity as a function of time. 
 
 
4.3.3.2. Oxidation of cyclohexene. Oxidation of cyclohexene, catalyzed by 
dioxidomolybdenum(VI) complexes using aqueous 30% H2O2 as oxidant in the presence of 
NaHCO3 gave one product namely, cyclohexene oxide (Scheme 4.5).  
 
Scheme 4.5. Oxidation of cyclohexene with H2O2. 
[Mo
(VI)
O2L
1
(DMSO)] (1a) was considered as a representative catalyst for the oxidation of 
cyclohexene by H2O2 in presence of NaHCO3. In order to achieve optimum reaction conditions, 
the effect of catalyst considering three different amounts viz. 0.0005, 0.0010 and 0.0015 g as a 
function of time was studied for the fixed amount of cyclohexene (0.41 g, 5 mmol), NaHCO3 
(0.126 g, 1.5 mmol) and 30% H2O2 (1.70 g, 15 mmol) in 5 ml of CH3CN and reaction was 
carried out at 60°C and results are illustrated in Figure 4.19(a) (entries no. 1, 2 and 3 of Table 
4.11).  It is clear from the plot that 0.0005 gave 81% conversion of the substrate whereas 0.0010 
g and 0.0015 g of catalyst gave 93% and 95% out of these 0.0010 g was the best one to obtain a 
maximum of 93% conversion of cyclohexene. For the effect of oxidant three different 
cyclohexene to aqueous 30% H2O2 molar ratios viz. 1:2, 1:3 and 1:4 were considered for the 
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fixed amount of cyclohexene (0.41 g, 5 mmol), NaHCO3 (0.126 g, 1.5 mmol) and catalyst 
(0.0010 g) in 5 ml of CH3CN and reaction was carried out at 60°C. As presented in entries no. 2, 
6 and 7 of Table 4.11 and Figure 4.19(b), a maximum of 63.6% conversion was obtained at a 
cyclohexene to H2O2 molar ratio of 1:2 in 4 h of reaction time. This conversion reached 93% on 
increasing this ratio to 1:3 while 1:4 ratios improve the conversion slightly (99%). Under the 
operating conditions as fixed above i.e. cyclohexene (0.41 g, 5 mmol), 30% H2O2 (1.70 g, 15 
mmol), NaHCO3 (0.126 g, 1.5 mmol) in 5 ml of CH3CN. We have also optimized the amount of 
NaHCO3 (entries no. 1, 4 and 5), the amount of solvent (acetonitrile, entries no. 1, 8 and 9) and 
temperature (entries no. 1, 10 and 11) of the reaction and found that 1.5 mmol of NaHCO3, 5 ml 
of solvent and 60°C reaction temperature were sufficient enough to obtain 93% conversion under 
above reaction conditions. Table 4.11 and Figure 4.19 summarize all the conditions and 
conversions obtained under a particular set of conditions. No conversion of substrate in the 
absence of NaHCO3 was obtained. Blank reaction under above reaction conditions gave 32% 
conversion. 
Oxidation of cyclohexene, TOF and selectivity of cyclohexene oxide using different 
dioxidomolybdenum(VI) complexes as catalyst is given in Table 4.12. 
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Table 4.11. Conversion of cyclohexene (0.410g, 5 mmol) using [Mo
(VI)
O2L
1
(DMSO)] (1a) as 
catalyst in 4 h of reaction time under different reaction conditions 
Entry 
No. 
Catalyst 
[g (mmol)] 
   H2O2 
[g (mmol)] 
NaHCO3 
[g (mmol)] 
CH3CN 
[ml] 
Temp.  
(
o
C) 
Conv. 
[%] 
1 0.0005  1.70 (15) 0.126 (1.5) 5 60 81 
2 0.0010  1.70 (15) 0.126 (1.5) 5 60 93 
3 0.0015  1.70 (15) 0.126 (1.5) 5 60 95 
4 0.0010 1.70 (15) 0.084 (1.0) 5 60 78.4 
5 0.0010 1.70 (15) 0.168 (2.0) 5 60 95.2 
6 0.0010 1.14 (10) 0.126 (1.5) 5 60 63.6 
7 0.0010 2.27 (20) 0.126 (1.5) 5 60 99 
8 0.0010 1.70 (15) 0.126 (1.5) 7 60 76.5 
9 0.0010 1.70 (15) 0.126 (1.5) 10 60 43.6 
10 0.0010 1.70 (15) 0.126 (1.5) 5 50 71.3 
11 0.0010 1.70 (15) 0.126 (1.5) 5 40 42.2 
 
 
Table 4.12. Oxidation of cyclohexene, TOF and selectivity of cyclohexene oxide using 1a‒6a 
as catalyst 
Catalyst TOF  
[h
–1
]
a
 
Conv.  
[%] 
Selectivity  
[%] 
[Mo
(VI)
O2L
1
(DMSO)] (1a) 646 93 100 
[Mo
(VI)
O2L
2
(H2O)] (2a) 579 92.7 100 
[Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) 705 96 100 
[Mo
(VI)
O2L
4
(H2O)] (4a) 593 95 100 
[Mo
(VI)
O2L
5
(DMSO)] (5a) 664 95.6 100 
[Mo
(VI)
O2L
6
(DMSO)] (6a) 670 96.4 100 
Blank reaction – 32 100 
a
 TOF values calculated at 4 h of reaction time. 
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Figure 4.19. (a) Effect of catalyst amount on the oxidation of cyclohexene. Reaction conditions: 
cyclohexene (0.410 g, 5 mmol), 30% H2O2 (1.70 g, 15 mmol), NaHCO3 (0.126 g, 1.5 mmol), 
temperature 60°C and acetonitrile (5 ml). (b) Effect of oxidant amount on the oxidation of 
cyclohexene. Reaction condition: cyclohexene (0.410 g, 5 mmol), catalyst (0.0010 g), NaHCO3 
(0.126 g, 1.5 mmol), temperature 60°C and acetonitrile (5 ml). (c) Effect of NaHCO3 amount on 
the oxidation of cyclohexene. Reaction condition: cyclohexene (0.410 g, 5 mmol), catalyst 
(0.0010 g), 30% H2O2 (1.70 g, 15 mmol), temperature 60°C and acetonitrile (5 ml). (d) Effect of 
solvent amount on the oxidation of cyclohexene. Reaction conditions: cyclohexene (0.410 g, 5 
mmol), 30% H2O2 (1.70 g, 15 mmol), NaHCO3 (0.126 g, 1.5 mmol), catalyst (0.0010 g) and 
temperature 60°C (e) Effect of temperature on the oxidation of cyclohexene. Reaction 
conditions: cyclohexene (0.410 g, 5 mmol), 30% H2O2 (1.70 g, 15 mmol), NaHCO3 (0.126 g, 1.5 
mmol), catalyst (0.0010 g) and acetonitrile (5 ml). (f) Plot showing conversion of all metal 
complexes. 
(a) (b) 
(c) (d) 
(e) (f) 
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4.3.3.3. Reactivity of complexes with H2O2. Dioxidomolybdenum(VI) complexes react with 
H2O2 to give the corresponding oxido‒peroxido complexes. The generation of such species has 
been established in DMSO by electronic absorption spectroscopy. In a typical reaction, 20 ml of 
ca. 3.6×10
–5
 M solution of [Mo
(VI)
O2L
1
(DMSO)] (1a) was treated with one drop portion of 30% 
aqueous H2O2 (0.260 g, 2.3 mmol) dissolved in 5 ml of DMSO and the resultant spectroscopic 
changes are presented in Figure 4.20. The bands at 312 nm and 343 nm increases while 267 and 
420 nm bands decrease their intensity considerably. These changes indicate the interaction of 
[Mo
(VI)
O2L
1
(DMSO)] (1a) with H2O2 and formation of oxido‒peroxido species.
43 
 
Figure 4.20. UV–Vis spectral changes observed during titration of complex 1a with H2O2. The 
spectra were recorded after successive additions of 1–drop portion of 30% H2O2 (2.3 mmol) 
dissolved in 5 ml of DMSO to 20 ml of 3.6×10
–5
 M solution of complex 1a in DMSO. 
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4.4. CONCLUSION 
(a) Dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1‒6
] (1‒6), of thiosemicarbazone ligands are 
reported. 
(b) Dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1/5/6
(DMSO)] (1a, 5a & 6a), 
[Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and [Mo
(VI)
O2L
3
(DMSO)]4.2DMSO (3a) and 
monooxidomolybdenum(IV) complexes [Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) {where, N‒N = 2,2'–
bipyridyl or 1,10–phenanthroline} are also reported as product of substrate binding and oxygen 
atom transfer reactivity respectively of precursor dioxidomolybdenum(VI) complexes 
[Mo
(VI)
O2L
1‒6
] (1‒6) respectively. 
(c) All the Mo(VI) and Mo(IV) complexes have been charecterized by physicochemical 
techniques. Molecular structures of some of the Mo(VI) (1a‒4a) and Mo(IV) complexes (7 and 
9‒11) have been determined by single crystal X–ray crystallography. 
(d) The assessment of oxygen atom transfer from [Mo
(VI)
O2L
1‒6
] (1‒6) to PPh3 has been 
monitored by the gradual appearance of OPPh3 (27 ppm) as probed by 
31
P NMR. 
(e) The oxygen atom transfer from the substrate DMSO to the system [Mo
(IV)
OL
1‒6
(N‒N)] 
(7‒12) has been studied spectrophotometrically in DMSO solution. 
(f) The catalytic activity (oxidation of styrene and cyclohexene) of Mo
(VI) 
complexes (1a‒6a) 
have been studied. 
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Chapter 5 
 
Synthesis, reactivity and structural characterization of oxidovanadium(IV/V) complexes: 
Methylation of aliphatic hydrocarbon by dimethyl sulfoxide 
 
ABSTRACT 
 
The synthesis and characterization of an oxidovanadium(IV) [V
IV
O(L)(acac)] (1) and two 
dioxidovanadium(V) [V
V
O2(L')] (2) and [V
V
O2(L)] (2a) complexes of {(4–(p–
fluorophenyl)thiosemicarbazone) of pyridine–2–aldehyde} (HL) is described in the present 
study. The oxidovanadium(IV) species [V
IV
O(L)(acac)] (1) was synthesized in usual way by the 
reaction of metal precursor VO(acac)2 with thiosemicarbazone ligand (HL) in refluxing ethanol. 
The recrystallization of [V
IV
O(L)(acac)] (1) in DMF, CH3CN or EtOH gave the same product i.e. 
dioxidovanadium(V) complex [V
V
O2(L)] (2a), whereas [V
V
O2(L')] (2) was synthesized during 
recrystallization of [V
IV
O(L)(acac)] (1) in DMSO where the original ligand (HL) is transformed 
to a rearranged new ligand (HL'). The ligand in complex 1 is found to undergo methylation at the 
carbon centre attached to imine nitrogen in presence of DMSO and transformed to the 
corresponding dioxidovanadium(V) species through in situ reaction. The synthesized ligand and 
the metal complexes were characterized by elemental analysis, IR, UV–Vis, NMR and EPR 
spectroscopy. Molecular structures of complex 1 [V
IV
O(L)(acac)] and complex 2 [V
V
O2(L')] 
have been determined by single crystal X–ray crystallography. Complexes 1 & 2 show in vitro 
insulin mimetic activity against insulin responsive L6 myoblast cells, with complex 1 being more 
potent, is comparable to insulin at 100 µM concentration, while complex 2 has considerable 
insulin mimetic activity. In addition, the in vitro antiproliferative activity of the complexes 1 & 2 
against the MCF–7 and Vero cell lines were also assayed. 
 
  
157 
 
5.1. INTRODUCTION 
Coordination chemistry of vanadium has attracted increasing interest, due to its biological 
properties,
1–5
 and for the use of oxidovanadium complexes as oxidation and oxo transfer 
catalysis,
6,7
 and potential medicinal applications.
8,9
 Vanadium is one of the trace bio-elements 
existing in the human body, its complexes have been found to present antibacterial, antitumor, 
insulin-enhancing and antiparasitic effects.
10–13
 Vanadium complexes could also suppress the 
growth and spread of existing tumors by inhibiting tumor cell proliferation, inducing apoptosis 
and limiting the invasion and metastatic potential of neoplastic cells.
13–15
 Inorganic vanadyl and 
vanadate, as well as some vanadium(IV)/(V) complexes, are influential insulin mimics.
16
 The 
discovery of the in vivo insulin mimesis per os of oxidovanadates(V),
17
 the oxidovanadium(IV) 
precursor, vanadyl sulfate,
18
 and the much more potent bis(maltolato)-oxidovanadium(IV) 
(BMOV)
19
 encourages the explore of vanadium complexes having application in the treatment of 
type II diabetes.
20,21
 Thus different approaches have been attempted to develop orally active 
vanadium containing insulin enhancing agents.
22 
Multidentate ligands with donor functionalities including combinations of oxygen, sulfur and 
nitrogen have been used to mimic relevant biological molecules that vanadium ions may interact 
with. Thiosemicarbazone is an important class of N, S donor ligands which have considerable 
pharmacological interest, due to their significant antibacterial, antiviral, antimalarial, antileprotic, 
antitumor and anticancer activities.
23–26
 Metal complexes of thiosemicarbazone ligands have 
shown variable bonding properties and structural diversity, along with promising biological 
implications and ion sensing abilities.
25,27–34 
Here we report the formation of a dioxidovanadium(V) complex [V
V
O2(L')] (2) of (4–(p–
fluorophenyl)thiosemicarbazone) of pyridine–2–aldehyde (HL). The whole reaction takes place 
in two steps, first of which is the formation of oxidovanadium(IV) complex [V
IV
O(L)(acac)] (1), 
which slowly oxidises to the dioxidovanadium(V) complex [V
V
O2(L')] (2) in presence of 
DMSO. The change in coloration of the complex (from green to orange) and UV–Vis data fully 
supports the observation.  
Recrystallization of the crude green complex [V
IV
O(L)(acac)] (1) in DMSO interestingly 
methylates the C(8)–imine carbon which is confirmed by the X–ray crystal data of 
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dioxidovanadium(V) complex [V
V
O2(L')] (2). This interesting observation lead us to repeat the 
experiment in different other solvents like DMF, CH3CN, EtOH but surprisingly the methylation 
took place only in DMSO, and instead of [V
V
O2(L')] (2), [V
V
O2(L)] (2a) was prepared. 
Thus the methylation of the imine carbon in DMSO may be attributed to the methylene transfer 
from the methylsulfinyl radical anion resulting from the oxidation of the [V
IV
O(L)(acac)] (1). 
The radical anion rapidly converts to a methyl sufinyl carbanion (CH3SOCH2
–
) which is a unique 
methylating ylide and known to methylate olefin and aromatic systems.
35
 
The synthesized ligand and the metal complexes were characterized by elemental analysis, IR, 
UV–Vis, NMR and EPR spectroscopy. Molecular structures of complex 1 [VIVO(L)(acac)] and 
complex 2 [V
V
O2(L')] have been determined by single crystal X–ray crystallography. Complexes 
1 & 2 show in vitro insulin mimetic activity against insulin responsive L6 myoblast cells, with 
complex 1 being the most potent, is comparable to insulin at 100 µM concentration, while the 
complex 2 has considerable insulin mimetic activity. In addition, the in vitro antiproliferative 
activity of complexes 1 & 2 against MCF–7 and Vero cell lines were also assayed. 
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5.2. EXPERIMENTAL SECTION 
5.2.1. General methods and materials. [VO(acac)2] was prepared as described in the 
literature.
36
 Reagent grade solvents were dried and distilled prior to use. All other chemicals 
were reagent grade, available commercially and used as received. HPLC grade DMSO and 
CH3CN was used for spectroscopic and electrochemical studies and ethanol, methanol were used 
for synthesis of ligands and metal complexes. Commercially available TEAP (tetra ethyl 
ammonium perchlorate) was properly dried and used as a supporting electrolyte for recording 
cyclic voltammograms of the complexes. Elemental analyses were performed on a Vario ELcube 
CHNS Elemental analyzer. IR spectra were recorded on a Perkin-Elmer Spectrum RXI 
spectrometer. 
1
H and 
13
C NMR spectra were recorded with a Bruker Ultrashield 400 MHz 
spectrometer using SiMe4 as an internal standard. Electronic spectra were recorded on a 
Lamda25, PerkinElmer spectrophotometer. Electrochemical data were collected using PAR 
Versastat-II instrument driven by E-chem software (PAR) at 298 K in a dry nitrogen atmosphere. 
Cyclic voltammetry experiments were carried out with Pt working and auxiliary electrodes and 
Ag/AgCl as reference electrode. X-band EPR measurements were performed on a JEOL JES-FA 
200 and Bruker EMX EPR Spectrometer. 
 
5.2.2. Synthesis of ligand (HL). The thiosemicabazide was prepared from distilled                   
p–fluoroaniline by a known method reported earlier.37 Schiff base ligand,                                   
4–(p–fluorophenyl)thiosemicarbazone of pyridine–2–aldehyde was prepared in 80–90% yield, 
by stirring equimolar ratio of the thiosemicabazide with pyridine–2–aldehyde in methanol 
medium by standard procedures.
38
 The resulting compound was filtered, washed thoroughly with 
methanol and dried over fused CaCl2. HL: Yield: 85%. Anal. calc. for C13H11N4SF: C, 56.92; H, 
4.04; N, 20.42. Found: C, 56.95; H, 4.00; N, 20.41. Main IR peaks (KBr, cm
‒1
): 3311 s ν(N(1)–
H), 2967 s ν(N(2)–H), 2825 m ν(C(8)–H), 1638 s ν(C=C), 836 s ν(C(7)–S(1)). 1H NMR 
(DMSO–d6, 400 MHz) : 12.08 (s, 1H, N(1)H), 10.29 (s, 1H, N(2)H), 8.59 (s, 1H, C(8)H), 8.58–
7.20 (m, 8H, C6H4). 
13
C NMR (DMSO-d6, 100 MHz) : 177.25, 161.46, 159.05, 153.58, 149.82, 
143.62, 136.98, 135.77, 128.86, 128.77, 124.76, 121.12, 115.37. 
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5.2.3. Synthesis of complex [V
IV
O(L)(acac)] (1). To a solution of HL (0.274 g, 0.100 mmol) in 
hot ethanol, VO(acac)2 (0.265 g, 1.0 mmol) was added. The mixture was refluxed for 2 h, 
yielding dark green colored crystalline residue of the complex. [V
IV
O(L)(acac)] (1): Yield: 75%. 
Anal. calc. for C18H17FN4VO3S: C, 49.21; H, 3.90; N, 12.75. Found: C, 49.24; H, 3.87; N, 12.73. 
Main IR peaks (KBr, cm
‒1
): 3317 s ν(N(1)–H), 1602 s ν(C=C), 949 s ν(V=O), 762 s ν(C(7)–
S(1)). 
5.2.4. Synthesis of complex [V
V
O2(L´)] (2). The dark green crystalline residue of 
[V
IV
O(L)(acac)] (1) was dissolved in DMSO for recrystallization and allowed to evaporate at 
room temperature. Reddish brown colored crystals of the complex were obtained from DMSO 
after 1–2 weeks. [VVO2(L´)] (2): Yield: 65%. Anal. calc. for C14H12FN4VO2S: C, 45.41; H, 3.27; 
N, 15.13. Found: C, 45.43; H, 3.25; N, 15.16. Main IR peaks (KBr, cm
‒1
): 3268 s ν(N(1)–H), 
1604 s ν(C=C), 937, 925 s ν(V=O), 765 s ν(C(7)–S(1)). 1H NMR (DMSO–d6, 400 MHz) : 
10.20 (s, 1H, N(1)H), 8.72–7.18 (m, 8H, C6H4), 2.66 (s, 3H, C(8)H3).
 13
C NMR (DMSO-d6, 100 
MHz) : 154.34, 153.80, 143.72, 141.34, 137.23, 130.68, 129.12, 126.94, 125.35, 122.48, 
122.40, 115.88, 115.65, 67.87. 
5.2.5. Synthesis of complex [V
V
O2(L)] (2a). The dark green crystalline residue of 
[V
IV
O(L)(acac)] (1) was dissolved in EtOH for recrystallization and allowed to evaporate at 
room temperature. Yellow colored residue of the complex was obtained after few days. 
[V
V
O2(L)] (2a): Yield: 70%. Anal. calc. for C13H10FN4VO2S: C, 43.83; H, 2.83; N, 15.73. 
Found: C, 43.80; H, 2.85; N, 15.76. Main IR peaks (KBr, cm
‒1
): 3256 s ν(N(1)–H), 2834 m 
ν(C(8)–H), 1589 s ν(C=C), 934, 922 s ν(V=O), 775 s ν(C(7)–S(1)). 1H NMR (DMSO–d6, 400 
MHz) : 10.29 (s, 1H, N(1)H), 8.79 (s, 1H, C(8)H), 8.78–7.16 (m, 8H, C6H4).
 13
C NMR (DMSO-
d6, 100 MHz) : 166.16, 160.28, 159.10, 156.73, 150.24, 149.31, 138.11, 137.27, 125.45, 119.96, 
119.88, 116.29, 116.06. 
 
[V
IV
O(L)(acac)] (1) when recrystallized in CH3CN and DMF gave similar results as 2a. 
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5.2.6. X‒ray crystallography. The structure of both the complexes 1 & 2, were measured at 
room temperature on an Agilent Technologies SuperNova Dual CCD with an Atlas detector 
fitted with Mo Kα radiation (λ = 0.71073 Å) to θmax = 27.5°. Data processing and absorption 
correction were accomplished with CrysAlis PRO.
39
 The structure was solved by direct methods 
with SHELXS–9740 and refinement anisotropic displacement parameters, C–bound hydrogen 
atoms in the riding model approximation and a weighting scheme of the form w = 1/[σ2(Fo
2
) + 
(0.059P)
2 
+ 3.139 P] for P = (Fo
2
 + 2Fc
2
)/3) was on F
2
 by means of SHELXL-97.
40
 
Crystallographic data and final refinement details are given in Table 5.1. The ORTEP plots of 
the complexes were drawn with ORTEP–3 for Windows41 at the 50% probability level and the 
remaining crystallographic figures were drawn with DIAMOND
42
 using arbitrary spheres. Data 
manipulation and interpretation were with WinGX
41
 and PLATON.
43 
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Table 5.1. Crystal and refinement data of [V
IV
O(L)(acac)] (1) and [V
V
O2(L´)] (2) 
Compound 1 2 
Formula C18H17FN4VO3S C14H12FN4VSO2 
M 439.36 370.28 
Crystal system Triclinic Monoclinic 
Space group P ī C2/c 
a(Å) 9.9204(13) 19.600(3) 
b(Å) 13.6766(15) 14.7000(8) 
c(Å) 14.9965(19) 14.922(2) 
 (°) 68.292(11) 90.00 
β (°) 84.254(11) 134.83(3) 
γ (°) 89.768(10) 90.00 
V(Å
3
) 1879.7(4) 3049.1(17) 
Z 2 8 
Dcalc(g.cm
-3
) 1.554 1.613 
F(000) 1.904 1.613 
(Mo-K)(mm-1) 0.784 0.812 
Reflections collected / 
unique 
11536 / 3211 11673 / 3449 
R1[I>2(I)] 0.062, 0.134 0.050, 0.118 
wR2[all data] 0.086, 0.151 0.090, 0.143 
S[goodness of fit] 1.56 1.01 
min./max. res. 
(e.Å
–3
) 
–0.31, 0.45 –0.27, 0.41 
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5.2.7. In vitro Glucose uptake assay on L6 myotubes. L6 myoblast were cultured in DMEM 
containing 10% FBS and penicillin (100 U/ml) and streptomycin (100 µg/ml) in a humidified 5% 
CO2 incubator at 37°C. To differentiate to myotubes, the myoblast cells (5x10
4
) were seeded in 
24 well plates in DMEM containing 2% FBS. The myoblast cells (5x10
4
) were grown for 11 
days in 0.4 ml of 2% FBS/DMEM to allow the formation of myotubes. The medium was 
changed every 2 days. On the 11
th
 day, the cells were washed and incubated in Kreb’s 
bicarbonate buffer (KRBB) for 2 h. Myotubes were then further cultured in KRBB containing 25 
mM glucose along with 25, 50, 100 µM of vanadium compounds ([V
IV
O(L)(acac)] (1), 
[V
V
O2(L´)] (2) and VO(acac)2) for 4 h, respectively. The insulin (2 µM) was taken as positive 
control.
44
 The residual glucose in the buffer aliquots remaining in each well after 4 h was 
estimated using hexokiase method by Randox autoanalyser.  
5.2.8. Cell culture. MCF–7 and Vero cells were obtained from National Centre of Cell Science 
(NCCS), Pune, India and were maintained in minimal essential medium supplemented with 10% 
fetal bovine serum, penicillin-streptomycin solution and incubated at 37°C in 5% CO2 and 95% 
humidified incubator 
5.2.9. Cytotoxicity studies. The effect of the drugs on the cancer cell viability was studied using 
MTT dye reduction assay by measuring the optical density at 595 nm using micro plate reader 
spectrophotometer. After the cells were grown for 24 h to a subconfluent state (~ 60–70%), the 
cells were treated with different concentrations of complexes [V
IV
O(L)(acac)] (1) and 
[V
V
O2(L´)] (2) (5, 50, 100, 200 μM) in culture medium. The samples were tested in triplicates. 
After 24, 48 and 72 h the effect of the compound on cell viability was examined by MTT 
(thiazolyl blue tetrazolium bromide) test. Optical density was measured at 595 nm using 
automatic microplate reader. 
5.2.10. DAPI staining. DAPI (4´,6–diamidino–2–phenylindole dihydrochloride) staining was 
performed to see the morphology of the nuclei after treatment. The cells were grown in the 96–
well plate. After reaching approximately 90% confluency, the cells were treated with complexes 
[V
IV
O(L)(acac)] (1) and [V
V
O2(L´)] (2) at different concentrations (5, 50 100, 200 µM) and were 
incubated for 24, 48 and 72 h. Cells were observed with inverted fluorescence microscope after 
treatment to check for morphological changes, during cell death. Then the cells were washed 
twice with 1 x PBS and 3.7% of paraformaldehyde was added and incubated for 15 min. After 
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that the cells were again washed twice with PBS and treated with 0.2% triton–X 100 and 2% 
BSA in PBS for 30 seconds. Again the cells were washed twice with PBS and DAPI was added 
and kept for 30 min in dark. Finally the cells were washed twice with PBS and imaged under 
fluorescence microscope (FLoiD, Life technologies). 
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5.3. RESULTS AND DISCUSSION 
5.3.1. Synthesis. Scheme 5.1 illustrates the synthesis of dioxidovanadium(V) complex, 
[V
V
O2(L´)] (2) of ligand HL {(4–(p–fluorophenyl)thiosemicarbazone) of pyridine–2–aldehyde}. 
The whole reaction takes place in two steps, first of which is the formation of 
monooxidovanadium(IV) complex, [V
IV
O(L)(acac)] (1) which slowly oxidizes to the 
dioxidovanadium(V) complex [V
V
O2(L´)] (2) (containing rearranged ligand HL´) in presence of 
DMSO. The same process when repeated in different other solvents like DMF, CH3CN and 
EtOH doesn’t leads to the rearrangement of the ligand and corresponding dioxidovanadium(V) 
complex [V
V
O2(L)] (2a) is formed. The spectroscopic data were consistent with the X–ray 
structures of 1 & 2. The purity of these compounds was further confirmed by elemental analyses. 
All the complexes were soluble in MeOH, CH3CN, DMF and DMSO. 
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Scheme 5.1. Schematic representation of ligand (HL) and synthesis of variable valence 
vanadium complexes [V
IV
O(L)(acac)] (1), [V
V
O2(L´)] (2) and [V
V
O2(L)] (2a). 
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5.3.2. Spectral characteristics  
5.3.2.1. IR spectroscopy. The IR spectrum of the ligand exhibits bands due to ν(N(1)–H) and 
ν(N(2)–H) moieties in 3311–2967 cm–1 region, however the complexes 1, 2 & 2a do not exhibit, 
ν(N(2)–H) band. Thus it reveals that the ligand coordinates to the metal centre in the anionic 
form. The sharp band at 836 cm
–1 due to ν(C(7)–S(1)) stretching in the ligand is lowered to 775–
762 cm
–1
 in the complexes, indicating participation of the thione sulfur in the coordination.
45
 The 
presence of a strong sharp band at 949 cm
–1
 in complex 1 shows the presence of monooxido 
(V=O), whereas two peaks in the range 937–922 cm–1 in complexes 2 & 2a are assigned to 
dioxido (V=O) stretching.
46
 Figure 5.1 shows the IR spectra of complexes 1 and 2. The IR data 
are summarized in Table 5.2. 
Table 5.2. IR and electronic spectra for complexes 1, 2 & 2a 
Complex V−O str,a cm-1 UV−visb λmax, nm (ϵ, M
-1
cm
-1
) 
[V
IV
O(L)(acac)] (1) 949  252 (19216), 410 (10521), 586 (7893), 762 (6567) 
[V
V
O2(L´)] (2) 937, 925 256 (18968), 431 (8500) 
[V
V
O2(L)] (2a) 934, 922 260 (17564), 428 (8134) 
a
In KBr pellet. 
b
In CH3OH.  
 
 
Figure 5.1. FTIR spectra of complexes [V
IV
O(L)(acac)] (1) (a) and [V
V
O2(L´)] (2) (b) showing 
(V=O) stretching. 
(a) (b) 
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5.3.2.2. UV−Vis spectroscopy. The electronic spectra of the complexes (1, 2 & 2a) were 
recorded using CH3OH solution. In all the complexes two strong absorptions are observed in the 
wavelength range 431–252 nm. The lower energy absorptions at 431–410 nm are ascribable to 
the ligand to metal charge transfer transitions
46a
 whereas the higher energy absorptions are likely 
to be due to ligand centered transitions.
46b
 Two weak absorptions at 762 nm and 586 nm were 
observed for 1 (V
IV
 complex), which are assigned to d−d transitions.47,48 The UV−Vis data are 
summarized in Table 5.2. Electronic absorption spectra of complexes 1 & 2 are shown in Figure 
5.2.
 
 
Figure 5.2. Electronic absorption spectra of complexes [V
IV
O(L)(acac)] (1) (a) and [V
V
O2(L´)] 
(2) (b). 
 
5.3.2.3. NMR spectroscopy. The 
1
H NMR spectra of the free ligand (Figure 5.3) and its 
corresponding dioxidovanadium(V) complexes [V
V
O2(L´)] (2) (Figure 5.4) and [V
V
O2(L)] (2a) 
(Figure 5.5) were recorded in DMSO-d6. The spectrum of the free ligand exhibits two singlets in 
the range 12.08 to 10.29 ppm due to two NH groups {N(1)H & N(2)H}, whereas in the spectra 
of the complexes 2 and 2a there is only one peak in the range 10.29 to 10.20 ppm for one NH 
group{N(1)H} indicating coordination of the ligand to the metal center in anionic form. The 
peak due to C(8)H appears as singlet at 8.59 ppm for ligand and at 8.79 ppm for 2a. The 
presence of a methyl peak at 2.66 ppm in the spectra of the complex [V
V
O2(L´)] (2) and absence 
of C(8)H peak indicates the methylation at imine carbon C(8) and formation of a new ligand. 
The detailed NMR data has been included in the experimental section. 
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Figure 5.3. NMR spectra of ligand HL. 
 
Figure 5.4. NMR spectra of complex [V
V
O2(L´)] (2). 
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Figure 5.5. NMR spectra of complex [V
V
O2(L)] (2a). 
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5.3.3. Electrochemical properties. The electrochemical properties of complexes 1 & 2 were 
examined in CH3CN solution (0.1 M TEAP) by cyclic voltammetry using a platinum working 
electrode, platinum auxiliary electrode, and Ag/AgCl reference electrode. The potential data are 
listed in Table 5.3. The voltammogram pattern for complex 1 includes both oxidation and 
reduction processes (Figure 5.6(a)). Redox couple at E1/2 value 0.62 V corresponds to V
IV
/V
V
 
oxidation, whereas E1/2 value at –1.13 V corresponds to V
IV
/V
III
 reduction couple. The 
voltammogram pattern for complex 2 includes only a quasi-reversible redox couple at E1/2 value 
–0.73 V corresponding to VV/VIV reduction (Figure 5.6(b)). The redox property of complex 2a 
was also examined, and the result matched well with that of complex 2. 
 
Table 5.3. Cyclic voltammetric
[a]
 results for complexes [V
IV
O(L)(acac)] (1) (a) and 
[V
V
O2(L´)] (2) at 298 K 
Complex Potentials (V) versus Ag/AgCl 
V
IV
/V
V
 
E
a
1/2(ΔE
a
P) 
V
IV
/V
III
 
E
c
1/2(ΔE
c
P) 
V
V
/V
IV
 
E
c
1/2(ΔE
c
P) 
[V
IV
O(L)(acac)] (1) 0.62(450) –1.13(200) – 
[V
V
O2(L´)] (2) – – –0.73(120) 
[a]
In CH3CN at a scan rate 100 mV/s. E1/2 = (Epa + Epc)/2, where Epa and Epc are anodic and 
cathodic peak potentials vs. Ag/AgCl, respectively.  ΔEP = Epa – Epc. 
 
 
Figure 5.6. Cyclic voltammogram of the complexes [V
IV
O(L)(acac)] (1) (a) and [V
V
O2(L´)] (2) 
(b). 
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5.3.4. EPR spectroscopy. X–band EPR spectra of [VIVO(L)(acac)] 1, was recorded in CH2Cl2 
solution in room temp. The spectrum of the complex [V
IV
O(L)(acac)] is shown in Figure 5.7, 
which reveals well–resolved 8-line isotropic signals, characteristic of a mononuclear vanadium 
complex with nuclear spin (
51
V, I = 7/2). The data are listed in Table 5.4. 
 
Table 5.4. X-band EPR data for complex 1 at 300 K 
_________________________________________________________________ 
Complex                                      g                                        A x 10
-4
 cm
-1
       
_________________________________________________________________ 
[V
IV
O(L)(acac)] (1)                  1.973                                    83.2 
_________________________________________________________________ 
 
 
Figure 5.7. Room temperature solution X–band EPR spectrum in CH2Cl2 of complex 
[V
IV
O(L)(acac)] (1). Instrument settings: power, -0.009 dB; modulation, 100 kHz; sweep center, 
2500G; sweep time, 120s; sweep width, 2500G. 
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5.3.5. Structure. The structure of complexes [V
IV
O(L)(acac)] (1) and [V
V
O2(L´)] (2) were 
elucidated by X-ray crystallography. 
 
5.3.5.1. Description of X-ray structures of [V
IV
O(L)(acac)] (1). The atom numbering scheme 
for the complex 1 is given in Figure 5.8. The structure shows that the thiosemicarbazone ligand 
(L
−1
) is coordinated to vanadium in the expected tridentate fashion (Scheme 5.1), forming two 
five-membered chelate rings with S(1)–V(1)–N(3) and N(3)–V(1)–N(4) bite angles. The 
coligand acetyl acetone group is coordinated in bidentate fashion forming a six membered ring. 
Thus the complex forms a monooxido distorted V(IV) octahedral structure with pyridyl nitrogen 
N(4), the imino nitrogen N(3), and the thiolate sulfur S(1) atom, together with acac oxygen O(2), 
constitute the basal plane and oxido oxygen O(1) and acac oxygen O(3) in the axial position. 
This is preliminary X–ray report of complex 1, so we could not include the bond parameters. 
 
 
 
Figure 5.8. A view of the molecular structure of [V
IV
O(L)(acac)] (1). 
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5.3.5.2. Description of X-ray structures of [V
V
O2(L´)] (2). A view of the molecular structure 
of 2 is shown in Figure 5.9 and selected geometric parameters are collected in Table 5.5. The 
[V
V
O2(L´)] atom is bonded to the S, N, N-donors of the uninegative tridentate ligand and two 
oxido atoms. The length of the C‒S bond (1.730(3) Å) suggests that the ligand is coordinating as 
a thiolate, a conclusion supported by the short C(7)–N(2) (1.305(4) Å) and C(8)–N(3) (1.306(4)) 
bonds. The VSCN2 and VNC2N five-membered chelate rings are each planar, having r.m.s. 
deviations of 0.0175 and 0.0149 Å, respectively, and form a dihedral angle of 2.6(1)°. The 
pyridyl ring forms dihedral angles of 4.26(17)° and 4.0(5)° with the adjacent chelate ring and 
terminal fluorobenzene ring, respectively, indicating that the entire molecule is approximately 
planar. The N2O2S donor set defines a highly distorted coordination geometry as seen in the 
value of the trigonality index, τ = 0.43, which is intermediate between square pyramidal (τ = 0.0) 
and trigonal bipyamdial (τ = 1.0).49 To a first approximation, the observed molecular structure of 
[V
V
O2(L´)] matches that reported for the N-bound methyl derivative which differs in geometric 
parameters. In the latter the V–S (2.3759(9) Å), V–O (1.631(2) Å) and N(3)–C(8) (1.323(4) Å) 
bond lengths are marginally longer than in [V
V
O2(L´)].
50
 Also, the coordination geometry is 
closer to square pyramidal (τ = 0.22). 
In the crystal packing, supramolecular chains aligned along the a-axis and with a zig-zag 
topology are formed through N–H…O hydrogen bonding (Figure 5.9(a); details of the 
intermolecular interactions are given in the caption). Chains are consolidated into the three-
dimensional architecture by a combination of C–H…O (involving the other oxido–O atom) and 
C–H…π interactions as well as π.…..π stacking between pyridyl and benzene rings. Of particular 
interest is the presence of the C–H….π interactions as the π-system is defined by the VSCN2 
chelate ring. Such C–H… π (chelate) synthons are gaining increasing recognition in the 
crystallographic literature, including for rings that contain sulfur.
51
 Globally, the structure can be 
described in terms of columns of molecules parallel to the c-axis connected by N–H…O and C–
H…O interactions; a view of the unit cell contents is shown in Figure 5.10(b). 
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Table 5.5. Selected geometric parameters (Å, °) for [V
V
O2(L´)] (2) 
 
Atoms Parameter Atoms Parameter 
V–S(1) 2.365(1) V–O(1) 1.607(2) 
V–O(2) 1.596(3) V–N(3) 2.143(3) 
V–N(4) 2.086(3) C(7)–S(1) 1.730(3) 
C(7)–N(2) 1.305(4) N(2)–N(3) 1.374(4) 
C(8)–N(3) 1.306(4) 
S(1)–V–O(1) 101.93(1) S(1)–V–O(2) 98.93(1) 
S(1)–V–N(4) 77.58(7) S(1)–V–N(4) 151.34(1) 
O(1)–V–O(2) 110.14(2) 
 
 
 
 
Figure 5.9. A view of the molecular structure of [V
V
O2(L´)] (2); one of the disorder components 
has been omitted for reasons of clarity. 
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(a)                                                                                 (b) 
Figure 5.10. (a) A view of the supramolecular zig–zag chain mediated by N–H…O hydrogen 
bonding and orientated along [1 0 1]. (b) A view in projection down the c-axis of the unit cell 
contents for 2. The N‒H...O [N1–H1...O1i = 2.22(4) Å, N1...O1i = 2.959(4) Å, angle at H1 = 
142(3)° for symmetry operation i: -½+x, ½-y, -½+z], C‒H...O [C11–H11a...O2ii = 2.47 Å, 
C11...O2
ii
 = 3.173(5) Å, angle at H11a = 133° for ii: 1½-x, ½+y, 1½-z], C‒H...π[C9–H9b... 
π(VSCN2)
iii
 = 2.77 Å, C9... π(VSCN2)
iii
 = 3.647(5) Å, angle at H9b = 152° for iii: 1–x, 1–y, 1–z] 
and π....π [Cg(C1-C6)...Cg(N4,C10-C14)iii = 3.514(7) Å] interactions are shown as orange, pink, 
blue, and purple dashed lines, respectively. 
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5.3.6. In Vitro insulin mimetic activity. Vanadium compounds are known to have insulin 
mimetic effect.
52
 In this study [V
IV
O(L)(acac)] (1) and [V
V
O2(L´)] (2) were tested for their 
insulin mimetic potential in an in vitro glucose uptake assay. In L6 myotubes, a cell line of 
skeletal muscle origin, glucose uptake in response to insulin stimulation plays a key role in the 
whole body glucose homeostasis. Glucose transporter (GLUT) 4 is the major glucose transporter 
of muscle exquisitely regulated by insulin through posttranslational events.
53
 The L6 myotubes 
differentiated from L6 myoblast have the ability to respond to insulin via insulin receptor 
signaling and translocation of Glut 4 to the plasma membrane. The hyperglycemic condition was 
created in cell culture by incubating the cells in 25 mM glucose. In the present experiment, at 
100 µM concentration 1 showed glucose uptake stimulating activity in the myotubes which was 
found to be comparable to that of 2 µM of insulin. Therefore, it can be concluded that complex 1 
mimic’s insulin action possibly via insulin receptor signaling with translocation of Glut 4 to the 
plasma membrane (Figure 5.11). Complex 2 at 100 µM concentration also showed considerable 
insulin mimetic activity compared to insulin, whereas VO(acac)2 showed negligible insulin 
mimetic activity at the concentrations tested. In case of 1, the enhancement of the insulin 
mimetic activity, with respect to 2, might be related to the difference in the oxidation state of the 
complexes as vanadium(IV) complexes have been already established as anti diabetic drugs.
18,19
 
 
Figure 5.11. Effect of complexes (1 & 2) on glucose uptake in cultured L6 myotubes under high 
glucose conditions (25 mM Glucose). Three concentrations 25 µM, 50 µM and 100 µM were 
tested for each complex. The data is indicated as mean ± SEM (n=3). Student’s t–Test was used 
where bars with asterisk show a significant difference (*P< .05) with respect to the untreated 
control. 
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5.3.7. Inhibition of cancer cell viability. In the present study antiproliferative efficacy of 
complexes 1 and 2 was assayed by determining the viability of MCF–7 and Vero cells using the 
MTT assay. The ligand, HL
 
and VO(acac)2 gave high IC50 values of >200 μM, whereas 
[V
IV
O(L)(acac)] (1) & [V
V
O2(L´)] (2) gave values in the range 23.15–115.62 μM for MCF–7 
cells and 3.10–120.55 μM for Vero cells over a period of 72 h. Under similar conditions the IC50 
values of standard drugs vincristine and cisplatin on MCF–7 cells were 1 µM and 10 µM 
respectively. The significant decrease in the inhibitory concentration for the ligand compared to 
the metal complex clearly indicates that incorporation of vanadium in the ligand environment has 
a marked effect on cytotoxicity. A possible explanation is that by coordination the polarity of the 
ligand and the central metal ion are reduced through the charge equilibration, which favors 
permeation of the complexes through the lipid layer of the cell membrane.
54,55
 The present 
results are consistent with the observation that metal complexes can exhibit greater biological 
activities than the free ligand.
56 
 
Comparing the activity of the two complexes, the cytotoxic activity of [V
IV
O(L)(acac)] (1) is 
greater than [V
V
O2(L´)] (2) which is reflected from their IC50 values with dose dependency 
illustrated in Figure 5.12 and Table 5.6, which can be correlated with the difference in the 
oxidation states of the complexes as oxidovanadium(IV) complexes are known to have enhance 
bioactivity that oxidovanadium(V) complexes. 
Table 5.6. IC50 (µM) in both MCF–7 and Vero cell lines for complexes 1 and 2 
Cytotoxicity on MCF–7 cells 
IC50 values (µM) 
[V
IV
O(L)(acac)] (1) [V
V
O2(L´)] (2) 
24h 48h 72h 24h 48h 72h 
28.49 26.34 23.15 115.62 90.61 84.04 
Cytotoxicity on Vero cells 
IC50 values (µM) 
[V
IV
O(L)(acac)] (1) [V
V
O2(L´)] (2) 
24h 48h 72h 24h 48h 72h 
41.57 3.10 3.20 120.55 30.06 29.42 
 
178 
 
 
 
 
Figure 5.12. Effect of [V
IV
O(L)(acac)] (1) and [V
V
O2(L´)] (2) on cell viability and growth: 
MCF–7 and Vero cells were treated with different concentrations of the test compound for 24 h, 
48 h & 72 h and then cell viability was measured by MTT assay. Data reported as the mean ± 
S.D. for n = 3 and compared against control (considered as 100% viability). 
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5.3.8. Nuclear staining assay. The mechanism of cell death due to the complexes (1 & 2) was 
checked by staining dying cells with DAPI. The density of the DAPI stained nuclei was used to 
check the live cells in different treatment groups. Figure 5.13 shows images taken after DAPI 
staining in blue fluorescence at different concentrations of the complexes. It can be seen from the 
figure that the number of DAPI stained nuclei were reduced in treated wells with increasing 
concentrations of the complexes indicating the dose dependent cell death. Figure 5.14 shows the 
grey scale images at different time points after the treatment with minimum toxic concentrations 
of the complexes. The distinct nuclear condensation, fragmentation was seen in treated cells 
compared to control cells.  
(a) [V
IV
O(L)(acac)] (1) 
 
 
(b) [V
V
O2(L´)] (2) 
  
 
Figure 5.13 (a & b). Study of apoptosis by morphological changes in nuclei of MCF–7 cells: 
After treatment MCF–7 cells from control and treated group were fixed with 3.7% 
paraformaldehyde for 15 min, permeabilized with 0.1% Triton X–100 and 2% BSA and stained 
with 2 μg/ml DAPI for 30 min in the dark. The cells were then washed with PBS and examined 
by fluorescence microscopy (FloiD, Invitrogen). A–E (A–control, B–5 µM, C–50 µM, D–100 
µM, E–200 µM) shows the decrease in cell density with increasing concentration of the drug 
compared to control. 
A B C D E 
A B D C E 
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(a) [V
IV
O(L)(acac)] (1) 
 
 
 
(b) [V
V
O2(L´)] (2) 
 
 
 
Figure 5.14 (a & b). F–I (F–control, G–24 h, H–48 h, I–72 h) shows the morphological changes 
in nuclei of MCF–7 with respect to treatment time on applying complexes (1 and 2) in 
comparison to control. 
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5.4. CONCLUSION 
The syntheses and characterization of oxidovanadium(IV) complex [V
IV
O(L)(acac)] (1) and 
two dioxidovanadium(V) complexes [V
V
O2(L')] (2) and [V
V
O2(L)] (2a) of {(4–(p–
fluorophenyl)thiosemicarbazone) of pyridine–2–aldehyde} (HL) is reported. The 
oxidovanadium(IV) complex [V
IV
O(L)(acac)] (1) is found to undergo methylation at the carbon 
centre attached to imine nitrogen of the ligand in presence of DMSO forming the 
dioxidovanadium(V) species[V
V
O2(L')] (2). The synthesized ligand and the metal complexes 
were characterized by elemental analysis, IR, UV–Vis, NMR and EPR spectroscopy. Molecular 
structures of complexes 1 & 2 have been determined by X–ray crystallography. 
Complexes 1 & 2 show in vitro insulin mimetic activity against insulin responsive L6 
myoblast cells, with complex 1 being the most potent, is comparable to insulin at 100 μM 
concentration, while 2 has considerable insulin mimetic activity. In addition, the in vitro 
antiproliferative activity of complexes 1 & 2 against the MCF–7 and Vero cell lines were also 
assayed. 
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Chapter 6 
 
Zinc(II) complexes as functional models of phosphatases: Synthesis, structure and 
characterization 
ABSTRACT 
___________________________________________________________________________ 
4‒(p‒methoxyphenyl)thiosemicarbazone of o‒hydroxynapthaldehyde (H2L
1
), 
4‒(p‒methoxyphenyl)thiosemicarbazone of benzoyl pyridine (HL2) and                                      
4–(p–chlorophenyl)thiosemicarbazone of o‒vanillin (H2L
3
) and their dimeric Zn(II) complexes 
[{ZnL
1
(DMSO)}2]·3DMSO (1), [{ZnL
2
Cl}2] (2), and a novel tetrameric Zn(II) complex 
[(Zn2L
3
)2(–OAc)2(3–O)2] (3) are reported. The synthesized ligands and their zinc complexes 
were characterized by elemental analysis, NMR, IR and UV–Vis spectroscopy. Molecular 
structures of all the complexes (1‒3) have been determined by single crystal X–ray 
crystallography. 
___________________________________________________________________________ 
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6.1. INTRODUCTION 
Metal complexes of d
10 
system constitute an especially attractive topic in view of their 
differences with regard to their chemical and biological behavior. Zn(II) is an essential metal ion 
because of its presence in certain metalloenzymes,
1,2
 while Cd(II) and Hg(II), present in the 
environment are toxic.
3
 
Zn(II) ions, as a cofactor are part of over 300 enzymes (carbonic anhydrases, zinc proteinases, 
histone deacetylases, alkaline phosphatases, alcohol dehydrogenases, aminopeptidases, etc.), 
which are involved in metabolic processes of living organisms: viruses, bacteria, plants and 
animals.
2,4–10
 Zinc is cytoprotective and suppresses apoptotic pathways; it has a specific function 
as a neuromodulator in addition to its other typical cellular functions.
11–13
 Some of the Zn(II) 
complexes of thiosemicarbazone have been considered as agents with antitumor activity against 
some of the human cancer cell lines.
14
 
Thiosemicarbazones have been extensively studied due to their biological properties, 
analytical applications and their interesting chemical and structural properties towards metal 
ions.
15–17
 The biological properties of thiosemicarbazone complexes are often related to metal 
ion. The lipophilicity, which is related to the tendency of a molecule to be transported through 
biological membranes, can be modified by coordination. The metal in the complex has its own 
influence in enhancing the overall activity of the complex compared to the free ligand through a 
synergic effect.
18,19
  
Zn(II) ion has either a structural or catalytic role in several proteins.
20
 It has been recognized 
as an important cofactor in biological molecules, either as a structural template in protein folding 
or as a Lewis acid catalyst that can readily adopt 4–, 5– or 6–coordination.21 Therefore, it is a 
challenging area of research to get compounds which are able to form stable complexes with 
Zn(II), thiosemicarbazone ligands could be well appropriate for this purpose.  
Considering these facts and as a continuation of our ongoing research on the study of 
pharmacological and catalytic properties
22
 of transition metal complexes,
 
we report the synthesis 
and characterization of two new Zn(II) dimeric complexes [{ZnL
1
(DMSO)}2]·3DMSO (1) and 
[{ZnL
2
Cl}2] (2), and a novel tetranuclear zinc(II) complex [(Zn2L
3
)2(–OAc)2(3–O)2] (3). The 
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physical and structural characteristics of the complexes suggest that they may be considered as 
functional model of phosphatase enzyme. 
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6.2. EXPERIMENTAL SECTION 
6.2.1. General methods and materials. All chemicals were purchased from commercial sources 
and used without further purification. Reagent grade solvents were dried and distilled prior to 
use. The thiosemicabazides were prepared from distilled substituted aniline by a known method 
reported earlier.
23
 Elemental analyses were performed on a Vario ELcube CHNS Elemental 
analyser. IR spectra were recorded on a Perkin–Elmer Spectrum RXI spectrometer. Electronic 
spectra were recorded on a Lamda25, PerkinElmer spectrophotometer. 
1
H and
 13
C spectra were 
recorded with a Bruker Ultrashield 400 MHz spectrometer using SiMe4 as an internal standard.  
 
6.2.2. Synthesis of ligands. The ligands 4‒(p‒methoxyphenyl)thiosemicarbazone of 
o‒hydroxynapthaldehyde (H2L
1
), 4‒(p‒methoxyphenyl)thiosemicarbazone of benzoyl pyridine 
(HL
2
) and 4–(p–chlorophenyl)thiosemicarbazone of o‒vanillin (H2L
3
) were prepared by reported 
methods.
22c,24
 To the stirring solution of the substituted thiosemicabazide, required aldehyde was 
added in equimolar ratio in methanol medium and the mixture was stirred for 2 h. The resulting 
compound was filtered, washed thoroughly with methanol and dried over fused CaCl2.  
H2L
1
: Yield: 86%. Anal. calc. for C19H17N3SO2: C, 64.94; H, 4.88; N, 11.96. Found: C, 64.95; 
H, 4.86; N, 11.95. Main IR peaks (KBr, cm
–1
): 3432 s ν(O(1)–H), 3128 s ν(N(1)–H), 2996 s 
ν(N(2)–H), 2831 m ν(C(8)–H), 1621 s ν(C=C), 1539 s ν(C(8)=N(3)), 815 s ν(C(7)=S(1)). 1H 
NMR (DMSO–d6, 400 MHz) : 11.70 (s, 1H, –C(18)–O(1)H), 10.01 (s, 1H, –C(7)–N(1)H), 9.21 
(s, 1H, –C(7)–N(2)H), 8.45 (s, 1H, –N(3)=C(8)H), 7.90–6.93 (m, 10H, C6H4), 3.74 (s, 3H, 
OCH3). 
13
C NMR (DMSO–d6, 100 MHz) : 176.63, 157.40, 157.04, 143.92, 133.03, 132.50, 
132.16, 129.24, 128.55, 128.28, 127.60, 123.99, 122.83, 119.03, 113.91, 113.71, 112.64, 110.13, 
55.70. 
HL
2
: Yield: 86%. Anal. calc. for C20H18N4SO: C, 66.28; H, 5.01; N, 15.46. Found: C, 66.25; H, 
5.02; N, 15.41. Main IR peaks (KBr, cm
–1
): 3165 s ν(N(1)–H), 2961 s ν(N(2)–H), 2837 m 
ν(C(8)–H), 1637 s ν(C=C), 1510 s ν(C(8)=N(3)), 832 s ν(C(7)=S(1)). 1H NMR (DMSO–d6, 400 
MHz) : 9.53 (s, 1H, –C(7)–N(1)H), 9.01 (s, 1H, –C(7)–N(2)H), 7.44–6.85 (m, 13H, C6H4), 3.71 
(s, 3H, OCH3). 
13
C NMR (DMSO–d6, 100 MHz) : 180.65, 180.21, 175.46, 171.45, 156.99, 
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156.65, 149.04, 141.32, 138.15, 133.51, 132.59, 131.06, 128.71, 127.23, 126.66, 126.22, 124.65, 
114.09, 113.68, 55.65.  
H2L
3
: Yield: 86%. Anal. calc. for C15H14N3SO2Cl: C, 53.65; H, 4.20; N, 12.51. Found: C, 53.68; 
H, 4.18; N, 12.50. Main IR peaks (KBr, cm
–1
): 3421 s ν(O(1)–H), 2988 s ν(N(1)–H), 2867 s 
ν(N(2)–H), 2752 m ν(C(8)–H), 1614 s ν(C=C), 1531 s ν(C(8)=N(3)), 839 s ν(C(7)=S(1)). 1H 
NMR (DMSO–d6, 400 MHz) : 11.85 (s, 1H, –C(14)–O(1)H), 10.07 (s, 1H, –C(7)–N(1)H), 9.35 
(s, 1H, –C(7)–N(2)H), 8.52 (s, 1H, –N(3)=C(8)H), 7.68–6.77 (m, 7H, C6H4), 3.82 (s, 3H, OCH3). 
13
C NMR (DMSO–d6, 100 MHz) : 175.73, 147.90, 146.22, 145.56, 140.40, 138.04, 129.27 
127.93, 127.74, 127.36, 120.45, 119.04, 118.45, 113.09, 55.87. 
 
6.2.3. Synthesis of Zn(II) complexes. Zn(OAc)2·2H2O (1 & 3) or ZnCl2 (2) (1.0 mmol) was 
added to 20 ml of hot ethanolic solution of the ligand H1–2L
1–3
 (1.0 mmol), and the contents were 
refluxed for 2 h. The resulting yellow solution was filtered and slow evaporation of the filtrate 
over 4–5 days produced light yellow crystalline product. X–ray quality crystals of complex 1 
were obtained by slow evaporation from DMSO. 
[{ZnL
1
(DMSO)}2]·3DMSO (1): Yield: 74%. Anal. calc. for C48H60N6O9S7Zn2: C, 47.25; H, 
4.96; N, 6.89. Found: C 47.28; H, 4.92; N, 6.87. Main IR peaks (KBr, cm
‒1
): 3048 m ν(N(1)–H), 
2863 m ν(C(8)–H), 1595 s ν(C=C), 1507 s ν(–C(8)=N(3)), 743 s ν(C(7)–S). 1H NMR (DMSO–
d6, 400 MHz) : 9.32 (s, 1H, –C(7)–N(1)H), 8.63 (s, 1H, –N(3)=C(8)H), 8.06–6.83 (m, 10H, 
C6H4), 3.71 (s, 3H, OCH3), 2.54 (s, 3H, DMSO). 
13
C NMR (DMSO‒d6, 100 MHz) : 167.02, 
162.24, 159.35, 157.53, 153.95, 150.32, 145.43, 135.80, 134.68, 132.34, 130.34, 129.00, 127.19, 
126.24, 121.35, 119.95, 115.46, 113.91, 55.55, 49.06. 
[{ZnL
2
Cl}2] (2): Yield: 77%. Anal. calc. for C40H34Cl2N8O2S2Zn2: C, 51.96, H, 3.71, N, 12.12. 
Found: C, 51.94, H, 3.74, N, 12.15. Main IR peaks (KBr, cm
‒1
): 3318 m ν(N(1)–H), 1592 s 
ν(C=C), 1503 s ν(–C(8)=N(3)), 792 s ν(C(7)–S). 1H NMR (DMSO–d6, 400 MHz) : 9.54 (s, 1H, 
–C(7)–N(1)H), 8.00–6.54 (m, 13H, C6H4), 3.65 (s, 3H, OCH3). 
13
C NMR (DMSO‒d6, 100 MHz) 
: 154.72, 154.34, 149.77, 147.58, 147.05, 140.96, 134.94, 133.26, 129.77, 129.56, 129.15, 
128.86, 125.63, 125.45, 123.97, 122.30, 121.97, 113.57, 113.45, 55.53. 
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[(Zn2L
3
)2(–OAc)2(3–O)2] (3): Yield: 63%. Anal. calc. for C34H30Cl2N6O10S2Zn4: C, 37.84, H, 
2.80, N, 7.79. Found: C, 37.81, H, 2.84, N, 7.76. Main IR peaks (KBr, cm
‒1
): 3024 m ν(N(1)–H), 
2761 m ν(C(8)–H), 1590 s ν(C=C), 1533 s ν(–C(8)=N(3)), 810 s ν(C(7)–S). 1H NMR (DMSO–
d6, 400 MHz) : 8.92 (s, 1H, –C(7)–N(1)H), 8.43 (s, 1H, –N(3)=C(8)H), 7.84–6.35 (m, 7H, 
C6H4), 3.69 (s, 3H, OCH3), 2.06 (s, 6H, OAc). 
13
C NMR (DMSO‒d6, 100 MHz) : 168.86, 
165.78, 156.77, 141.13, 140.51, 132.76, 130.12, 128.68, 128.44, 125.27, 124.21, 121.36, 121.22, 
121.05, 56.51, 28.80, 25.36. 
 
6.2.4. X‒ray crystallography. Single crystals of complexes were mounted on a SuperNova 
diffractometer (Agilent) (1) with a CCD detector and Cu–Kα radiation and Bruker Smart Apex II 
diffractometer (2 and 3) equipped with a graphite monochromator and a Mo K radiator (λ) 
0.71073 Å. Crystallographic data and details of refinement are given in Table 6.1. The unit cell 
dimensions and intensity data were measured at 100(2) K for 1 and 297(2) K for 2 and 3. The 
intensity data were corrected for Lorentz, polarization and absorption effects. Absorption 
corrections were applied using SADABS
25
 and the structures were solved by direct methods 
using the program SHELXS–9726 and refined using least squares with the SHELXL–9726 
software program. Hydrogens were either found or placed in calculated positions and 
isotropically refined using a riding model. The non–hydrogen atoms were refined 
anisotropically. 
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Table 6.1. Crystal and refinement data of complexes [{ZnL
1
(DMSO)}2]·3DMSO (1), 
[{ZnL
2
Cl}2] (2) and [(Zn2L
3
)2(–OAc)2(3–O)2] (3) 
Compound 1 2 3 
Formula C48H60N6O9S7Zn2 C40H34Cl2N8O2S2Zn2 C34H30Cl2N6O10S2Zn4 
M 1220.29 924.51 1079.14 
Crystal system monoclinic triclinic triclinic 
Space group P 21/c P ī P ī 
a(Å) 14.477 (6) 11.969(9) 12.225(2)  
b(Å) 15.959(7) 13.427(10) 12.823(2) 
c(Å) 23.632(8) 14.197(11) 13.848(2) 
 (°) 90.00 75.202(5) 70.957(10) 
β (°) 97.8659(3) 65.407(4) 80.706(10) 
γ (°) 90.00 83.354(5) 80.579(10) 
V(Å
3
) 5408.76(4) 2006.0(3) 2011.05(6) 
Z 4 2 2 
Dcalc(g.cm
–3
) 1.499 1.531 1.782 
F(000) 2536 944 1084 
(Mo–K)(mm–1) 4.104 1.480 2.657 
2(max)(o) 71.98 20.90 22.03 
Reflections 
collected / unique 
10657 / 9711 56236 / 4233 57117 / 4932 
R1[I>2(I)] R1 = 0.0461 
wR2 = 0.137 
R1 = 0.0361, 
wR2 = 0.078 
R1 = 0.0414, 
wR2 = 0.090 
wR2[all data] R1 = 0.049 
wR2 =0.142 
R1 = 0.059, 
wR2 = 0.088 
R1 = 0.086, 
wR2 = 0.1068 
S[goodness of fit] 1.100 1.002 1.007 
max. / min. res. 
(e.Å
–3
) 
1.404 and –0.842 0.387 and –0.341 0.402 and –0.408 
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6.3. RESULTS AND DISCUSSION 
6.3.1. Synthesis. Reaction of Zn(OAc)2·2H2O (1 & 3) or ZnCl2 (2) with 
4‒(p‒methoxyphenyl)thiosemicarbazone of o‒hydroxynapthaldehyde (H2L
1
), 
4‒(p‒methoxyphenyl)thiosemicarbazone of benzoyl pyridine (HL2) and                                      
4–(p–chlorophenyl)thiosemicarbazone of o‒vanillin (H2L
3
) in equimolar ratio in ethanol medium 
yielded light yellow coloured dimeric complexes [{ZnL
1
(DMSO)}2]·3DMSO (1), [{ZnL
2
Cl}2] 
(2) and tetrameric complex [(Zn2L
3
)2(–OAc)2(3–O)2] (3). NMR spectra were consistent with 
the X–ray structures. The purity of these compounds was further confirmed by elemental 
analyses. The synthetic methods of all the complexes are illustrated in Scheme 6.1. All the 
complexes were soluble in MeOH, MeCN, DMF and DMSO, and were stable in both solid and 
solution phases. 
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Scheme 6.1. Schematic representation of ligands H1–2L
1–3
 and synthetic pathways of their 
corresponding Zn(II) complexes [{ZnL
1
(DMSO)}2]·3DMSO (1), [{ZnL
2
Cl}2] (2) and 
[(Zn2L
3
)2(–OAc)2(3–O)2] (3). 
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6.3.2. Structure. The observed elemental analysis (C, H, N) data of all the complexes (1–3) are 
consistent with their composition. In order to authenticate the molecular structure of the 
complexes, the molecular structures have been determined by X–ray crystallography. 
 
6.3.2.1. Description of X–ray structure of [{ZnL1(DMSO)}2]·3DMSO (1). The structure of 
the binuclear Zn(II) complex [{ZnL
1
(DMSO)}2]·3DMSO is illustrated in Figure 6.1 and 
selected bond parameters are collected in Table 6.2(a). Compound 1 contains three DMSO 
molecules as solvent of crystallization. The structure contains two identical units of 
ZnL
1
(DMSO). In other words, the dimeric Zn(II) species is formed by the dimerisation of two 
ZnL
1
(DMSO) units bridged by two reciprocal coordinated phenolate oxygen atom of the 
individual ZnL
1
(DMSO) unit. Each zinc atom is coordinated by phenolate oxygen O(1)/O(4), 
imine nitrogen N(3)/N(6) and thiolate sulfur S(1)/S(3) of the thiosemicarbazone moiety and 
O(3)/O(6) of DMSO group. The length of metal coordinated bonds (Zn(1)−S(1)/S(3) and 
Zn(1)−N(3)/N(6)) is usual like similar systems reported earlier.27 The bond angles are also in 
conformity with a distorted square pyramidal structure around the zinc centers. The phenolate 
oxygen O(1), the imine nitrogen N(3), and the thiolate sulfur S(1) atom, along with bridging 
oxygen O(4), constitute the basal plane and O(3) of DMSO in the axial position around the Zn(1) 
center. Similar orientation was observed for Zn(2) center also. The bond lengths in the basal 
plane agree with those found in Zn(II) complexes containing thiosemicarbazones as binegative 
tridentate ligand.
27
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Table 6.2(a). Selected geometric parameters (Å, º) for [{ZnL
1
(DMSO)}2]·3DMSO (1) 
 
Bond Distances 
Zn(1)‒S(1) 2.337(6) Zn(1)‒O(3) 2.039(2) 
Zn(1)‒N(3) 2.077(2) Zn(1)‒O(4) 2.072(2) 
Zn(1)‒O(1) 2.040(2)   
Bond Angles 
O(3)‒Zn(1)‒O(1) 102.08(7) O(4)‒Zn(1)‒N(3) 148.68(7) 
O(3)‒Zn(1)‒O(4) 96.37(7) O(3)‒Zn(1)‒S(1) 105.00(5) 
O(1)‒Zn(1)‒O(4) 75.81(6) O(1)‒Zn(1)‒S(1) 152.88(5) 
O(3)‒Zn(1)‒N(3) 111.83(7) O(4)‒Zn(1)‒S(1) 102.50(5) 
O(1)‒Zn(1)‒N(3) 84.89(7) N(3)‒Zn(1)‒S(1) 83.68(5) 
 
 
 
Figure 6.1. ORTEP diagram of [{ZnL
1
(DMSO)}2]·3DMSO (1) with atom labeling scheme. 
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6.3.2.2. Description of X–ray structures of [{ZnL2Cl}2] (2). The structure of the binuclear 
Zn(II) complex [{ZnL
2
Cl}2] is illustrated in Figure 6.2 and selected bond parameters are 
collected in Table 6.2(b). The structure contains two identical units of ZnL
2
Cl. In other words, 
the dimeric Zn(II) species is formed by the dimerisation of two ZnL
2
Cl units bridged by two 
reciprocal coordinated thiolate sulfur atoms of the individual ligand unit. Each zinc atom is 
coordinated by a pyridyl nitrogen N(4)/N(8), imine nitrogen N(3)/N(7) and thiolate sulfur 
S(1)/S(2) of the thiosemicarbazone moiety and a chlorine atom Cl(1)/Cl(2). The length of metal 
coordinated bonds (Zn(1)−S(1)/S(2) and Zn(1)−N(3)/N(7)) is usual like similar systems reported 
earlier.
27
 The bond angles are also in conformity with a distorted square pyramidal structure 
around the zinc centers. The pyridyl nitrogen N(4), the imine nitrogen N(3), and the thiolate 
sulfur S(1) atom, together with chlorine Cl(1) atom, constitute the basal plane around Zn(1), and 
the bridging thiolate sulfur S(2) in the axial position. The coordination around Zn(2) is similar to 
Zn(1). 
 
Table 6.2(b). Selected geometric parameters (Å, º) for [{ZnL
2
Cl}2] (2) 
 
Bond Distances 
Zn(1)‒N(3) 2.123(4) Zn(1)‒N(4) 2.135(4) 
Zn(1)‒Cl(1) 2.222(2) Zn(1)‒S(1) 2.477(1) 
Zn(1)‒S(2) 2.488(2)   
Bond Angles 
N(3)‒Zn(1)‒N(4) 75.27(2) N(3)‒Zn(1)‒Cl(1) 145.66(1) 
N(4)‒Zn(1)‒Cl(1) 100.35(1) N(3)‒Zn(1)‒S(1) 78.31(1) 
N(4)‒Zn(1)‒S(1) 153.58(1) Cl(1)‒Zn(1)‒S(1) 101.32(6) 
N(3)‒Zn(1)‒S(2) 108.12(1) N(4)‒Zn(1)‒S(2) 95.12(1) 
Cl(1)‒Zn(1)‒S(2) 106.19(7) S(1)‒Zn(1)‒S(2) 93.17(5) 
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Figure 6.2. ORTEP diagram of [{ZnL
2
Cl}2] (2) with atom labeling scheme. 
 
6.3.2.3. Description of X–ray structures of [(Zn2L
3
)2(–OAc)2(3–O)2] (3). The structure of 
the tetranuclear Zn(II) complex [(Zn2L
3
)2(–OAc)2(μ3–O)2] is illustrated in Figure 6.3 and 
selected bond parameters are collected in Table 6.2(c). The molecular structure of 3, a 
centrosymmetric zinc tetramer, consists of two [(Zn2L
3
)(–OAc)(μ3–O)] dimeric units, is built 
up by two chelating bidentate dianionic ligands (H2L
3
), two three–coordinate oxygen (μ3–O) 
atoms and two bridging bidentate (ethoxide) chelators. Like complex 1 the ligands are 
coordinated to Zn center by phenolate oxygen of ligand O(1)/O(3), imine nitrogen N(3)/N(6) and 
thiolate sulfur S(1)/S(2) of the thiosemicarbazone moiety. The coordination geometry of Zn(1) is 
distorted square pyramidal formed by two oxygen atoms (one μ3–O(10) and one phenolate O(1) 
atom from the ligand), imine nitrogen N(3) and thiolate sulfur S(1) of the ligands in the basal 
plane and one O(5) atom of the bridging acetate in the apical site. The coordination geometry of 
Zn(2) is also a distorted square pyramidal but it is formed by four oxygen atoms in the basal 
plane (one μ3–O(10), one phenolate O(1) atom from the ligand, one O(8) atom of the bridging 
acetate and a methoxide O(2)–atom of the ligand) and one three coordinate oxygen μ3–O(7) atom 
is in the apical site. Similar coordination is observed for Zn(3) and Zn(4) also. The length of all 
the metal coordinated bonds is usual like similar systems reported earlier.
27
 The bond angles are 
also in conformity with a distorted square pyramidal structure around the zinc centers.
27
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Table 6.2(c). Selected geometric parameters (Å, º) for [(Zn2L
3
)2(–OAc)2(3–O)2] (3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. ORTEP diagram of [(Zn2L
3
)2(–OAc)2(3–O)2] (3) with atom labeling scheme. 
Bond Distances 
Zn(1)‒O(1) 2.016(4) Zn(1)‒O(5) 2.077(5) 
Zn(1)‒N(3) 2.081(5) Zn(1)‒O(10) 2.101(4) 
Zn(1)‒S(1) 2.289(2) Zn(2)‒O(8) 1.919(5) 
Zn(2)‒O(1) 1.923(4) Zn(2)‒O(7) 1.957(4) 
Zn(2)‒O(10) 2.200(4) Zn(2)‒O(2) 2.247(5) 
Bond Angles 
O(1)‒Zn(1)‒O(5) 96.90(2) O(1)–Zn(1)–N(3) 85.02(2) 
O(5)–Zn(1)–N(3) 104.17(2) O(1)–Zn(1)–O(10) 79.20(2) 
O(5)–Zn(1)–O(10) 96.90(2) N(3)–Zn(1)–O(10) 155.02(2) 
O(1)–Zn(1)–S(1) 153.81(1) O(5)–Zn(1)–S(1) 108.96(1) 
N(3)–Zn(1)–S(1) 84.74(2) O(10)–Zn(1)–S(1) 101.11(1) 
O(8)–Zn(2)–O(1) 130.40(2) O(8)–Zn(2)–O(7) 114.74(2) 
O(1)–Zn(2)–O(7) 114.79(2) O(8)–Zn(2)–O(10) 107.10(2) 
O(1)–Zn(2)–O(10) 78.78(2) O(7)–Zn(2)–O(10) 85.17(2) 
O(8)–Zn(2)–O(2) 94.90(2) O(1)–Zn(2)–O(2) 76.24(2) 
O(7)–Zn(2)–O(2) 98.42(2) O(10)–Zn(2)–O(2) 153.88(2) 
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6.3.3. Spectral characteristics 
6.3.3.1. IR spectroscopy. The IR spectra of all the complexes (1–3) showed the presence of 
ν(N‒H) band in the range 3318‒3024 cm–1 for ‒N(1)‒H. The ν(C‒H) band for 1 & 3 appeared in 
the range 2863‒2761 cm‒1 for ‒C(8)‒H stretching. The peaks for ν(C=N) and ν(C=C) vibrational 
modes appeared in the range 1595‒1503 cm–1, while the thioamide bands ν(C‒S) appeared in the 
range 810‒743 cm–1 (compared to free ligands, 839–815 cm–1).22f The detailed IR data has been 
included in the experimental section. The representative IR spectra of complex 
[{ZnL
2
Cl}2]·3DMSO (2) is shown in Figure 6.4. 
 
 
Figure 6.4. IR spectra of [{ZnL
2
Cl}2]·3DMSO (2). 
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6.3.3.2. UV spectroscopy. The electronic spectra of all the complexes (Table 6.3) were recorded 
in methanol solutions. In the spectra of 1‒3 three strong absorptions are observed in the 
wavelength range 453–255 nm. The lower energy absorptions at around 453–422 nm are 
ascribable to metal to ligand charge transfer transitions whereas the higher energy absorptions 
are likely to be due to ligand centered transitions.
28
 The representative electronic absorption 
spectra of [{ZnL
2
Cl}2] (2) is shown in Figure 6.5. 
Table 6.3. Electronic spectra for complexes [{ZnL
1
(DMSO)}2]·3DMSO (1), [{ZnL
2
Cl}2] (2) 
and [(Zn2L
3
)2(–OAc)2(3–O)2] (3) in CH3OH 
Complex λmax/nm (ε/dm
3
mol
–1
 cm
–1
) 
[{ZnL
1
(DMSO)}2]·3DMSO (1) 268(41042), 333(26629), 422(33670) 
[{ZnL
2
Cl}2] (2) 265(16388), 338(12425), 425(6666) 
[(Zn2L
3
)2(–OAc)2(3–O)2] (3) 255(12022), 310(18411), 357(10943), 453(9770) 
 
Figure 6.5. Electronic spectra of [{ZnL
2
Cl}2] (2). 
 
6.3.3.3. NMR spectroscopy. The NMR spectra (
1
H and
 13
C) of all the complexes and ligands 
were recorded in DMSO–d6. The 
1
H NMR spectrum of all the complexes (1–3) exhibits one 
singlet in the range 9.54–8.92 ppm due to NH (–C(7)–N(1)H), and one singlet in the range 8.63–
8.43 ppm due to CH (–N(3)=C(8)H) for 1 & 3. Signals for aromatic protons found as multiplets 
in 8.06–6.35 ppm range.22f The detailed NMR data has been included in the experimental 
section. The representative 
1
H NMR spectra of ligand H2L
3
 and its corresponding Zn complex 
[(Zn2L
3
)2(–OAc)2(3–O)2] (3) in DMSO‒d6 is shown in Figures 6.6 and 6.7 respectively. 
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Figure 6.6. NMR spectra of ligand H2L
3
. 
 
Figure 6.7. NMR spectra of [(Zn2L
3
)2(–OAc)2(3–O)2] (3). 
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6.4. CONCLUSION 
The syntheses and characterization of three new TSC ligands and their corresponding Zn(II) 
complexes [{ZnL
1
(DMSO)}2]·3DMSO (1), [{ZnL
2
Cl}2] (2) and [(Zn2L
3
)2(–OAc)2(3–O)2] (3) 
have been reported. The synthesized ligands and the complexes were characterized by elemental 
analysis, NMR, IR and UV–Vis spectroscopy. Molecular structures of all the Zn(II) complexes 
(1‒3) have been determined by single crystal X–ray crystallography. The spectroscopic data are 
in accordance with the X–ray structures. The physical and structural characteristics of the 
complexes suggest that they may be considered as functional model of phosphatase enzyme. 
Considering the future scope of work, the study of reactivity as biomimetic phosphate hydrolysis 
catalyst is under progress. 
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A Brief Resume of the Work Embodied in this Dissertation and Concluding Remark  
The aim of this dissertation was to explore in depth certain aspects of the chemistry of a series of 
variable valence transition metal (Ni, Cu, Mo, V & Zn) complexes of some selected tridentate 
ONS, NNS and monodentate S donor thiosemicabazone (TSC) ligands. Major emphasis was 
given to the structural and spectroscopic characterization of the synthesized complexes as well as 
their study of chemical, electrochemical, pharmacological and catalytic activities. Work 
described in chapter 2-6 reveals the results of the attempts taken to fulfill all the objectives. The 
following chapter-wise summary of the work presented in this dissertation reveals the extent to 
which the above-mentioned objectives are fulfilled. 
Chapter 2 deals with the syntheses and characterization of some mixed-ligand nickel(II) 
complexes {[Ni(L
1
)(PPh3)] (1); [Ni(L
1
)(Py)] (2); [Ni(L
2
)(PPh3)]∙DMSO (3); [Ni(L
2
)(Imz)] (4), 
[Ni(L
3)(4‒pic)] (5) and [{Ni(L3)}2(μ‒4,4′‒byp)]∙2DMSO (6)} of the selected three 
thiosemicarbazones {4‒(p‒X‒phenyl)thiosemicarbazone of salicylaldehyde} (H2L
1‒3
), differing 
in the inductive effect of the substituent X (X = F, Br and OCH3), in order to observe their 
influence, if any, on the redox potentials and biological activity of the complexes. All the 
synthesized ligands and the metal complexes were successfully characterized by elemental 
analysis, IR, UV‒Vis, NMR spectroscopy and cyclic voltammetry. Molecular structures of four 
mononuclear (1‒3 and 5) and one dinuclear (6) Ni(II) complexes have been determined by X‒ray 
crystallography. The complexes have been screened for their antibacterial activity against 
Escherichia coli and Bacillus. Minimum inhibitory concentration of these complexes indicates 
compound 4 as the potential lead molecule for drug designing.  
In Chapter 3 4–(p–X–phenyl)thiosemicarbazone of napthaldehyde {where, X = Cl (HL1) and 
X = Br (HL
2
)}, thiosemicarbazone of quinoline–2–carbaldehyde (HL3) and 4–(p–
fluorophenyl)thiosemicarbazone of salicylaldehyde (H2L
4
) and their copper(I), 
{[Cu(HL
1
)(PPh3)2Br]·CH3CN (1) and [Cu(HL
2
)(PPh3)2Cl]·DMSO (2)} and copper(II), 
{[(Cu2L
3
2Cl)2(–Cl)2]·2H2O (3) and [Cu(L
4
)(Py)] (4)} complexes are reported. The synthesized 
ligands and their copper complexes were successfully characterized by elemental analysis, cyclic 
voltammetry, NMR, ESI–MS, IR and UV–Vis spectroscopy. Molecular structures of all the 
Cu(I) and Cu(II) complexes have been determined by X–ray crystallography. All the complexes 
(1–4) were tested for their ability to exhibit DNA binding and cleavage activity. The complexes 
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effectively interact with CT–DNA possibly by groove binding mode, with binding constants 
ranging from 10
4 −105 M–1. Among the complexes, 3 show highest chemical (60%) as well as 
photo-induced (80%) DNA cleavage activity against pUC19 DNA. Finally, the in vitro 
antiproliferative activity of all the complexes were assayed against the HeLa cell line. Some of 
the complexes proved to be as active as the clinically referred drugs, and the greater potency of 3 
may be correlated with its aqueous solubility and the presence of quinonoidal group in the 
thiosemicarbazone ligand coordinated to the metal.  
Chapter 4 describes oxygen atom transfer (OAT) reactivity of dioxidomolybdenum(VI) 
complexes [Mo
(VI)
O2L
1‒6
] (1‒6) {4–(p–bromophenyl)thiosemicarbazone of salicylaldehyde 
(H2L
1
), 4–(p–X–phenyl)thiosemicarbazone of o–vanillin {where, X = F (H2L
2
) and X = Cl 
(H2L
3
) and  X = OMe (H2L
4
)}, 4–(p–bromophenyl)thiosemicarbazone of 5–
bromosalicylaldehyde (H2L
5
), and 4–(p–chlorophenyl)thiosemicarbazone of o–
hydroxynaphthaldehyde (H2L
6
)} with PPh3. The OAT reactions proceed through the formation 
of OPPh3, which have been characterized by 
31
P NMR. Dioxidomolybdenum(VI) complexes 
[Mo
(VI)
O2L
1/5/6
(DMSO)] (1a, 5a & 6a), [Mo
(VI)
O2L
2/4
(H2O)] (2a & 4a), and 
[Mo
(VI)
O2L
3
(DMSO)]4·2DMSO (3a) and monooxidomolybdenum(IV) complexes 
[Mo
(IV)
OL
1‒6
(N‒N)] (7‒12) {where, N‒N = 2,2'‒bipyridyl or 1,10‒phenanthroline} are reported 
as the product of substrate binding and oxygen atom transfer reactivity of 
dioxidomolybdenum(VI) complexes [Mo
(VI)
O2L
1‒6
] (1‒6) respectively. All the complexes have 
been spectroscopically characterized. Molecular structures of some of the Mo(VI) (1a‒4a) and 
Mo(IV) complexes (7 and 9‒11) have been determined by single crystal X–ray crystallography. 
The catalytic activity of Mo
(VI) 
complexes (1a‒6a) have also been studied. 
In chapter 5 the synthesis and characterization of an oxidovanadium(IV) [V
IV
O(L)(acac)] (1) 
and two dioxidovanadium(V) [V
V
O2(L')] (2) and [V
V
O2(L)] (2a) complexes of                               
{(4–(p–fluorophenyl)thiosemicarbazone) of pyridine–2–aldehyde} (HL) is described in the. The 
oxidovanadium(IV) species [V
IV
O(L)(acac)] (1) was synthesized in usual way by the reaction of 
metal precursor VO(acac)2 with thiosemicarbazone ligand (HL) in refluxing ethanol. The 
recrystallization of [V
IV
O(L)(acac)] (1) in DMF, CH3CN or EtOH gave the same product i.e. 
dioxidovanadium(V) complex [V
V
O2(L)] (2a), whereas [V
V
O2(L')] (2) was synthesized during 
recrystallization of [V
IV
O(L)(acac)] (1) in DMSO where the original ligand (HL) is transformed 
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to a rearranged new ligand (HL'). The ligand in complex 1 is found to undergo methylation at the 
carbon centre attached to imine nitrogen in presence of DMSO and transformed to the 
corresponding dioxidovanadium(V) species through in situ reaction. The synthesized ligand and 
the metal complexes were characterized by elemental analysis, IR, UV–Vis, NMR and EPR 
spectroscopy. Molecular structures of complex 1 [V
IV
O(L)(acac)] and complex 2 [V
V
O2(L')] 
have been determined by single crystal X–ray crystallography. Complexes 1 & 2 show in vitro 
insulin mimetic activity against insulin responsive L6 myoblast cells, with complex 1 being more 
potent, is comparable to insulin at 100 µM concentration, while complex 2 has considerable 
insulin mimetic activity. In addition, the in vitro antiproliferative activity of the complexes 1 & 2 
against the MCF–7 and Vero cell lines were also assayed. 
In chapter 6 4‒(p‒methoxyphenyl)thiosemicarbazone of o‒hydroxynapthaldehyde (H2L
1
), 
4‒(p‒methoxyphenyl)thiosemicarbazone of benzoyl pyridine (HL2) and 4–(p–
chlorophenyl)thiosemicarbazone of o‒vanillin (H2L
3
) and their dimeric Zn(II) complexes 
[{ZnL
1
(DMSO)}2]·3DMSO (1), [{ZnL
2
Cl}2] (2), and a novel tetrameric Zn(II) complex 
[(Zn2L
3
)2(–OAc)2(3–O)2] (3) are reported. The synthesized ligands and their zinc complexes 
were characterized by elemental analysis, NMR, IR and UV–Vis spectroscopy. Molecular 
structures of all the complexes (1‒3) have been determined by single crystal X–ray 
crystallography. 
The author is very much aware of the fact that some portions of the work described in the present 
dissertation left scope for future work especially the phosphoesterase, pharmacological and 
catalytic studies. All the reported complexes can be used for the study of several other catalytic 
and bio activities. This dissertation also left scope for further qualitative improvement by the 
utilization of some relevant instrumental data, which could have been really helpful in arriving at 
completely unambiguous conclusions. As those instrumental facilities were not available to us, 
we were rather helpless. However, the above discussion on the entire work presented in chapter 
2-6 reveals that the aims and objectives of the present dissertation are mostly fulfilled.  
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